Patent Publication Number: US-2006004197-A1

Title: Sulfonamide-based compounds as protein tyrosine kinase inhibitors

Description:
BACKGROUND  
      1. Technical Field  
      Novel sulfonamide compounds are disclosed which are useful for the treatment of diseases related to increased protein tyrosine kinase activity. Methods of synthesis of these compounds and methods of treatment employing these compounds are also disclosed. The novel compounds include mono-sulfonamides and bis-sulfonamides capable of inhibiting the protein tyrosine kinases (PTKs).  
      2. Background of the Related Art  
      Within the Src family of PTKs, Src is associated with cellular membranes and is involved in signal transduction and growth regulation pathways (Sridhar and Cooper, 2000, Frame, 2002). Src propagates cellular signals by transferring the gamma phosphate of ATP to the side chain of tyrosine residues on substrate proteins. Alterations in the phosphorylation of Src substrates are key events in cellular signaling. Most normal cells contain very low levels and activity of Src (Barnekow, 1989) and the Src enzyme is not required for the establishment or maintenance of cell viability (Soriano, et al., 1991).  
      However, excessive Src activity is associated with various cancers, and therefore Src is a drug target in oncology (Cartwright et al., 1990). For example, Src activity is greatly increased in breast cancer (Partanen, 1994); stomach cancer (Takeshima et al., 1991); colon cancer (Termuhlen et al., 1993); hairy cell leukemia and a subgroup of B-cell lymphomas (Lynch et al., 1993); low grade human bladder carcinoma (Fanning et al., 1992); neuroblastoma (Bjelfman et al., 1990); ovarian cancer (Wiener et al., 1999); and non-small cell lung carcinoma (Budde et al., 1994). In the case of colon cancer, Src is activated more frequently than Ras or p53 (Jessup et al., 1993). Src undergoes two distinct activations corresponding with malignant transformation of colonocytes (Cartwright et al., 1990) and tumor progression (Termuhlen et al., 1993).  
      Antisense to Src inhibits growth of human monoblastoid leukemia cells (Waki et al., 1994), K562 human leukemia cells (Kitanaka et al., 1994) and HT-29 human colon cancer cells (Staley et al., 1997). Src activity has been reduced in a human ovarian cancer cell line (SKOv-3) by antisense technology. The reduced Src activity in SKOv-3 is associated with altered cellular morphology, reduced anchorage-independent growth, diminished tumor growth and reduced vascular endothelial growth factor mRNA expression in vitro (Wiener et al., 1999).  
      Inhibition of Src would have the effect of interrupting the signal transduction pathways in which it participates and would thereby reduce the rate of growth of cancer cells.  
      Src inhibitors are currently being studied for use in the treatment of hematologic and solid tumors, inflammatory and autoimmune diseases (Sinha et al., 1999). Src inhibitors have potential for treatment of osteoporosis, a condition in which bone resorption is increased resulting in weakening of bone. It was shown that mice depleted of the Src gene developed osteopetrosis (Soriano et al., 1991) and that Src is involved with bone resorption (20).  
      Potential sites for targeting inhibitors of Src family PTKs are the SH2 and SH3 domains (Park et al., 2003), the phosphoryl transfer site (SH1 domain), i.e., the active site or other unknown sites on the enzyme. Compounds binding to SH2 and SH3 domains would block the protein-protein interactions and the recruitment of other signal transduction proteins mediated by these domains. Active-site directed inhibitors could be targeted to the ATP binding site, the protein substrate binding site, or both (bisubstrate analogues).  
     SUMMARY OF THE DISCLOSURE  
      In satisfaction of the aforenoted needs, disclosed herein are a number of small-molecule sulfonamide PTK inhibitors that are suitable to act as pharmaceuticals. The inhibitors disclosed herein may be targeted to the phosphoryl transfer site (SH1 domain), i.e., the active site. Active-site directed inhibitors can be targeted to the ATP binding site, the protein substrate binding site, or both (bisubstrate analogues). While the disclosed sulfonamide compounds serve as inhibitors for the Src family of PTKs, it will be understood that the disclosed compounds may very well serve as inhibitors to additional families of PTKs or other protein kinases as well.  
      The disclosed compounds are selected from the following general formulas:  
                 
          wherein R 1  is p-(C 6 H 4 )CH 3  or CH 3 ;     wherein R 2  is p-(C 6 H 4 )CH 3  or CH 3 ;     wherein R 3  is F, Cl, p-(C 6 H 4 )OCH 3 , o-(C 6 H 4 )OCH 3 , m-(C 6 H 4 )OCH 3 , p-(C 6 H 4 )OH, p-(C 6 H 4 )Cl, o-(C 6 H 4 )Cl, m-(C 6 H 4 )Cl, p-(C 6 H 4 )F, p-(C 6 H 4 )CH 3 , o-(C 6 H 4 )CH 3 , M-(C 6 H 4 )CH 3 , 3,5-(C 6 H 3 )(CH 3 ) 2 , 2,6-(C 6 H 3 )(CH 3 ) 2 , o-(C 6 H 4 )[CH(CH 3 ) 2 ], C 6 H 5 , 2-furyl, morpholin-4-yl, n-Me-piperazin-1-yl, thiomorpholin-4-yl, 3-pyridyl, 2-pyridyl, cyclohexyl, cyclohexyl-1-ol, or 5-Me-pyrazol-4-yl;     wherein X 1  is S, NH or O; and     wherein Y 1  is (CH 2 ) n  wherein n ranges from 1 to 3;  
                 
    wherein R 4  is p-(C 6 H 4 )CH 3 , p-(C 6 H 4 )(CH 2 CH 3 ), p-(C 6 H 4 )[CH(CH 3 ) 2 ], p-(C 6 H 4 )Cl, p-(C 6 H 4 )F, p-(C 6 H 4 )OC 6 H 5 , m-(C 6 H 4 )NO 2 , CH 2 (C 6 H 5 ), 1-naphthyl, 2-naphthyl, p-(C 6 H 4 )NH(C═O)CH 3 , p-(C 6 H 4 )OCH 3 , (CH 2 ) 3 CH 3 , 3,4-(C 6 H 3 )(OCH 3 ) 2 , C 6 H 5 , p-(C 6 H 4 )[C(CH 3 )] 3 , 2,4,6-(C 6 H 2 )(CH 3 ) 3 , p-(C 6 H 4 )NO 2 , CH 3 , 4-methyl-2-acetamidothiazol-5-yl, 3,5-dimethylisoxazol-4-yl, 1-methylimidazol-4-yl, 5-Br-6-Cl-pyrid-3-yl, 7-Cl-benzo[1,2,5]oxadiazol-4-yl, 5-[3-(isoxazolyl)]thien-2-yl, 1,2,5-trimethyl-3-carbomethoxypyrrol-4-yl, p-(C 6 H 4 )CH 2 CH 2 CH 2 CH 3 , 2-(1-naphthyl)ethyl, p-(C 6 H 4 )SO 2 CH 3 , m-(C 6 H 4 )OCH 3 , 5-bromothien-2-yl, or isoquinolin-5-yl;     wherein R 5  is p-(C 6 H 4 )CH 3 , p-(C 6 H 4 )(CH 2 CH 3 ), p-(C 6 H 4 )[CH(CH 3 ) 2 ], p-(C 6 H 4 )Cl, p-(C 6 H 4 )F, p-(C 6 H 4 )OC 6 H 5 , m-(C 6 H 4 )NO 2 , CH 2 (C 6 H 5 ), 1-naphthyl, 2-naphthyl, p-(C 6 H 4 )NH(C═O)CH 3 , p-(C 6 H 4 )OCH 3 , (CH 2 ) 3 CH 3 , 3,4-(C 6 H 3 )(OCH 3 ) 2 , C 6 H 5 , p-(C 6 H 4 )[C(CH 3 )] 3 , 2,4,6-(C 6 H 2 )(CH 3 ) 3 , p-(C 6 H 4 )NO 2 , CH 3 , 3,5-dimethylisoxazol-4-yl, 1-methylimidazol-4-yl, 1,2,5-trimethyl-3-carbomethoxypyrrol-4-yl, 2-(1-naphthyl)ethyl, p-(C 6 H 4 )SO 2 CH 3 , 5-bromothien-2-yl, or 2-methoxy-4-methylphenyl;     wherein R 6  is F, Cl, p-(C 6 H 4 )OCH 3 , (CH 2 ) 4 CH 2 OH, p-(C 6 H 4 )F, 2-naphthyl, CH 3 , p-(C 6 H 4 )Cl, m-(C 6 H 4 )CO 2 H, m-(C 6 H 4 )CH 2 CO 2 H, p-(C 6 H 4 )CO 2 H, p-(C 6 H 4 )CH 2 CO 2 H, CH 2 CH 2 CH 2 OH, allyl, (CH 2 ) 7 CH 2 OH, (CH 2 ) 7 CH 2 C(═O)CH 3 , (CH 2 ) 3 CH 3 , m-(C 6 H 4 )Cl, o-(C 6 H 4 )Cl, cyclohexyl, pyrazol-1-yl, benzimidazol-1-yl, N(CH 3 ) 2 , imidazol-1-yl, N-(4-toluenesulfonyl)piperazin-1-yl, morpholin-4-yl, p-CH 2 CH 2 (C 6 H 4 )OCH 3 , C(CH 3 ) 3 , 3-pyridyl, C 6 H 5 , CH 2 C(CH 3 ) 2 CH 2 OH, CH 2 (naphth-1-yl), CH 2 C 6 H 5 , 2-thienyl, 3,5-dimethylisoxazol-4-yl, or OH;     wherein R 7  is H, CH 2 CHCH 2  or OCH 3 ;     wherein X 2  is O, S, H, C(═O), NH, CH 2 , C(═NOCH 2 C 6 H 5 ), C(═NOH), or C(═NOCH 3 ); and     wherein Y 2  is CH 2 , NH, C(═O), or SO 2 ;  
                 
    wherein R 8  is p-(C 6 H 4 )CH 3 ;     wherein R 9  is p-(C 6 H 4 )CH 3 ;     wherein R 10  is p-(C 6 H 4 )Cl, p-(C 6 H 4 )OCH 3 , Br, or o-(C 6 H 4 )Cl,     wherein R 11  is NH 2 , NHC(═O)CH 3 , CO 2 CH 3 , CO 2 H, CH 3 , Br, CF 3 , or F;     wherein X 3  is S, O, or SO 2 ; and     wherein Y 3  is CH 2 ;  
                 
    wherein R 12  is p-(C 6 H 4 )CH 3 , OCH 3 , H, NH 2 , 2-cyanopyrid-5-yl, 2-trifluoromethylpyrid-5-yl, p-(C 6 H 4 )CN, p-(C 6 H 4 )NHC(═O)CH 3 , benzofuran-2-yl, quinolin-2-yl, 5-methyl-pyrazin-2-yl, CN, CO 2 H, C 6 H 5 , C(═O)NH 2 , CH 2 NH 2 , CH 3 , 7-chloro-benzo[1,2,5]oxadiazol-4-yl, and p-(C 6 H 4 )CH 2 CH 3 ,     wherein R 13  is p-(C 6 H 4 )CH 3 , OP(═O)(OCH 2 CH 3 ) 2 , OP(═O)(OH) 2 , p-(C 6 H 4 )CH 3 , NH 2 , OH, OCH 3 , CH 2 CH 2 OH, CH 2 CH 2 CH 2 OH, rac-CH 2 CH(OH)CH 2 OH, CH 2 CO 2 H, CO 2 CH 3 , CO 2 H, H, CH 2 NH 2 , quinolin-2-yl, 6-methylnaphth-2-yl, or CH 2 CH 2 CH 3 ;     wherein R 14  is p-(C 6 H 4 )OCH 3 , p-(C 6 H 4 )Cl, C 6 H 5 , morpholin-4-yl, cyclohexyl, naphth-1-yl, o-(C 6 H 4 )Cl, or CH 3 ;     wherein R 15  is H, NO 2 , or CF 3 ;     wherein X 4  O, CH 2 , S, NH, or SO 2 ;     wherein Y 4  is O, C(═O), or CH 2 ;     wherein A is NHSO 2 , O—SO 2 , NHC(═O), N(CH 3 )SO 2 , NHCH 2 , CH 2 NHSO 2 , NHC(═O)CH 2 , CH 2 NHC(═O), or SO 2 NH;     wherein B is O—SO 2 , NHC(═O), N(CH 3 )SO 2 , O, NHSO 2 , CH 2 NHSO 2 , N[C(═O)C 6 H 5 )]SO 2 , CH 2 NHC(═O), E/Z N═C, NHC(═O), NH 2 CH 2 , or NHC(═O)NHSO 2 ;  
                 
    wherein R 16  is p-(C 6 H 4 )CH 3  or H;     wherein R 17  is p-(C 6 H 4 )CH 3  or H;     wherein R 18  is p-(C 6 H 4 )OCH 3 ;     wherein X 5  is O; and     wherein Y 5  is C(═O) or SO 2 .        

      In an embodiment, the PTK inhibitor compound is selected from the group consisting of: 
      N-[4-fluoro-5-nitro-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-(4-methoxy-phenylsulfanyl)-5-nitro-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-(2-methoxy-phenylsulfanyl)-5-nitro-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-(3-methoxy-phenylsulfanyl)-5-nitro-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-(4-hydroxy-phenylsulfanyl)-5-nitro-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-(4-chloro-phenylsulfanyl)-5-nitro-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-(2-chloro-phenylsulfanyl)-5-nitro-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-(3-chloro-phenylsulfanyl)-5-nitro-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-(4-fluoro-phenylsulfanyl)-5-nitro-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[5-nitro-2-(4-toluenesulfonylamino)-4-(p-tolylsulfanyl)-phenyl]-4-toluenesulfonamide;     N-[5-nitro-2-(4-toluenesulfonylamino)-4-(o-tolylsulfanyl)-phenyl]-4-toluenesulfonamide;     N-[5-nitro-2-(4-toluenesulfonylamino)-4-(m-tolylsulfanyl)-phenyl]-4-toluenesulfonamide;     N-[4-(2,4-dimethyl-phenylsulfanyl)-5-nitro-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-(2,6-dimethyl-phenylsulfanyl)-5-nitro-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-(2-isopropyl-phenylsulfanyl)-5-nitro-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[5-nitro-4-phenylsulfanyl-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-(furan-2-ylmethylsulfanyl)-5-nitro-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-(4-chloro-benzylsulfanyl)-5-nitro-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-(2-chloro-benzylsulfanyl)-5-nitro-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-(4-methoxy-benzylsulfanyl)-5-nitro-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-benzylsulfanyl-5-nitro-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[5-(4-chloro-phenylsulfanyl)-2-methanesulfonylamino-4-nitro-phenyl]-methanesulfonamide;     N-[4-chloro-5-nitro-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[5-nitro-4-phenyl-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-(morpholin-4-yl)-5-nitro-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-(4-methyl-piperazin-1-yl)-5-nitro-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[5-nitro-4-(thiomorpholin-4-yl)-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[5-nitro-4-[(pyridin-3-ylmethyl)-amino]-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[5-nitro-4-[(pyridin-2-ylmethyl)-amino]-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-(4-methoxy-benzylamino)-5-nitro-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-(2-chloro-benzylamino)-5-nitro-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-(cyclohexylmethyl-amino)-5-nitro-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-(1-hydroxy-cyclohexylmethyl-amino)-5-nitro-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-cyclohexylamino-5-nitro-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-[3-(5-methyl-1H-pyrazol-4-yl)-propylamino]-5-nitro-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-fluoro-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-chloro-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     4-ethyl-N-[2-(4-ethyl-benzenesulfonylamino)-4-(4-methoxy-phenoxy)-phenyl]-benzenesulfonamide;     4-isopropyl-N-[2-(4-isopropyl-benzenesulfonylamino)-4-(4-methoxy-phenoxy)-phenyl]-benzenesulfonamide;     4-chloro-N-[2-(4-chloro-benzenesulfonylamino)-4-(4-methoxy-phenoxy)-phenyl]-benzenesulfonamide;     4-fluoro-N-[2-(4-fluoro-benzenesulfonylamino)-4-(4-methoxy-phenoxy)-phenyl]-benzenesulfonamide;     N-[4-(4-methoxy-phenoxy)-2-(4-phenoxy-benzenesulfonylamino)-phenyl]-4-phenoxy-benzenesulfonamide;     N-[4-(4-methoxy-phenoxy)-2-(3-nitro-benzenesulfonylamino)-phenyl]-3-nitro-benzenesulfonamide;     N-[4-(4-methoxy-phenoxy)-2-phenylmethanesulfonylamino-phenyl]-C-phenyl-methanesulfonamide;     naphthalene-1-sulfonic acid [4-(4-methoxy-phenoxy)-2-(naphthalen-1-yl-sulfonylamino)-phenyl]-amide;     naphthalene-2-sulfonic acid [4-(4-methoxy-phenoxy)-2-(naphthalen-2-yl-sulfonylamino)-phenyl]-amide;     N-[2-(4-acetamido-benzenesulfonylamino)-4-(4-methoxy-phenoxy)-phenyl]-4-acetamido-benzenesulfonamide;     N-[2-(4-methoxy-benzenesulfonylamino)-4-(4-methoxy-phenoxy)-phenyl]-4-methoxy-benzenesulfonamide;     butane-1-sulfonic acid [2-(butane-1-sulfonylamino)-4-(4-methoxy-phenoxy)-phenyl]-amide;     N-[2-(3,4-dimethoxy-benzenesulfonylamino)-4-(4-methoxy-phenoxy)-phenyl]-3,4-dimethoxy-benzenesulfonamide;     N-[2-benzenesulfonylamino-4-(4-methoxy-phenoxy)-phenyl]-benzenesulfonamide;     N-[2-(4-t-butyl-benzenesulfonylamino)-4-(4-methoxy-phenoxy)-phenyl]-4-t-butyl-benzenesulfonamide;     N-[4-(4-methoxy-phenoxy)-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-(4-methoxy-phenoxy)-2-(2,4,6-trimethylbenzenesulfonylamino)-phenyl]-2,4,6-trimethylbenzenesulfonamide;     N-[4-(4-methoxy-phenoxy)-2-(4-nitrobenzenesulfonylamino)-phenyl]-4-nitrobenzenesulfonamide;     N-[4-(5-hydroxy-pentyloxy)-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-(4-fluoro-phenoxy)-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-(naphthalene-2-yloxy)-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-methoxy-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide     N-[4-(4-chloro-phenoxy)-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-(3-carboxy-phenoxy)-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     {3-[3,4-bis(4-toluenesulfonylamino)-phenoxy]-phenyl}-acetic acid;     N-[4-(3-carboxy-phenoxy)-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     {4-[3,4-bis(4-toluenesulfonylamino)-phenoxy]-phenyl}-acetic acid;     N-[4-(3-hydroxy-propoxy)-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-allyloxy-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-(8-hydroxy-octyloxy)-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     5-[3,4-bis-(4-toluenesulfonylamino)-phenoxy]-pentyl acetate;     N-[4-(4-chloro-phenylsulfanyl)-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-(4-methoxy-phenylsulfanyl)-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-butylsulfanyl-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[3-allyl-4-(4-methoxy-benzyloxy)-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-(4-chloro-benzyloxy)-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-(3-chloro-benzyloxy)-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-(2-chloro-benzyloxy)-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-(4-methoxy-benzyloxy)-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-cyclohexylmethoxy-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-(2-chloro-benzylsulfanyl)-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-(pyrazol-1-yl)-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-(benzimidazol-1-yl)-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-dimethylamino-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-(imidazol-1-yl)-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-{2-(4-toluenesulfonylamino)-4-[4-(toluene-4-sulfonyl)-piperazin-1-yl]-phenyl}-4-toluenesulfonamide;     N-[4-(morpholin-4-yl)-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-(4-chloro-phenyl)-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[3-methoxy-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[2-(4-methoxy-phenyl)-ethyl]-3,4-bis-(4-toluenesulfonylamino)-benzamide;     N-t-butyl-3,4-bis-(4-toluenesulfonylamino)-benzamide;     N-pyridin-3-yl-3,4-bis-(4-toluenesulfonylamino)-benzamide;     N-phenyl-3,4-bis-(4-toluenesulfonylamino)-benzamide;     N-(3-hydroxy-2,2-dimethyl-propyl)-3,4-bis-(4-toluenesulfonylamino)-benzamide;     N-naphthalen-1-ylmethyl-3,4-bis-(4-toluenesulfonylamino)-benzamide;     2-phenyl-N-[3,4-bis-(4-toluenesulfonylamino)-phenyl]-acetamide;     N-[3,4-bis-(4-toluenesulfonylamino)-phenyl]-thiophene-2-sulfonamide;     3,5-dimethyl-N-[3,4-bis-(4-toluenesulfonylamino)-phenyl]-isoxazole-4-sulfonamide;     3,4-bis-(4-toluenesulfonylamino)-benzoic acid;     N-[4-hydroxymethyl-2-(4-toluenesulfonylamino-phenyl]-4-toluenesulfonamide;     N-[2-methanesulfonylamino-4-(4-methoxy-phenoxy)-phenyl]-4-toluenesulfonamide;     3,5-dimethyl-N-[5-(4-methoxy-phenoxy)-2-(4-toluenesulfonylamino)-phenyl]-isoxazole-4-sulfonamide;     N-[5-(4-methoxy-phenoxy)-2-(4-toluenesulfonylamino)-phenyl]-1-methyl-1H-imidazole-4-sulfonamide;     N-[2-methanesulfonylamino-5-(4-methoxy-phenoxy)-phenyl]-4-toluenesulfonamide;     N-{5-[4-(4-methoxy-phenoxy)-2-(4-toluenesulfonylamino)-phenylsulfamoyl]-4-methyl-thiazol-2-yl}-acetamide;     3,5-dimethyl-N-[4-(4-methoxy-phenoxy)-2-(4-toluenesulfonylamino)-phenyl]-isoxazole-4-sulfonamide;     N-[4-(4-methoxy-phenoxy)-2-(4-toluenesulfonylamino)-phenyl]-1-methyl-1H-imidazole-4-sulfonamide;     5-bromo-6-chloro-N-[4-(4-methoxy-phenoxy)-2-(4-toluenesulfonylamino)-phenyl]-pyridine-3-sulfonamide;     7-chloro-N-[4-(4-methoxy-phenoxy)-2-(4-toluenesulfonylamino)-phenyl]-benzo[1,2,5]oxadiazole-4-sulfonamide;     5-isoxazol-3-yl-N-[4-(4-methoxy-phenoxy)-2-(4-toluenesulfonylamino)-phenyl]-thiophene-2-sulfonamide;     methyl 4-[4-(4-methoxy-phenoxy)-2-(4-toluenesulfonylamino)-phenylsulfamoyl]-1,2,5-trimethyl-1H-pyrrole-3-carboxylate;     4-butyl-N-[4-(4-methoxy-phenoxy)-2-(4-toluenesulfonylamino)-phenyl]-benzenesulfonamide;     N-[5-(4-methoxy-phenoxy)-2-(2-naphthalen-1-yl-ethanesulfonylamino)-phenyl]-4-toluenesulfonamide;     4-methanesulfonyl-N-[4-(4-methoxy-phenoxy)-2-(4-toluenesulfonylamino)-phenyl]-benzenesulfonamide;     3-methoxy-N-[4-(4-methoxy-phenoxy)-2-(4-toluenesulfonylamino)-phenyl]-benzenesulfonamide;     N-[4-(4-methoxy-phenoxy)-2-(4-toluenesulfonylamino)-phenyl]-5-bromo-thiophene-2-sulfonamide;     N-[4-(4-methoxy-phenoxy)-2-(4-toluenesulfonylamino)-phenyl]-isoquinoline-5-sulfonamide;     methyl 4-[5-(4-methoxy-phenoxy)-2-(4-toluenesulfonylamino)-phenylsulfamoyl]-1,2,5-trimethyl-1H-pyrrole-3-carboxylate;     N-[4-(4-methoxy-phenoxy)-2-(2-naphthalen-1-yl-ethanesulfonylamino)-phenyl]-4-toluenesulfonamide;     4-methanesulfonyl-N-[5-(4-methoxy-phenoxy)-2-(4-toluenesulfonylamino)-phenyl]-benzenesulfonamide;     5-bromo-N-[5-(4-methoxy-phenoxy)-2-(4-toluenesulfonylamino)-phenyl]-thiophene-2-sulfonamide;     2-methoxy-N-[5-(4-methoxy-phenoxy)-2-(4-toluenesulfonylamino)-phenyl]-4-methyl-benzenesulfonamide;     N-[4-(benzyloxyimino-phenyl-methyl)-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-(hydroxyimino-phenyl-methyl)-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-(methoxyimino-phenyl-methyl)-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[5-(2-chloro-benzylsulfanyl)-2-methanesulfonylamino-phenyl]-4-toluenesulfonamide;     N-[4-(2-chloro-benzylsulfanyl)-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-(2-chloro-benzylsulfanyl)-2-methanesulfonylamino-phenyl]-4-toluenesulfonamide;     N-[5-amino-4-(4-chloro-phenylsulfanyl)-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[2-(4-chloro-phenylsulfanyl)-4,5-bis-(4-toluenesulfonylamino)-phenyl]-acetamide;     methyl 2-(4-methoxy-phenoxy)-4,5-bis-(4-toluenesulfonylamino)-benzoate;     2-(4-methoxy-phenoxy)-4,5-bis-(4-toluenesulfonylamino)-benzoic acid;     N-[4-(4-methoxy-phenoxy)-5-methyl-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4,5-dibromo-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-(4-methoxy-phenoxy)-2-(4-toluenesulfonylamino)-5-trifluoromethyl-phenyl]-4-toluenesulfonamide;     N-[4-(2-chloro-benzylsulfanyl)-5-fluoro-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     N-[4-(2-chloro-phenylmethanesulfonyl)-5-fluoro-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     diethyl-5-(4-methoxy-phenoxy)-2-(4-toluenesulfonylamino)-phenyl phosphate;     [5-(4-methoxy-phenoxy)-2-(4-toluenesulfonylamino)-phenyl]-monophosphate;     4-(4-methoxy-phenoxymethyl)-2-(4-toluenesulfonyloxy)-phenyl 4-toluenesulfonate;     N-[4-(4-chloro-phenylsulfanyl)-5-nitro-2-(4-toluamido)-phenyl]-4-toluamide;     N-[4-(4-chloro-phenylsulfanyl)-2-(4-toluoylamino)-phenyl]-4-toluamide;     N-[4-(4-chloro-phenylsulfanyl)-5-nitro-2-(4-toluenesulfonyl-methyl-amino)-phenyl]-N-methyl-4-toluenesulfonamide;     N-[2-amino-4-(4-chloro-phenylsulfanyl)-5-nitro-phenyl]-4-toluenesulfonamide;     N-[2-amino-4-(4-chloro-phenylsulfanyl)-5-nitro-phenyl]-4-toluamide;     N-[2-hydroxy-4-(4-methoxy-phenoxy)-phenyl]-4-toluenesulfonamide;     N-[2-methoxy-4-(4-methoxy-phenoxy)-phenyl]-4-toluenesulfonamide;     N-[2-methoxy-4-(4-methoxy-phenoxy)-phenyl]-N-methyl-4-toluenesulfonamide;     N-[2-(2-hydroxy-ethoxy)-4-(4-methoxy-phenoxy)-phenyl]-4-toluenesulfonamide;     N-[2-(3-hydroxy-propoxy)-4-(4-methoxy-phenoxy)-phenyl]-4-toluenesulfonamide;     N-[2-(2,3-dihydroxy-propoxy)-4-(4-methoxy-phenoxy)-phenyl]-4-toluenesulfonamide;     [5-(4-methoxy-phenoxy)-2-(4-toluenesulfonylamino)-phenoxy]-acetic acid;     N-[2-methoxy-5-(4-methoxy-phenoxymethyl)-phenyl]-4-toluenesulfonamide;     methyl 5-(4-methoxy-phenoxy)-2-(4-toluenesulfonylamino)-benzoate;     5-(4-methoxy-phenoxy)-2-(4-toluenesulfonylamino)-benzoic acid;     N-[4-(4-chloro-phenylsulfanyl)-3-nitro-phenyl]-4-toluenesulfonamide;     N-[3-(4-chloro-phenylsulfanyl)-4-nitro-phenyl]-4-toluenesulfonamide;     N-[2-amino-5-(4-methoxy-phenoxy)-phenyl]-4-toluenesulfonamide;     6-cyano-N-[4-(4-methoxy-phenoxy)-2-(4-toluenesulfonylamino)-phenyl]-nicotinamide;     N-[4-(4-methoxy-phenoxy)-2-(4-toluenesulfonylamino)-phenyl]-6-trifluoromethyl-nicotinamide;     N-[2-(4-cyano-benzylamino)-5-(4-methoxy-phenoxy)-phenyl]-4-toluenesulfonamide;     N-(4-{[4-(4-methoxy-phenoxy)-2-(4-toluenesulfonylamino)-phenylamino]-methyl}-phenyl)-acetamide;     N-[2-[(benzofuran-2-ylmethyl)-amino]-5-(4-methoxy-phenoxy)-phenyl]-4-toluenesulfonamide;     N-{5-(4-methoxy-phenoxy)-2-[(quinolin-2-ylmethyl)-amino]-phenyl}-4-toluenesulfonamide;     N-[5-(4-methoxy-phenoxy)-2-(4-toluenesulfonylamino)-phenyl]-5-methyl-pyrazine-2-carboxamide;     N-[2-amino-5-(4-methoxy-phenoxy)-benzyl]-4-toluenesulfonamide;     N-[2-cyano-4-(4-methoxy-phenoxy)-phenyl]-4-toluenesulfonamide;     5-(4-methoxy-phenoxy)-2-(4-toluenesulfonylamino)-benzamide;     N-[2-amino-4-(4-methoxy-phenoxy)-phenyl]-4-toluenesulfonamide;     N-[4-(4-methoxy-phenoxy)-2-(4-toluenesulfonylamino-methyl)-phenyl]-4-toluenesulfonamide;     N-[2-aminomethyl-4-(4-methoxy-phenoxy)-phenyl]-4-toluenesulfonamide;     N-[3-[benzoyl-(4-toluenesulfonyl)-amino]-4-(4-toluenesulfonylamino)-phenyl]-benzamide;     N-[5-(4-methoxy-phenoxy)-2-(4-toluenesulfonylamino)-benzyl]-4-toluamide;     N-[5-(4-methoxy-phenoxy)-2-(4-toluenesulfonylamino)-phenyl]-4-toluamide;     N-[4-(4-methoxy-phenoxy)-2-(4-toluenesulfonylamino)-phenyl]-4-toluamide;     N-[4-(4-methoxy-phenoxy)-2-(4-toluenesulfonylamino)-phenyl]-2-phenyl-acetamide;     N-[2-amino-5-(4-methoxy-phenoxy)-phenyl]-N-methyl-4-toluenesulfonamide;     N-{4-(4-methoxy-phenoxy)-2-[(quinolin-2-ylmethylene)-amino]-phenyl}-4-toluenesulfonamide;     4-(4-methoxy-phenoxymethyl)-2-(4-toluenesulfonylamino)-benzamide;     N-[2-aminomethyl-5-(4-methoxy-phenoxymethyl)-phenyl]-4-toluenesulfonamide;     N-[2-(methanesulfonylamino-methyl)-5-(4-methoxy-phenoxymethyl)-phenyl]-6-methyl-naphthalene-2-sulfonamide;     N-(4-morpholin-4-yl-5-nitro-2-(4-toluoylamino)-phenyl)-4-toluamide;     N-[5-(4-methoxy-phenoxy)-2-(4-toluenesulfonylamino)-phenyl]-butyramide;     N-[4-(cyclohexylmethyl-amino)-5-nitro-2-(4-toluoylamino)-phenyl]-4-toluamide;     N-{4-[(naphthalen-1-ylmethyl)-amino]-5-nitro-2-(4-toluoylamino)-phenyl}-4-toluamide;     N-[2-amino-4-(4-methoxy-phenoxy)-5-nitro-phenyl]-4-toluenesulfonamide;     N-[4-(4-methoxy-phenoxy)-2-(4-toluenesulfonyl-methyl-amino)-phenyl]-4-toluenesulfonamide;     N-[2-amino-4-(4-methoxy-phenoxy)-5-trifluoromethyl-phenyl]-4-toluenesulfonamide;     N-[4-(4-methoxy-phenoxymethyl)-2-(4-toluenesulfonylamino)-benzyl]-4-toluamide;     N-[2-amino-5-(4-methoxy-phenoxy)-4-trifluoromethyl-phenyl]-4-toluenesulfonamide;     N-[4-(4-methoxy-phenoxy)-2-(4-methyl-benzylamino)-phenyl]-4-toluenesulfonamide;     N-{4-(4-methoxy-phenoxy)-2-[3-(4-toluenesulfonyl)-ureido]-phenyl}-4-toluenesulfonamide;     N-[5-(4-methoxy-phenoxy)-2-(4-methyl-benzylamino)-phenyl]-4-toluenesulfonamide;     N-[2-amino-5-(2-chloro-benzylsulfanyl)-phenyl]-4-toluenesulfonamide;     N-[2-amino-4-(2-chloro-benzylsulfanyl)-5-nitro-phenyl]-7-chloro-benzo[1,2,5]oxadiazole-4-sulfonamide;     N-(4-ethyl-phenyl)-4-methoxy-2-(4-toluenesulfonylamino)-benzenesulfonamide;     N-[4-(2-chloro-phenylmethanesulfonyl)-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide;     6-(4-methoxy-phenoxy)-1-(4-toluenesulfonyl)-1,3-dihydro-benzoimidazol-2-one;     5-(4-methoxy-phenoxy)-1-(4-toluenesulfonyl)-1,3-dihydro-benzoimidazol-2-one;     5-(4-methoxy-phenoxy)-1,3-bis-(4-toluenesulfonyl)-1,3-dihydro-benzoimidazol-2-one;     5-(4-methoxy-phenoxy)-1,3-dihydro-benzo[1,2,5]thiadiazole 2,2-dioxide;     5-(4-methoxy-phenoxy)-1,3-dihydro-benzoimidazol-2-one;     5-(4-methoxy-phenoxy)-1-(4-toluenesulfonyl)-1,3-dihydro-benzo[1,2,5]thiadiazole 2,2-dioxide; and mixtures thereof.    

      A further embodiment is a pharmaceutical composition for the treatment of human and mammal diseases including but not limited to hyperproliferative diseases, hematologic diseases such as osteoporosis, neurological diseases such as Alzheimer&#39;s Disease, epilepsy or senility, autoimmune diseases, allergic/immunological diseases such as anaphylaxis, or viral infections which comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one cobalt complex disclosed herein or a pharmaceutically acceptable salt or hydrate thereof. The uses of the disclose PTK inhibiting sulfonamide compounds are not limited to the diseases listed herein.  
      Another embodiment is a method of synthesizing one or more of the sulfonamide compounds disclosed. Synthesis procedures are explained in detail below.  
      Another embodiment is a method of inhibiting PTKs by administering to a subject one or more sulfonamide compounds disclosed herein.  
      In a further embodiment, the step of the binding at least one of the disclosed sulfonamide compounds to protein tyrosine kinases may be included. In a further embodiment, the cell may be contacted with one or more of the disclosed sulfonamide compounds in order to alter cell morphology, migration, adhesion, cell cycle progression, secretion, differentiation, proliferation, anchorage-independent growth, vascular endothelial growth factor expression, microtubule binding by tau, viral infectivity, or bone reabsorption.  
      The protein tyrosine kinase may be Src, Fyn, Yes, Lyn, Lck, Blk, Hck, Fgr, or Yrk.  
      Another embodiment is a method of treating a PTK-related disease in a subject comprising the step of administering to the subject a pharmaceutically acceptable carrier and a therapeutically effective amount of one or more of the disclosed sulfonamide compounds.  
      In further embodiments, the administering may parenteral. In still further embodiments, the parenteral administration may be intravenous, intramuscular, subcutaneous, intraperitoneal, intraarterial, intrathecal or transdermal. In a further embodiment, the administering may be alimentary. In a further embodiment, the alimentary administration may be oral, rectal, sublingual, or buccal. In a further embodiment, the administration may be topical. In a further embodiment, the administration may be by inhalation. In a further embodiment, the administering may be combined with a second method of treatment.  
      Another embodiment is a method of preventing replication of a virus in an organism by administering to the organism infected with the virus one or more of the sulfonamide compounds disclosed herein. In a further embodiment, the virus may be a herpesvirus, papovavirus, hepadnavirus or retrovirus.  
      As used herein the specification, “a” or “an” may mean one or more. As used herein in the claim(s), when used in conjunction with the word “comprising,” the words “a” or “an” may mean one or more than one. As used herein “another” may mean at least a second or more.  
      Other features and advantages of the disclosed sulfonamide compounds, synthesis methods and treatment methods will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating certain preferred embodiments, are given by way of illustration only, since various changes and modifications that fall within the spirit and scope of this disclosure will become apparent to those skilled in the art from this summary and the following detailed description.  
    
    
     BRIEF DESCRIPTION OF THE DRAWINGS  
      The following drawings form part of the present disclosure and are included to further demonstrate certain aspects of the disclosed compounds and methods, wherein:  
       FIG. 1  is a schematic flow chart illustrating the step-wise synthesis of N-[4-(2-chloro-benzylsulfanyl)-5-nitro-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide (4r) using a process comprising i) 4-toluenesulfonyl chloride, pyridine, 80° C., 82%, ii) fuming HNO 3 , acetic acid, 60° C., 36%, and, iii) 2-chlorophenyl-methanethiol, K 2 CO 3 , reflux, 77%;  
       FIG. 2  is a schematic flow chart illustrating the step-wise synthesis of N-[5-nitro-4-phenyl-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide (8) using a process comprising i) 4-toluenesulfonyl chloride, pyridine, 80° C., 78%, ii) fuming HNO 3 , acetic acid, 75° C., 64%, and iii) PhB(OH) 2 , Pd(PPh 3 ) 4 , NaHCO 3 , DME/H 2 O, reflux, 52%;  
       FIG. 3  is a schematic flow chart illustrating the step-wise synthesis of N-[5-(4-methoxy-phenoxy)-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide (12p) using a process comprising i) 4-methoxyphenol, K 2 CO 3 , DMSO, 130° C., 30%, ii) sodium dithionite, EtOH/H 2 O, reflux, iii) 4-toluenesulfonyl chloride, pyridine, 80° C., 20%;  
       FIG. 4  is a schematic flow chart illustrating the step-wise synthesis of N-[4-(2-chloro-benzyloxy)-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide (15d) using a process comprising i) 2-chlorobenzyl chloride, K 2 CO 3 , acetone, reflux, 86%, ii) sodium dithionite, EtOH/H 2 O, reflux, and iii) 4-toluenesulfonyl chloride, pyridine, 80° C., 42%;  
       FIG. 5  is a schematic flow chart illustrating the step-wise synthesis of N-[4-(imidazol-1-yl)-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide using a process comprising i) imidazole, K 2 CO 3 , DMSO, 130° C., 38%, ii) 3 atm H 2 , Pd/C, EtOH, room temperature, and iii) 4-toluenesulfonyl chloride, pyridine, 80° C., 42%;  
       FIG. 6  is a schematic flow chart illustrating the step-wise synthesis of N-[4-(4-chloro-phenyl)-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide (21) using a process comprising i) Br 2 , sodium acetate trihydrate, acetic acid, 0° C. to room temperature, 66%, ii) 4-chlorophenylboronic acid, Pd(PPh 3 ) 4 , NaHCO 3 , DME/H 2 O, reflux, 65%, iii) 3 atm H 2 , Pd/C, EtOH, and iv) 4-toluenesulfonyl chloride, pyridine, 80° C., 24%;  
       FIG. 7  is a schematic flow chart illustrating the step-wise synthesis of N-[2-(4-chloro-phenylsulfanyl)-4,5-bis-(4-toluenesulfonylamino)-phenyl]-acetamide (24) using a process comprising i) Na 2 S 2 O 4 , EtOH/H 2 O, reflux, 100%. ii) Ac 2 O, DMAP, pyridine, room temperature;  
       FIG. 8  is a schematic flow chart illustrating the step-wise synthesis of 2-(4-methoxy-phenoxy)-4,5-bis-(4-toluenesulfonylamino)-benzoic acid (34) using a process comprising i) Ac 2 O, DMAP, pyridine, room temperature, 100%, ii) HNO 3 , Ac 2 O, AcOH, 0° C., 22%, iii) NBS, cat. benzoyl peroxide, CCl 4 , reflux, 32%, iv) hexamethylenetetramine, CHCl 3 , reflux, 23%, v) 2-methyl-2-butene, NaH 2 PO 4 .H2O, NaClO 2 , t-butanol/H 2 O, room temperature, 81%, vi) 50% HCl, MeOH, reflux, 90%, vii) 4-methoxyphenol, K 2 CO 3 , acetone, reflux, 93%, viii) sodium dithionite, EtOH/H 2 O, reflux, ix) 4-toluenesulfonyl chloride, pyridine, 80° C., 42%, and x) KOH, MeOH, reflux, 64%;  
       FIG. 9  is a schematic flow chart illustrating the step-wise synthesis of N-[4-(4-methoxy-phenoxy)-5-methyl-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide (37) using a process comprising i) 4-methoxyphenol, K 2 CO 3 , acetone, reflux, 48%, ii) HCl, MeOH, reflux, 97%, iii) H 2 , Pd/C, acetic acid, room temperature, and iv) 4-toluenesulfonyl chloride, pyridine, 80° C.;  
       FIG. 10  is a schematic flow chart illustrating the step-wise synthesis of [5-(4-methoxy-phenoxy)-2-(4-toluenesulfonylamino)-phenyl]-phosphate (43) using a process comprising i) 4-methoxyphenol, K 2 CO 3 , DMSO, 140° C., 58%, ii) diethyl chlorophosphate, TEA, toluene, 80° C., 78%, iii) 3 atm H 2 , Pd/C, EtOH, room temperature, iv) 4-toluenesulfonyl chloride, pyridine, room temperature, 42% and v) TMSI, CH 3 CN, 0° C. to room temperature, 85%;  
       FIG. 11  is a schematic flow chart illustrating the step-wise synthesis of [4-(4-methoxy-phenoxymethyl)-2-(4-toluenesulfonyloxy)-phenyl]-4-toluenesulfonate (48) using a process comprising i) 4-toluenesulfonyl chloride, pyridine, room temperature, 87%, ii) NaBH 4 , EtOH, 0° C. to room temperature, 83%, iii) thionyl chloride, CH 2 Cl 2 , 45° C., 78%, and iv) 4-methoxyphenol, NaI, K 2 CO 3 , acetone, reflux, 67%;  
       FIG. 12  is a schematic flow chart illustrating the step-wise synthesis of N-[4-(4-chloro-phenylsulfanyl)-5-nitro-2-(4-toluoylamino)-phenyl]-4-toluamide (51) using a process comprising i) H 2 O/conc., H 2 SO 4 , 80° C., 88%, ii) 4-toluoyl chloride, pyridine, room temperature, 35%, and iii) 4-chlorothiophenol, NaI, K 2 CO 3 , acetone, reflux, 62%;  
       FIG. 13  is a schematic flow chart illustrating the step-wise synthesis of N-[4-(4-chloro-phenylsulfanyl)-5-nitro-2-(4-toluenesulfonyl-methyl-amino)-phenyl]-N-methyl-4-toluenesulfonamide (53) using a process comprising MeI, K 2 CO 3 , acetone, reflux, 14%;  
       FIG. 14  is a schematic flow chart illustrating the step-wise synthesis N-[2-amino-4-(4-chloro-phenylsulfanyl)-5-nitro-phenyl]-4-toluenesulfonamide (55) using a process comprising i) 4-toluenesulfonyl chloride, pyridine, 80° C., 60%, and ii) 4-chlorothiophenol, K 2 CO 3 , acetone, reflux, 43%;  
       FIG. 15  is a schematic flow chart illustrating the step-wise synthesis of N-[2-hydroxy-4-(4-methoxy-phenoxy)-phenyl]-4-toluenesulfonamide (59) using a process comprising i) N,N-diisopropylethylamine, bromomethyl methyl ether, NaI, DME, room temperature, 98%, ii) sodium dithionite, EtOH/H 2 O, reflux, iii) 4-toluenesulfonyl chloride, pyridine, room temperature, 11%, and iv) conc. HCl, ZnCl 2 , EtOH, room temperature, 99%; and  
       FIG. 16  is a schematic flow chart illustrating the synthesis of various Formula V compounds using COCl 2  or SO 2 Cl 2  to form a Formula V compound where Y 5  is C═O or SO 2  respectively and starting with a compound where X 5  is —O— and R 18  is p-(C 6 H 4 )OCH 3  as indicated in Table 6 below. 
    
    
      The compounds synthesized using the schemes illustrated in  FIGS. 1-15  and other disclosed compounds are listed by compound number in Tables 1-2 below. The compound numbers used in the tables correspond to the numbers used in the drawings.  
     DETAILED DESCRIPTION OF THE PRESENTLY PREFERRED EMBODIMENTS  
      The Src family of PTKs catalyzes the transfer of the gamma phosphate of ATP to protein substrates within the cell. The sulfonamide-based inhibitors act by blocking this transfer of the phosphate thereby inhibiting the catalytic activity of the Src family. These compounds are reversible inhibitors. By blocking the catalytic activity of the Src family, the signal-transduction pathway regulating the growth of tumor cells can be stopped or significantly impeded. The disclosed sulfonamide-based inhibitors show specificity for Src over the two other kinases tested, Csk and FGFr.  
      Definitions  
      Hematologic Disease As used herein, “hematologic disease” refers to a disease in which there is abnormal generation of blood cells.  
      Neurologic Disease As used herein, “neurologic disease” refers to a disease caused by abnormalities within the nervous system.  
      Proliferative Disease As used herein, “proliferative disease” refers to a disease that occurs due to abnormal growth or extension by the multiplication of cells (Cambridge Dictionary of Biology, 1990).  
      Autoimmune Disease As used herein, “autoimmune disease” refers to a disease caused by the presence and activation of T or B lymphocytes capable of recognizing “self” constituents with the release of auto-antibodies or damage caused to cells by cell-mediated immunity (Cambridge Dictionary of Biology, 1990).  
      Allergic/Immunological Disease As used herein, “allergic/immunological disease” refers to disease caused by one or more aspects of the immune system. Examples of included types of diseases are immunodeficiency, characterized by increased susceptibility to infections due to the deficiency of a component of the immune system (B cells, T cells, phagocytic cells, and complement); hypersensitivity disorders which result from immunologically specific interactions between antigens (exogenous or endogenous) and humoral antibodies or sensitized lymphocytes; and reactions to transplantations, in which allografts are rejected through either a cell-mediated or a humoral immune reaction of the recipient against antigens present on the membranes of the donor&#39;s cells (The Merck Manual, 1999).  
      Viral Infection As used herein, “viral infection” refers to a disease caused by the invasion of body tissue by a micro-organism that requires a cell in which to multiply (Cambridge Dictionary of Biology, 1990).  
      Src family of protein tyrosine kinases As used herein, “Src family of protein tyrosine kinases” refers to a group of intracellular non-receptor tyrosine kinases that share similar structural features and regulation such as a N terminal sequence for lipid attachment, a unique domain, SH3, SH2, and kinase domains, followed by a C-terminal negative regulatory tail (Smithgall, 1998). Any reference to the Src family or its individual members includes all alternatively spliced forms of these proteins. Examples include alternatively spliced neuronal Src and alternatively spliced forms of Fyn and Lyn. Alternatively spliced forms of Src are referred to as N x , where x indicates the size of the N-loop within the SH3 domain where alternative splicing occurs. Therefore, Src is also referred to as N 6 . Examples of alternatively spliced forms of Src include N 12  and N 23 .  
      Src family of tyrosine kinase-related disease As used herein, “Src family of tyrosine kinase-related disease” refers to any disease in which the disorder occurs due to an alteration in the activity of the Src family of tyrosine kinases, or in which it is advantageous to block the signaling pathway of a Src family member.  
      Binding As used herein, “binding” refers to the non-covalent or covalent interaction of two chemical compounds.  
      Inhibiting As used herein, “inhibiting” refers to the ability of a substance to reduce the velocity of an enzyme-catalyzed reaction (Biochemical Calculations, 1976). A substance is a better inhibitor than another if it is able to cause the same amount of reduction in velocity at a lower concentration than another substance.  
      Halogen As used herein, “halogen” refers to fluoro, chloro, bromo, or iodo.  
      Alkyl As used herein, “alkyl” refers to a group of carbon and hydrogen atoms derived from an alkane molecule by removing one hydrogen atom. “Alkyl” may include saturated monovalent hydrocarbon radicals having straight, cyclic or branched moieties. Said “alkyl” group may include an optional carbon-carbon double or triple bond where said alkyl group comprises at least two carbon atoms. It is understood that for cyclic moieties at least three carbon atoms are required in said alkyl group.  
      Aryl As used herein, “aryl” refers to an organic radical derived from an aromatic hydrocarbon by removal of one hydrogen.  
      Alkoxy As used herein, “alkoxy” refers to O-alkyl groups wherein “alkyl” is as defined above.  
      Hydrogen bond As used herein, “hydrogen bond” refers to the primarily electrostatic bond formed by interaction of a hydrogen atom covalently bound to a highly electronegative element (e.g., oxygen, nitrogen, or fluorine) and a second electronegative atom (e.g., oxygen, nitrogen, or fluorine). The bonding partners are called “hydrogen bond donor atom,” that is the atom to which hydrogen is covalently bound, and “hydrogen bond acceptor atom.” 
      Salt bridge As used herein, “salt bridge” refers to the attractive force, described by Coulomb&#39;s law, between either a cation and an anion or between a cationic and an anionic group of atoms; the cationic and anionic groups may be on the same molecule or on different molecules.  
      Heterocyclic As used herein, heterocyclic, refers to a cyclic compound in which one or more of the atoms in the ring are elements other than carbon. The atoms that are not carbon may be any possible substituent. Heterocyclic compounds may or may not be aromatic.  
      Orientation of Compounds  
      Certain disclosed compounds may exist in different enantiomeric forms. This disclosure relates to the use of all optical isomers and stereoisomers of the disclosed compounds that possess the desired activity. One of skill in the art would be aware that if a given isomer does not possess the desired activity, that isomer should not be used for treatment.  
      Pharmaceutical Compositions  
      Pharmaceutically Acceptable Carriers  
      The disclosed compositions comprise an effective amount of one or more disclosed sulfonamide-based compounds or pharmaceutically acceptable salts thereof, dissolved and/or dispersed in a pharmaceutically acceptable carrier.  
      The phrases “pharmaceutically and/or pharmacologically acceptable” refer to molecular entities and/or compositions that do not produce an adverse, allergic and/or other unacceptable reaction when administered to an animal.  
      As used herein, “pharmaceutically acceptable carrier” includes any and/or all solvents, dispersion media, coatings, antibacterial and/or antifungal agents, isotonic and/or absorption delaying agents and/or the like. The use of such media and/or agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media and/or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions. For human administration, preparations should meet sterility, pyrogenicity, general safety and/or purity standards as required by FDA Office of Biologics standards. Various pharmaceutical preparations and administration methods are discussed in U.S. Pat. No. 6,503,914 and the references cited therein.  
      Lipid Formulations and/or Nanocapsules  
      In certain embodiments, the use of lipid formulations and/or nanocapsules is contemplated for the introduction of with the disclosed sulfonamide-based compounds or pharmaceutically acceptable salts thereof into host cells as disclosed in U.S. Pat. No. 6,503,914.  
      Kits  
      Disclosed therapeutic kits comprise the disclosed sulfonamide-based compounds or pharmaceutically acceptable salts thereof. Such kits will generally contain, in suitable container means, a pharmaceutically acceptable formulation of with the disclosed sulfonamide-based compounds in a pharmaceutically acceptable formulation as disclosed in U.S. Pat. No. 6,503,914. The kit may have a single container means, and/or it may have distinct container means for each compound.  
      Combination Treatments  
      In order to increase the effectiveness of with the disclosed sulfonamide-based compounds, it may be desirable to combine these compositions with other agents effective in the treatment of the disease as disclosed in U.S. Pat. No. 6,503,914. The disclosed sulfonamide-based compounds may also be combined with other agents, treatments and/or therapies in the treatment of hematologic diseases, osteoporosis, neurological diseases, autoimmune diseases, allergic/immunological diseases, viral infections, and hyperproliferative disease. Such treatments and therapies that may be combined with the use of the disclosed compounds include chemotherapy, radiotherapy, immunotherapy, gene therapy, antisense, inducers of cellular proliferation, inhibitors or cellular proliferation, regulators of programmed cell death, surgery and other agents and treatment as discussed in U.S. Pat. No. 6,503,914, the references cited therein and the references cited herein.  
     EXAMPLES  
      The following examples are included to demonstrate preferred embodiments. It should be appreciated by those skilled in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the disclosed techniques, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the concept, spirit and scope of this disclosure. More specifically, it will be apparent that certain agents that are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of this disclosure.  
      The number in parentheses next to a compound name, either final product or intermediate, refers to the compound reference numbers used in  FIGS. 1-15  and/or Tables 1-6.  
     Examples 1 and 2  
     Synthesis Formula I Compounds (FIGS.  1  and  2 )  
     
       
         
         
             
             
         
       
     
     Example 1  
     Representative Synthesis of 4a-4u (Scheme 1; FIG.  1 )  
      4-fluoro-1,2-phenylenediamine (1): Commercially available from Lancaster Synthesis, Windham, N.H., USA:  
      N-[4-fluoro-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide (2): 1.00 g 1 (7.9 mmol) was dissolved in 2 mL anhydrous pyridine. To the solution was added 3.18 g 4-toluenesulfonyl chloride (16.67 mmol, 2.1 eq) dissolved in 7 mL anhydrous pyridine. The solution was heated at 75° C. for 18 hours and then poured into 70 mL ice cold 20% HCl. The resulting solid was collected by vacuum filtration and washed with deionized H 2 O. After air drying, the product was recrystallized from 1:9H 2 O/acetic acid to afford a brown solid. Yield=2.82 g (82%).  
      N-[4-fluoro-5-nitro-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide (3): 2.77 g 2 (6.4 mmol) was suspended in 20 mL glacial acetic acid and heated to 60° C. To the suspension was added a solution of 0.7 mL filming HNO 3  (15.95 mmol, 2.5 eq) in 1 mL glacial acetic acid. One half of the fuming HNO 3  was added in one portion, and the remainder was slowly added dropwise. After 5 minutes, a thick orange precipitate had formed. Stirring was continued one hour more at 60° C., and the solid was collected by vacuum filtration. The resulting yellow solid was washed with deionized H 2 O and air dried. Purification was completed by recrystallization from EtOH. Yield=1.11 g (36%).  
      N-[4-(2-chloro-benzylsulfanyl)-5-nitro-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide (4r): 30 mg 3 (0.063 mmol) was dissolved in 5 mL acetone, and to the solution was added 16.5 μL 2-chlorophenyl-methanethiol (0.125 mmol, 2.0 eq) and 52 mg K 2 CO 3  (0.378 mmol, 6 eq). The reaction mixture was refluxed for 4 days at which time conversion of starting material was complete. The crude reaction mixture was diluted with EtOAc/10% HCl, and the EtOAc extract was washed once more with 10% HCl and twice with deionized H 2 O. After drying over anhydrous Na 2 SO 4  and filtering the EtOAc extract was stripped to dryness and then recrystallized from CHCl 3 /hexanes to give a yellow solid. Yield=30 mg (77%).  
     Example 2  
     Representatitve Synthesis of Compound 8 (Scheme 2; FIG.  2 )  
      4-chloro-1,2-phenylenediamine (5): Commercially available from Sigma-Aldrich Chemical Company, Milwaukee, Wis., USA.  
      N-[4-chloro-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide (6): 6.00 g 5 (42.1 mmol) was dissolved in 12 mL anhydrous pyridine. To the solution was added 16.45 g 4-toluenesulfonyl chloride (16.67 mmol, 2.1 eq) dissolved in 30 mL anhydrous pyridine. The solution was heated at 75° C. for 18 hours and then poured into 200 mL ice cold 20% HCl. The resulting purplish-black solid was collected by vacuum filtration and washed with deionized H 2 O. After air drying, the product was recrystallized from 1:9H 2 O/acetic acid to afford a purplish-red solid. Yield=14.83 g (78%).  
      N-[4-chloro-5-nitro-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide (7): 3.00 g 6 (6.4 mmol) was suspended in 12 mL glacial acetic acid and heated to 70° C. To the suspension was added a solution of 0.7 mL fuming HNO 3  (15.95 mmol, 2.5 eq) in 1 mL glacial acetic acid. One half of the fuming HNO 3  was added in one portion, and the remainder was slowly added dropwise. After 5 minutes, a thick orange precipitate had formed. Stirring was continued 45 minutes more at 70° C., and the solid was collected by vacuum filtration. The resulting yellow solid was washed with deionized H 2 O and air dried. Purification was completed by recrystallization from 9:1 acetic acid:H 2 O. Yield 2.11 g (64%).  
      N-[5-nitro-4-phenyl-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide (8): 25 mg 7 (0.051 mmol) and 6 mg Pd(PPh 3 ) 4  were dissolved in 1 ml DME. To the solution was added 0.2 mL 1 M NaHCO 3  (0.20 mmol, 4 eq) and 9 mg PhB(OH) 2  (0.071 mmol, 1.4 eq). The reaction was refluxed for 21 hours, at which time reaction progress appeared to have stalled. An additional 5 mg PhB(OH) 2  (0.75 eq) and 6 mg Pd(PPh 3 ) 4  (0.1 eq) were added, and reflux was maintained for an additional 6 hours. After cooling to room temperature, the reaction was diluted with EtOAc, and the EtOAc extract was washed with 10% HCl, followed by subsequent washes with deionized H 2 O and saturated aqueous NaCl. The extract was dried over anhydrous Na 2 SO 4 , filtered, and concentrated by rotary evaporation. The resulting reddish-orange solid was recrystallized from CHCl 3 /hexanes. A light-brown solid was isolated via filtration. Yield=14 mg (51%).  
      Compounds 9a-9k were synthesized by Tripos Receptor Research, Bude, Cornwall, UK.  
     Examples 3-6  
     Synthesis of Formula II Compounds (FIGS.  3 - 6 )  
     
       
         
         
             
             
         
       
     
     Example 3  
     Representative Synthesis of 12a-12hh (Scheme 3; FIG.  3 )  
      5-chloro-2-nitroaniline (10; see  FIG. 3 ): Commercially available from Sigma-Aldrich Chemical Company, Milwaukee, Wis., USA.  
      5-(4-methoxy-phenylsulfanyl)-2-nitroaniline (11gg): 100 mg of 5-chloro-2-nitroaniline (10) (0.58 mmol) and 144 μL 4-methoxybenzenethiol (1.17 mmol, 2 eq) were dissolved in 2 mL DMSO. To the solution was added 480 mg K 2 CO 3  (3.48 mmol, 6 eq), and the suspension was heated at 130° C. for 15 hours, at which time consumption of the 5-chloro-2-nitroaniline (10) was indicated. The reaction mixture was diluted with EtOAc/deionized H 2 O, and the EtOAc extract was washed three times more with deionized H 2 O and twice with saturated aqueous NaCl. After drying over anhydrous Na 2 SO 4  and filtering, the EtOAc extract was concentrated by rotary evaporation to give a red-brown solid. Purification was completed by recrystallization from CHCl 3 /hexanes. An orange powder was obtained after filtration and further washing of the precipitate with hexanes. Yield=113 mg (71%).  
      N-[5-(4-methoxy-phenylsulfanyl)-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide (12gg): 25 mg of 5-(4-methoxy-phenylsulfanyl)-2-nitroaniline (0.091 mmol) was suspended in 3 mL EtOH/1 mL deionized H 2 O, and the suspension was heated to near boiling. To the hot suspension was added 158 mg sodium dithionite (0.91 mmol, 10 eq). The reaction mixture was refluxed for 18 hours, and then an additional 53 mg sodium dithionite (3.3 eq) was added and reflux continued. After an additional 30 minutes of reflux, the reaction mixture was cooled to room temperature and poured into excess saturated aqueous NaHCO 3  solution. The product was extracted into EtOAc, and the extract was washed once more with saturated aqueous NaHCO 3  and once with deionized H 2 O. After drying over anhydrous Na 2 SO 4  and filtering, the product was collected as a brown-black solid following rotary evaporation.  
      The crude product was mixed with 38 mg 4-toluenesulfonyl chloride (0.20 mmol, 2.2 eq) and dissolved in 1 mL anhydrous pyridine. The reaction mixture was heated at 80° C. for 18 hours and then poured into 10 mL 20% HCl. A brown solid was isolated after filtering and washing with deionized H 2 O. The solid was redissolved in 1:9 deionized H 2 O/acetic acid, and deionized H 2 O was added until precipitation occurred. A tan solid was isolated after filtering and washing with deionized H 2 O. Yield=10 mg (20%).  
      5-(4-methoxy-phenoxy)-2-nitroaniline (11p; see  FIG. 3 ): 100 mg of (0.58 mmol) and 149 mg 4-methoxyphenol (1.16 mmol, 2 eq) were dissolved in 2 mL DMSO. To the solution was added 480 mg K 2 CO 3  (3.48 mmol, 6 eq), and the suspension was heated at 130° C. for 2.5 days. The reaction mixture was then diluted with EtOAc/deionized H 2 O, and the EtOAc extract was separated and washed three times more with deionized H 2 O and twice with saturated aqueous NaCl. After drying over anhydrous Na 2 SO 4  and filtering, the EtOAc extract was concentrated by rotary evaporation to give a red-brown solid. Purification was completed recrystallization from CHCl 3 /hexanes. An orange powder was obtained after filtration and further washing of the precipitate with hexanes. Yield=46 mg (30%).  
      N-[5-(4-methoxy-phenoxy)-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide (12p): 25 mg 11p (0.091 mmol) was suspended in 3 mL EtOH/1 mL deionized H 2 O, and the suspension was heated to near boiling. To the hot suspension was added 158 mg sodium dithionite (0.91 mmol, 10 eq). The reaction mixture was refluxed for 18 hours, and then an additional 53 mg sodium dithionite (3.3 eq) was added and reflux continued. After an additional 30 minutes of reflux, the reaction mixture was cooled to room temperature and poured into excess saturated aqueous NaHCO 3 . The product was extracted into EtOAc, and the extract was washed once more with saturated aqueous NaHCO 3  and once with deionized H 2 O. After drying over anhydrous Na 2 SO 4  and filtering, the product was collected as a brown-black solid following rotary evaporation.  
      The crude product was mixed with 38 mg 4-toluenesulfonyl chloride (0.20 mmol, 2.2 eq) and dissolved in 1 mL anhydrous pyridine. The reaction mixture was heated at 80° C. for 18 hours and then poured into 10 mL 20% HCl. A brown solid was isolated after filtering and washing with deionized H 2 O. The solid was redissolved in 1:9 deionized H 2 O/acetic acid, and deionized H 2 O was added until precipitation occurred. A tan solid was isolated after filtering and washing with deionized H 2 O. Yield=10 mg (20%).  
      4-amino-3-nitrophenol (13): Commercially available from Sigma-Aldrich Chemical Company, Milwaukee, Wis., USA.  
      4-(2-chloro-benzyloxy)-2-nitroaniline (14d; see  FIG. 4 ): 75 mg of 4-amino-3-nitrophenol (13) (0.49 mmol) and 94 mg 2-chlorobenzyl chloride (0.58 mmol, 1.2 eq) were dissolved in 2 mL acetone. To the solution was added 350 mg K 2 CO 3  (2.45 mmol, 5 eq), and the reaction mixture was refluxed for 18 hours. The reaction was diluted with EtOAc, and the EtOAc solution was washed three times with deionized H 2 O. The extract was dried over anhydrous Na 2 SO 4 , filtered and reduced to dryness by rotary evaporation. The residue was recrystallized from CHCl 3 /hexanes to yield an orange solid. Yield=117 mg (86%).  
      N-[4-(2-chloro-benzyloxy)-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide (15d): 25 mg of 4-(2-chloro-benzyloxy)-2-nitroaniline (14d) (0.090 mmol) was dissolved in 3 mL EtOH/1 ml deionized H 2 O and heated to near boiling. To the hot solution was added 156 mg sodium dithionite (0.90 mmol, 10 eq), and the solution was heated to reflux. After refluxing 4 hours, an additional 80 mg sodium dithionite (5 eq) was added, and reflux was maintained for an additional four hours. After cooling to room temperature, the reaction mixture was diluted with EtOAc and washed twice with saturated aqueous NaHCO 3 . After drying over anhydrous Na 2 SO 4 , the EtOAc extract was filtered, reduced to dryness and redissolved in 1 mL anhydrous pyridine. To the pyridine solution was added 43 mg 4-toluenesulfonyl chloride (0.23 mmol, 2.5 eq), and the reaction mixture was heated at 80° C. overnight. After overnight heating, the reaction mixture was poured into 20 mL 20% HCl, and a tan solid was collected via filtration. The crude solid was redissolved in a minimum of 1:1 1 M NaOH/EtOH and filtered. The filtered solution was acidified with 20% HCl and a tan solid precipitated. The solid was collected via filtration, washed with deionized H 2 O, and air dried. Yield=21 mg (42%).  
     Example 5  
     Representative Synthesis of 17a-f (Scheme 5; FIG.  5 )  
      5-(imidazol-1-yl)-2-nitroaniline (16d; see  FIG. 5 ): 100 mg of 5-chloro-2-nitroaniline (10) (0.58 mmol), 80 mg imidazole (1.18 mmol, 2 eq), and 480 mg K 2 CO 3  (3.48 mmol, 6 eq) were mixed in 2 mL DMSO. The reaction mixture was heated at 130° C. for 2.5 days and then diluted with EtOAc/H 2 O. The EtOAc phase was washed twice with deionized H 2 O and twice with saturated aqueous NaCl solution. After drying over anhydrous Na 2 SO 4  and filtering, the extract was concentrated by rotary evaporation to give a yellow-orange solid. The crude solid was recrystallized from CHCl 3 /hexanes to provide pure product as an orange solid. Yield=45 mg (38%).  
      N-[4-(imidazol-1-yl)-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide (17d): 15 mg of 5-(imidazol-1-yl)-2-nitroaniline (16d) (0.074 mmol) was dissolved in 2 mL EtOH, and to the solution was added 5 mg Pd/C. The suspension was then shaken for 6 hours under 3 atm H 2  in a Parr shaker and thereafter filtered through Celite. The filtrate was reduced to dryness by rotary evaporation and combined with 31 mg 4-toluenesulfonyl chloride (0.16 mmol, 2.2 eq). The solids were dissolved in 1 mL pyridine, and the reaction mixture was heated at 80° C. for 18 hours. After 18 hours, the pyridine solution was poured into 10 mL 20% HCl. A yellow precipitate formed initially before rapidly redissolving. The pH of the aqueous solution was adjusted to ˜6 with 1 M NaOH, and a yellow solid precipitated. The solid was collected by filtration, washed several times with deionized H 2 O, and air dried. Yield=16 mg (42%).  
     Example 6  
     Synthesis of 21 (Scheme 6; FIG.  6 )  
      2-nitroaniline (18; see  FIG. 6 ): Commercially available from Sigma-Aldrich Chemical Company, Milwaukee, Wis., USA.  
      4-bromo-2-nitroaniline (19): 2.50 g of 2-nitroaniline (18) (18.1 mmol) and 3.94 g sodium acetate trihydrate (29.0 mmol, 1.6 eq) were dissolved in 25 mL glacial acetic acid. The solution was chilled to 0° C., and a solution of 0.95 ml Br 2  (18.6 mmol, 1.03 eq) in 2 mL acetic acid was added dropwise over 10 minutes. The reaction mixture was warmed to room temperature and then stirred for one hour. After one hour, the reaction mixture was poured into 200 mL ice cold deionized H 2 O, and a bright orange solid was collected via filtration. The crude solid was recrystallized from EtOH and air dried to provide an orange crystalline solid. Yield=2.58 g (66%).  
      4-(4-chlorophenyl)-2-nitroaniline (20): 50 mg of 4-bromo-2-nitroaniline (19) (0.23 mmol) and 27 mg Pd(PPh 3 ) 4  (0.023 mmol, 0.1 eq) were dissolved in 1 mL DME. To the solution was added 50 mg 4-chlorophenylboronic acid (0.32 mmol, 1.4 eq) and 0.92 mL 1 M NaHCO 3  (0.92 mmol, 4 eq). The reaction mixture was refluxed for four hours, cooled to room temperature, and diluted with EtOAc. The EtOAc solution was washed once with saturated NaHCO 3 , once with deionized H 2 O, and once with saturated aqueous NaCl. After drying over anhydrous Na 2 SO 4  and filtering, an orange solid was isolated by rotary evaporation. The solid was recrystallized from CHCl 3 /hexanes to give an orange powder. Yield=37 mg (65%).  
      N-[4-(4-chloro-phenyl)-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide (21): 10 mg 20 (0.040 mmol) was dissolved in 1.5 mL EtOH, and to the solution was added 2 mg Pd/C. The suspension was shaken under 3 atm H 2  in a Parr shaker for 5 hours and then filtered through Celite. The filtrate was reduced to dryness by rotary evaporation, and the crude solid was combined with 18 mg 4-toluenesulfonyl chloride (0.090 mmol, 2.2 eq). The solids were dissolved in 1 mL pyridine, and the solution was heated at 80° C. for 20 hours. After 20 hours, the reaction mixture was poured into 20 mL 10% HCl, and a light brown solid precipitated. The crude solid was redissolved in a minimum of aqueous 10% HCl/EtOH (9:1), and additional 10% HCl was added until precipitation of a tan solid was complete. The solid was isolated via filtration and washed with deionized H 2 O. Yield=5 mg (24%).  
      Compounds 22b-22nn were synthesized by Tripos Receptor Research, Bude, Cornwall, UK.  
     Examples 7-9  
     Synthesis of Formula III Compounds (FIGS.  7 - 9 )  
     
       
         
         
             
             
         
       
     
     Example 7  
     Synthesis of 23 and 24 (Scheme 7; FIG.  7 )  
      N-[5-amino-4-(4-chloro-phenylsulfanyl)-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide (23): 22 mg of N-[4-(4-chloro-phenylsulfanyl)-5-nitro-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide (4e) (0.033 mmol) was suspended in 3 mL EtOH/1.5 mL H 2 O and heated to near reflux. To the hot suspension was added 59 mg sodium dithionite (0.33 mmol, 10 eq), and within 5 minutes a homogenous solution had formed. After refluxing for 1 hour, an additional 30 mg sodium dithionite (5 eq) was added and reflux was continued for 30 minutes more. The reaction was cooled to room temperature and diluted with CH 2 Cl 2 /saturated aqueous NaCl. The CH 2 Cl 2  phase was washed twice with 10% HCl, once with saturated NaHCO 3 , and once with deionized H 2 O. The extract was dried over anhydrous Na 2 SO 4 , filtered and rotary evaporated to a light yellow solid. Yield=24 mg (&gt;100%).  
      N-[2-(4-chloro-phenylsulfanyl)-4,5-bis-(4-toluenesulfonylamino)-phenyl]-acetamide (24): 19 mg of N-[5-amino-4-(4-chloro-phenylsulfanyl)-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide (23) (0.033 mmol) and 0.4 mg 4-dimethylaminopyridine (0.0033 mmol, 0.1 eq) were dissolved in 1 mL pyridine. To the solution was added 31 μL Ac 2 O (0.33 mmol, 10 eq), and the reaction mixture was stirred overnight at room temperature. After overnight stirring, the reaction mixture was diluted with EtOAc and washed once with deionized H 2 O, three times with 10% aqueous CuSO 4 , and twice more with deionized H 2 O. The crude extract was dried over anhydrous Na 2 SO 4 , filtered, and reduced to dryness by rotary evaporation. The crude solid was recrystallized from CHCl 3 /hexanes to provide a small amount of reddish-brown solid. Yield not determined.  
     Example 8  
     Synthesis of 33 and 34 (Scheme 8; FIG.  8 )  
      3-fluoro-4-methylaniline (25): Commercially available from Sigma-Aldrich Chemical Company, Milwaukee, Wis., USA.  
      (3-fluoro-4-methyl-phenyl)-acetamide (26): 5.00 g of 3-fluoro-4-methylaniline (25) (40.0 mmol) and 500 mg 4-dimethylaminopyridine (4.0 mmol, 0.1 eq) were dissolved in 16 mL pyridine. To the solution was added 23 mL Ac 2 O (240 mmol, 6 eq). Cooling in an ice bath was necessary immediately following addition to moderate the initial rise in temperature. After the initial cooling period, the reaction was stirred at room temperature for 4 hours, and the pyridine solution was then diluted with EtOAc/H 2 O. The organic phase was washed twice more with deionized H 2 O, three times with 10% aqueous CuSO 4 , and two further times with deionized H 2 O. The extract was dried over anhydrous Na 2 SO 4 , filtered, and reduced to a white solid after rotary evaporation. Yield=6.69 g (100%).  
      (5-fluoro-4-methyl-2-nitro-phenyl)-acetamide (27): 3.00 g of (3-fluoro-4-methyl-phenyl)-acetamide (26) (18.0 mmol) was dissolved in 4 mL glacial acetic acid/7 mL Ac 2 O. The solution was chilled to −5° C., and a solution of 1.0 mL. HNO 3  in 1.5 mL Ac 2 O was added dropwise. After addition of the HNO 3  solution was completed, the reaction was maintained at 0° C. for 1 hour and then poured into 60 mL deionized H 2 O. A yellow-orange oil separated and solidifed to a yellow solid. The solid was collected by filtration, and washed once with deionized H 2 O, once with isopropanol, and twice with hexanes. The product was then chromatographed with 1:7 EtOAc/hexanes to remove residual starting material. The purified product was a yellow solid. Yield=0.84 g (22%).  
      N-(4-bromomethyl-5-fluoro-2-nitro-phenyl)-acetamide (28): 1.15 g of (5-fluoro-4-methyl-2-nitro-phenyl)-acetamide (27) (5.42 mmol), 1.07 g NBS (5.97 mmol, 1.1 eq), and 33 mg benzoyl peroxide (0.136 mmol, 0.025 eq) were dissolved in 30 mL CCl 4 . The reaction mixture was refluxed for 22 hours, cooled to room temperature, filtered through Celite, and reduced to dryness by rotary evaporation. The crude material was chromatographed with 10% EtOAc/hexanes to provide pure product as a yellow solid. Yield=0.50 g (32%).  
      N-(5-fluoro-4-formyl-2-nitro-phenyl)-acetamide (29): 0.52 g of N-(4-bromomethyl-5-fluoro-2-nitro-phenyl)-acetamide (28) (1.78 mmol) and 0.30 g hexamethylenetetramine (2.14 mmol, 1.2 eq) were dissolved in CHCl 3  and refluxed for 18 hours. After 18 hours, 30 mL glacial acetic acid was added, and reflux was continued for one hour more. The reaction mixture was cooled to room temperature and diluted with EtOAc. The combined organic solution was washed three times with 10% HCl, three times with saturated aqueous NaHCO 3 , and twice with deionizized H 2 O. After drying over anhydrous Na 2 SO 4  and filtering, the organic phase was reduced to dryness to yield a yellow solid. Yield=93 mg (23%).  
      4-acetylamino-2-fluoro-5-nitro-benzoic acid (30): 93 mg of N-(5-fluoro-4-formyl-2-nitro-phenyl)-acetamide (29) (0.41 mmol) was dissolved in 8 mL t-butanol. To the solution was added 1.1 mL 2-methyl-2-butene (10.3 mmol, 25 eq), followed by a solution of 396 mg NaH 2 PO 4 .H 2 O (2.87 mmol, 7 eq) and 371 mg NaClO 2  (4.1 mmol, 10 eq) in 4 mL H 2 O. The reaction mixture was stirred at room temperature for 2.5 days and then concentrated by rotary evaporation. After dilution with deionized H 2 O, the aqueous phase was washed twice with hexanes and then acidified with 10% HCl. The product was extracted into EtOAc, and the organic extract was washed twice with deionized H 2 O. After drying over anhydrous Na 2 SO 4  and filtering, the product was isolated by rotary evaporation to yield a tan solid. Yield=80 mg (81%).  
      Methyl 4-amino-2-fluoro-5-nitro-benzoate (31): 80 mg of 4-acetylamino-2-fluoro-5-nitro-benzoic acid (30) (0.33 mmol) was dissolved in 20 mL MeOH, and 1 mL 50% aqueous HCl was added. The reaction mixture was refluxed for 18 hours and neutralized with saturated aqueous NaHCO 3 . MeOH was removed by rotary evaporation, and the remaining aqueous solution was extracted with EtOAc. The organic extract was washed twice more with saturated aqueous NaHCO 3  and twice with deionized H 2 O. After drying over anhydrous Na 2 SO 4  and filtering, the product was isolated as a yellow solid. Yield=64 mg (90%).  
      Methyl 4-amino-2-(4-methoxy-phenoxy)-5-nitro-benzoate (32): 64 mg of methyl 4-amino-2-fluoro-5-nitro-benzoate (31) (0.30 mmol) and 74 mg 4-methoxyphenol (0.60 mmol, 2 eq) were dissolved in 10 mL acetone. To the solution was added 250 mg K 2 CO 3  (1.8 mmol, 6 eq), and the suspension was refluxed for 2 days. The reaction was cooled to room temperature and diluted with EtOAc/deionized H 2 O. The EtOAc phase was washed twice with 1 M NaOH and twice with deionized H 2 O. After drying over anhydrous Na 2 SO 4  and filtering, the product was isolated as a yellow solid after rotary evaporation. Yield=88 mg (93%).  
      Methyl 2-(4-methoxy-phenoxy)-4,5-bis-(4-toluenesulfonylamino)-benzoate (33): 44 mg of methyl 4-amino-2-(4-methoxy-phenoxy)-5-nitro-benzoate (32) (0.14 mmol) was dissolved in 5 mL EtOH/2 mL deionized H 2 O and heated to reflux. To the refluxing solution was added 240 mg sodium dithionite (1.4 mmol, 10 eq), and reflux was continued for 3 hours more. Upon consumption of the starting material, the reaction mixture was cooled to room temperature and diluted with EtOAc. The organic phase was washed twice with saturated aqueous NaHCO 3  and once with saturated aqueous NaCl solution. The extract was dried over Na 2 SO 4 , filtered, and rotary evaporated to a brown oil. The crude product was redissolved in 1 mL pyridine, and 68 mg 4-toluenesulfonyl chloride (0.35 mmol, 2.5 eq) was added. After heating at 80° C. for 2.5 days, the reaction mixture was poured into 20 mL 10% HCl. A tan solid was collected and washed with deionized H 2 O. The tan solid was redissolved in a minimum of EtOH/1 M NaOH. The solution was filtered into 20 mL 10% HCl, and a tan solid again formed. The precipitate was collected via filtration and washed with deionized H 2 O. Yield=35 mg (42%).  
      2-(4-methoxy-phenoxy)-4,5-bis-(4-toluenesulfonylamino)-benzoic acid (34): 29 mg of methyl 2-(4-methoxy-phenoxy)-4,5-bis-(4-toluenesulfonylamino)-benzoate (33) (0.049 mmol) and 27 mg KOH (0.49 mmol, 10 eq) were dissolved in 2.5 mL MeOH. The reaction mixture was refluxed for two days, at which time consumption of starting material was indicated by TLC. The reaction mixture was cooled to room temperature and diluted with EtOAc/deionized H 2 O. The aqueous phase was extracted once more with EtOAc and then was made acidic with 10% HCl. The organic extracts were discarded. The acidified aqueous solution was extracted with EtOAc, and the yellow extract was washed once with deionized H 2 O. After drying over anhydrous Na 2 SO 4  and filtering, a tan solid was obtained after solvent evaporation. The crude material was redissolved in 10 mL 1 M NaOH, and the solution was poured into 20 mL 10% HCl. A tan precipitate was isolated after filtering and washing with deionized H 2 O. Yield=18 mg (64%).  
     Example 9  
     Synthesis of 37 (Scheme 9; FIG.  9 )  
      [5-(4-methoxy-phenoxy)-4-methyl-2-nitro-phenyl)-acetamide (35): 1.50 g of (5-fluoro-4-methyl-2-nitro-phenyl)-acetamide (27) (7.1 mmol) and 1.73 g 4-methoxyphenol (14.2 mmol, 2 eq) were dissolved in 30 mL acetone. To the solution was added 7.8 g K 2 CO 3  (56.5 mmol, 8 eq), and the suspension was refluxed for 5 hours. After cooling to room temperature, the reaction mixture was diluted with EtOAc/deionized H 2 O. The EtOAc phase was successively washed twice with deionized H 2 O, twice with 1 M NaOH, once with 10% HCl, once with deionized H 2 O, and twice with saturated aqueous NaCl. After drying over anhydrous Na 2 SO 4  and filtering, a brownish-orange solid was obtained after rotary evaporation. The solid was recrystallized from CHCl 3 /hexanes, and the recrystallized product was purified further by column chromatography (15% EtOAc/hexanes, increasing to 33% EtOAc/hexanes). A final recrystallization from EtOAc/hexanes yielded a brilliant orange solid pure product after filtration. Yield=1.07 g (48%).  
      5-(4-methoxy-phenoxy)-4-methyl-2-nitro-aniline (36): 500 mg of [5-(4-methoxy-phenoxy)-4-methyl-2-nitro-phenyl)-acetamide (35) (1.58 mmol) was dissolved in 10 mL MeOH, and to the solution was added 20 mL 25% HCl (60.5 mmol, 38 eq). The combined solution was refluxed for 4 hours and then cooled to room temperature. The reaction mixture was diluted with EtOAc/deionized H 2 O, and the EtOAc phase was washed twice with saturated aqueous NaHCO 3  and once with deionized H 2 O before drying over anhydrous Na 2 SO 4 . After filtration and removal of solvent by rotary evaporation, an oily orange solid was obtained. Yield=419 mg (97%).  
      N-[4-(4-methoxy-phenoxy)-5-methyl-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide (37): 200 mg of 5-(4-methoxy-phenoxy)-4-methyl-2-nitro-aniline (36) (0.73 mmol) was dissolved in 5 mL glacial acetic acid. To the solution was added 20 mg Pd/C, and the suspension was shaken for 2 days under 3 atm H 2 . The reaction mixture was filtered through Celite, and the acetic acid was removed by rotary evaporation: Remaining traces of acetic acid were removed by rotary evaporation of the residual solid from toluene (acetic acid/toluene azeotrope) and drying under vacuum.  
      The crude brown oil from above was redissolved in 4 mL pyridine, and 350 mg 4-toluenesulfonyl chloride (1.84 mmol, 2.5 eq.) was added to the solution. The reaction mixture was heated at 80° C. for 2.5 days and then poured into 30 mL 20% HCl. A tan solid was isolated after filtering and washing with deionized H 2 O. The crude solid was chromatographed with 3:7 EtOAc/hexanes, followed by 1:1 to separate the product from a closely-eluting impurity. The product was isolated as a tan foam after rotary evaporation. Yield not determined.  
      N-[4,5-dibromo-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide (38a): Commercially available from Sigma-Aldrich Chemical Company, Milwaukee, Wis., USA.  
      Compounds 38b-38d were synthesized by Tripos Receptor Research, Bude, Cornwall, UK.  
     Examples 10-15  
     Synthesis of Formula IV Compounds (FIG.  10 - 15 )  
     
       
         
         
             
             
         
       
     
     Example 10  
     Synthesis of 42 and 43 (Scheme 10; FIG.  10 )  
      5-fluoro-2-nitrophenol (39): Commercially available from Sigma-Aldrich Chemical Company, Milwaukee, Wis., USA.  
      5-(4-methoxy-phenoxy)-2-nitrophenol (40): 400 mg of 5-fluoro-2-nitrophenol (39) (2.55 mmol) and 632 mg 4-methoxyphenol (5.1 mmol, 2 eq) were dissolved in 10 mL DMSO. To the solution was added 2.80 g K 2 CO 3  (20.4 mmol, 8 eq), and the suspension was heated at 140° C. for 3.5 hours. The reaction mixture was then cooled to room temperature and diluted with EtOAc/10% HCl. The EtOAc phase was washed three additional times with deionized H 2 O and twice with saturated aqueous NaCl. After drying over anhydrous Na 2 SO 4  and filtering, a brown oil was obtained after rotary evaporation. The product was isolated by chromatography with 10% EtOAc/hexanes. A yellow solid was obtained after removal of solvent by rotary evaporation. Yield=384 mg (58%).  
      Diethyl [5-(4-methoxy-phenoxy)-2-nitro-phenyl]-phosphate (41): 70 mg of 5-(4-methoxy-phenoxy)-2-nitrophenol (40) (0.268 mmol) was dissolved in 2 mL anhydrous toluene. To the solution was added 35 μL diethyl chlorophosphate (0.282 mmol, 1.05 eq) and 39 μL TEA (0.282 mmol, 1.05 eq). The turbid yellow solution was heated at 80° C. for 42 hours. After 42 hours, the reaction mixture was filtered through Celite, and the filtrate was diluted with EtOAc and extracted twice with saturated aqueous Na 2 CO 3 . The organic phase was subsequently washed twice with 10% HCl and twice with deionized H 2 O. Washing of the organic phase was then continued with saturated aqueous Na 2 CO 3  followed by deionized H 2 O until residual 40 was removed. After drying over anhydrous Na 2 SO 4  and filtering, the crude product was obtained as a yellow oil after rotary evaporation. Yield=83 mg (78%).  
      Diethyl [5-(4-methoxy-phenoxy)-2-(4-toluenesulfonylamino)-phenyl]-phosphate (42): 249 mg of diethyl[5-(4-methoxy-phenoxy)-2-nitro-phenyl]-phosphate (41) (0.63 mmol) was dissolved in 5 mL EtOH. To the solution was added 50 mg Pd/C. The suspension was shaken under 3 atm H 2  for 18 hours and then filtered through Celite. The filtrate was diluted with EtOAc and washed successively with saturated aqueous Na 2 CO 3 , deionized H 2 O, saturated aqueous Na 2 CO 3 , and finally three times with deionized H 2 O. After drying over anhydrous Na 2 SO 4  and filtering, the crude product was obtained as a brown oil after rotary evaporation.  
      The brown oil was redissolved in 3 mL pyridine, and 182 mg 4-toluenesulfonyl chloride (0.94 mmol, 1.5 eq) was added to the solution. The reaction mixture was stirred at room temperature for 4 days and then diluted with EtOAc/deionized H 2 O. The EtOAc phase was washed once more with deionized H 2 O, four times with 10% aqueous CuSO 4 , and twice more with deionized H 2 O. After drying over anhydrous Na 2 SO 4  and filtering, the crude product was obtained as a brown oil after rotary evaporation. The crude product was chromatographed with 1:1 EtOAc/hexanes to provide pure product as a yellow oil after rotary evaporation. Yield=168 mg (51%).  
      [5-(4-methoxy-phenoxy)-2-(4-toluenesulfonylamino)-phenyl]-phosphate (43): 45 mg of diethyl[5-(4-methoxy-phenoxy)-2-(4-toluenesulfonylamino)-phenyl]-phosphate (42) (0.086 mmol) was dissolved in 1 mL anhydrous CH 3 CN. The solution was chilled to 0° C., and 51 μL (0.36 mmol, 4.2 eq) TMSI was added to the reaction mixture, and the solution was warmed gradually to room temperature and stirred for 20 hours. After 20 hours, the reaction was quenched with MeOH and diluted with EtOAc/deionized H 2 O. The EtOAc phase was extracted twice with 0.1 M NaOH, and the aqueous phase was then immediately acidified and extracted with EtOAc. The EtOAc extract was washed once more with deionized H 2 O, dried over anhydrous Na 2 SO 4 , filtered, and reduced to dryness by rotary evaporation to provide a pale yellow solid. Yield=34 mg (85%).  
     Example 11  
     Synthesis of 48 (Scheme 11; FIG.  11 )  
      3,4-dihydroxybenzaldehyde (44): Commercially available from Sigma-Aldrich Chemical Company, Milwaukee, Wis., USA.  
      [4-formyl-2-(4-toluenesulfonyloxy)-phenyl]-4-toluenesulfonate (45): 600 mg of 3,4-dihydroxybenzaldehyde (44) (4.35 mmol) and 1.99 g 4-toluenesulfonyl chloride (10.43 mmol, 2.4 eq) were dissolved in 10 mL anhydrous pyridine. The reaction mixture was stirred at room temperature for 2.5 days and then diluted with EtOAc/deionized H 2 O. The EtOAc phase was washed successively with deionized H 2 O, saturated aqueous Na 2 CO 3 , four times with 10% aqueous CuSO 4 , once more with deionized H 2 O, once more with saturated aqueous Na 2 CO 3 , and once with deionized H 2 O. After drying over anhydrous Na 2 SO 4  and filtering, the crude product was isolated as a brown oil. The product was purified by chromatography with 1:3 EtOAc/hexanes to yield an oily yellow solid after removal of solvent by rotary evaporation. Yield=1.68 g (87%).  
      [4-hydroxymethyl-2-(4-toluenesulfonyloxy)-phenyl]-4-toluenesulfonate (46): 200 mg of [4-formyl-2-(4-toluenesulfonyloxy)-phenyl]-4-toluenesulfonate (45) (0.45 mmol) was dissolved in 8 mL EtOH. The solution was chilled to 0° C., and 21 mg NaBH 4  (0.54 mmol, 1.2 eq) was added to the reaction mixture. The reaction was stirred at 0° C. for 1 hour and then warmed to room temperature and stirred for 17 hours. The reaction was then diluted with EtOAc/deionized H 2 O, and the organic phase was washed twice more with deionized H 2 O and dried over anhydrous Na 2 SO 4 . After filtration, the crude product was isolated as a colorless oil after rotary evaporation. The crude product was chromatographed with 40% EtOAc/hexanes to afford pure product as a colorless oil. Yield=167 mg (83%).  
      [4-chloromethyl-2-(4-toluenesulfonyloxy)-phenyl]-4-toluenesulfonate (47): 44 mg of [4-hydroxymethyl-2-(4-toluenesulfonyloxy)-phenyl]-4-toluenesulfonate (46) (0.098 mmol) was dissolved in 3 mL CH 2 Cl 2 , and 57 μL thionyl chloride (0.78 mmol, 8 eq) was added to the solution. The reaction mixture was heated at 45° C. for 24 hours and then cooled to room temperature. After cooling to room temperature, the reaction mixture was diluted with EtOAc and washed twice with saturated aqueous Na 2 CO 3  and once with deionized H 2 O. After drying over anhydrous Na 2 SO 4  and filtering, the solvent was removed by rotary evaporation. The crude product was chromatographed with 20% EtOAc/hexanes to afford pure product as a pale yellow oil. Yield=36 mg (78%).  
      [4-(4-methoxy-phenoxymethyl)-2-(4-toluenesulfonyloxy)-phenyl]-4-toluenesulfonate (48): 56 mg of [4-chloromethyl-2-(4-toluenesulfonyloxy)-phenyl]-4-toluenesulfonate (47) (0.12 mmol) and 18 mg 4-methoxyphenol (0.14 mmol, 1.2 eq) were dissolved in 2 mL acetone. To the solution was added 5 mg NaI (0.03 mmol, 0.25 eq) and 99 mg K 2 CO 3  (0.72 mmol, 6 eq), and the reaction mixture was refluxed for 25 hours. After 25 hours, the reaction was cooled to room temperature and diluted with EtOAc/deionized H 2 O. The organic phase was washed once with 1 M NaOH and once with deionized H 2 O. After drying over anhydrous Na 2 SO 4  and filtering, a yellow-green oil was obtained following rotary evaporation. The crude product was chromatographed with 1:3 EtOAc/hexanes to afford pure product as a white solid. Yield=45 mg (67%).  
     Example 12  
     Representative Synthesis of 51 and 52 (Scheme 12; FIG.  12 )  
      4-fluoro-5-nitro-1,2-phenylenediamine (49): 158 mg of N-[4-fluoro-5-nitro-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide (3) (0.33 mmol) was suspended in a solution of 35 μL deionized H 2 O/360 μL concentrated H 2 SO 4 , and the suspension was heated at 80° C. for one hour. After one hour, the reaction mixture was poured into 10 mL deionized H 2 O, and a yellow solid precipitated. The aqueous suspension was heated to boiling to redissolve the solids and then cooled to room temperature. After adjusting the solution pH to ˜9 with concentrated NH 4 OH, an orange solid precipitated. The solid was isolated by filtration, washed with deionized H 2 O, and air dried. Yield=49 mg (88%).  
      N-[4-fluoro-5-nitro-2-(4-toluoylamino)-phenyl]-4-toluamide (50): 40 mg of 4-fluoro-5-nitro-1,2-phenylenediamine (49) (0.23 mmol) was dissolved in 1 mL anhydrous pyridine, and to the solution was added 70 μL 4-toluoyl chloride (0.53 mmol, 2.25 eq). The solution was stirred for 19 hours at room temperature and then poured into 20 mL 0.25 M NaOH. An orange solid was isolated by filtration and subsequently recrystallized from EtOH. Pure product was isolated by filtration after chilling in ice. Yield=33 mg (35%).  
      N-[4-(4-chloro-phenylsulfanyl)-5-nitro-2-(4-toluoylamino)-phenyl]-4-toluamide (51): 10 mg of N-[4-fluoro-5-nitro-2-(4-toluoylamino)-phenyl]-4-toluamide (50) (0.025 mmol) and 7 mg 4-chlorothiophenol (0.049 mmol, 2 eq) were dissolved in 5 mL acetone. To the suspension was added 23 mg K 2 CO 3  (0.17 mmol, 6.7 eq), and the suspension was refluxed for 26 hours. The reaction mixture was then diluted with EtOAc/deionized H 2 O, and the organic phase was washed once with 10% HCl and twice with deionized H 2 O. After drying over anhydrous Na 2 SO 4  and filtering, the solvent was removed by rotary evaporation. The crude product was recrystallized from CHCl 3 /hexanes to afford a yellow-green solid after filtration. Yield=8 mg (62%).  
     Example 13  
     Synthesis of 53 (Scheme 13; FIG.  13 )  
      N-[4-(4-chloro-phenylsulfanyl)-5-nitro-2-(4-toluenesulfonyl-methyl-amino)-phenyl]-N-methyl-4-toluenesulfonamide (53): 20 mg of N-[4-(4-chloro-benzylsulfanyl)-5-nitro-2-(4-toluenesulfonylamino)-phenyl]-4-toluenesulfonamide (4q) (0.033 mmol) and 40 μL MeI (0.663 mmol, 20 eq) were dissolved in 4 mL acetone. To the solution was added 46 mg K 2 CO 3  (0.33 mmol, 10 eq), and the resulting suspension was refluxed for 48 hours. After cooling to room temperature, the reaction was diluted with EtOAc/10% HCl. The organic phase was washed twice with 10% HCl and twice with deionized H 2 O. There was a substantial amount of yellow solid that was insoluble in either phase that was removed by filtration subsequent to drying. The EtOAc phase was dried over anhydrous Na 2 SO 4 , filtered, and rotary evaporated to a yellow solid. After recrystallization from CHCl 3 /hexanes, a small quantity of yellow solid was collected and washed with hexanes. Yield=3 mg (14%).  
     Example 14  
     Representative Synthesis of 55 and 56 (Scheme 14; FIG.  14 )  
      N-(2-amino-4-fluoro-5-nitro-phenyl)-4-toluenesulfonamide (54): 21 mg of 4-fluoro-5-nitro-1,2-phenylenediamine (49) (0.23 mmol) and 31.5 mg 4-toluenesulfonyl chloride (0.16 mmol, 1.3 eq) were dissolved in 1 mL pyridine, and the solution was heated at 80° C. After 18 hours heating, the hot reaction mixture was poured into 10 mL 20% HCl to produce a brown precipitate. After recrystallization from 1:9H 2 O/AcOH, a tan solid was isolated after filtration. Yield=25 mg (60%).  
      N-[2-amino-4-(4-chloro-phenylsulfanyl)-5-nitro-phenyl]-4-toluenesulfonamide (55): 15 mg of N-(2-amino-4-fluoro-5-nitro-phenyl)-4-toluenesulfonamide (54) (0.046 mmol) and 13 mg 4-chlorothiophenol (0.092, 2 eq) were dissolved in 5 mL acetone. To the solution was added 37 mg K 2 CO 3  (0.27 mmol, 5.8 eq), and the suspension was refluxed for 23 hours. After cooling to room temperature, the reaction mixture was diluted with EtOAc/deionized H 2 O. The organic phase was washed twice more with deionized H 2 O, dried over anhydrous Na 2 SO 4 , and filtered. After recrystallization from CHCl 3 /hexanes and filtration, the product was obtained as a tan solid. Yield=9 mg (43%).  
     Example 15  
     Representative Synthesis of 59-65 (Scheme 15; FIG.  15 )  
      2-methoxymethoxy-4-(4-methoxy-phenoxy)-1-nitro-benzene (57): 120 mg of 5-(4-methoxy-phenoxy)-2-nitrophenol (40) (0.46 mmol) and 190 mg NaI (1.27 mmol, 2.75 eq) were dissolved in 5 mL anhydrous DME. To the solution was added 140 μL N,N-diisopropylethylamine (0.80 mmol, 1.75 eq) and 50 μL bromomethyl methyl ether (0.58 mmol, 1.26 eq). The reaction mixture was stirred at room temperature for 2 hours and then diluted with EtOAc/deionized H 2 O. The organic phase was washed twice successively with saturated aqueous Na 2 CO 3  followed by deionized H 2 O. After drying over anhydrous Na 2 SO 4  and filtering, the product was obtained as a yellow solid following rotary evaporation. Yield=137 mg (98%).  
      N-[2-methoxymethoxy-4-(4-methoxy-phenoxy)-phenyl]-4-toluenesulfonamide (58): 137 mg of 2-methoxymethoxy-4-(4-methoxy-phenoxy)-1-nitro-benzene (57) (0.45 mmol) was suspended in 4 mL EtOH/2 mL deionized H 2 O. The suspension was heated to near boiling, and 782 mg sodium dithionite (4.5 mmol, 10 eq) was added in small portions. The reaction mixture was heated at reflux for 2 hours, and 300 mg fresh sodium dithionite (4 eq) was added. An additional 200 mg fresh sodium dithionite (2.5 eq) was added one hour later, and reflux was continued for 18 hours. After 18 hours, the reaction was cooled to room temperature and diluted with EtOAc. The EtOAc solution was washed twice with saturated aqueous NaHCO 3 , dried over anhydrous Na 2 SO 4 , filtered, and rotary evaporated to dryness.  
      The crude reduction product and 108 mg 4-toluenesulfonyl chloride were dissolved in 2 mL pyridine, and the reaction mixture was stirred at room temperature for 2.5 days. The reaction mixture was diluted with EtOAc and washed with deionized water, and the organic phase was then washed 4 times with 10% aqueous CuSO 4 , and twice more with deionized H 2 O. After drying over anhydrous Na 2 SO 4  and filtering, the crude product was obtained as a brown oil following rotary evaporation. Purification of the product was completed by column chromatography with 1:3 EtOAc/hexanes. Yield=22 mg (11%).  
      N-[2-hydroxy-4-(4-methoxy-phenoxy)-phenyl]-4-toluenesulfonamide (59): 22 mg of N-[2-methoxymethoxy-4-(4-methoxy-phenoxy)-phenyl]-4-toluenesulfonamide (58) (0.051 mmol) was dissolved in 5 mL EtOH. To the yellow solution was added 0.5 mL concentrated HCl (excess), and 15 mg ZnCl 2  (0.11 mmol, 2.2 eq). The reaction was stirred at room temperature for 24 hours, and then diluted with EtOAc/deionized H 2 O. The organic phase was washed once more with deionized H 2 O and twice with saturated aqueous NaHCO 3 . After drying over anhydrous Na 2 SO 4  and filtering, the solvent was removed by rotary evaporation. Purification of the product was completed via column chromatography with 20% EtOAc/hexanes, followed by 33% EtOAc/hexanes, to provide the product as a white solid. Yield=17 mg (99%).  
      Compounds 71a-71nn were synthesized by Tripos Receptor Research, Bude, Cornwall, UK.  
     Example 16  
     (Hypothetical): Synthesis of Formula V Compounds (FIG.  16 )  
      As shown in  FIG. 16 , Formula V compounds can be synthesized using COCl 2  or SO 2 Cl 2  to form a Formula V compound where Y 5  is C═O or SO 2  respectively. While the scheme illustrated in  FIG. 16  starts with a compound where X 5  is —O— and R 18  is p-(C 6 H 4 )OCH 3  as indicated in Table 6 below, the starting compound may be synthesized by one skilled in the art from compound 11p (Example 3,  FIG. 3 ) or from compound 40 (Example 15,  FIG. 15 ).  
      A listing of compounds that can be synthesized using schemes 1-15 as illustrated in Examples 1-15 and  FIGS. 1-15  is provided in Table 1 below.  
                               TABLE 1                                       Purity       #   1H NMR   Name   MS   by HPLC                   2   (300MHz, acetone-d6): 7.91(d,   N-[4-fluoro-5-nitro-2-(4-   ND   ND           J=8.2Hz, 2H), 7.59(d, J=8.4Hz,   toluenesulfonylamino)-           2H), 7.39-7.48(m,   phenyl]-4-           6H), 2.43(m, 6H)   toluenesulfonamide        4a   (300MHz, acetone-d6):   N-[4-(4-methoxy-   M−1=598(ESI−)   &gt;94%           7.59-7.66(m, 3H), 7.47(d, J=6Hz,   phenylsulfanyl)-5-nitro-2-(4-           2H), 7.36-7.42(m,   toluenesulfonylamino)-           6H), 7.23(d, J=6Hz, 2H),   phenyl]-4-           6.90(s, 1H, 3.93(s, 3H), 2.45(s,   toluenesulfonamide           3H), 2.43(s, 3H)        4b   (300MHz, acetone-d6): 7.76(dt,   N-[4-(2-methoxy-   M−1=598(ESI−)   &gt;79%           J=7.5Hz, J′=2Hz, 1   phenylsulfanyl)-5-nitro-2-(4-           H), 7.56-7.63(m, 3H), 7.53(dd,   toluenesulfonylamino)-           J=7.5Hz, J′=2Hz,   phenyl]-4-           1H), 7.37-7.47(m, 3H), 7.21-7.39(m,   toluenesulfonamide           5H), 6.90(s, 1H),           3.82(s, 3H), 2.40(m, 6H)        4c   (300MHz, acetone-d6):   N-[4-(3-methoxy-   M−1=598(ESI−)   &gt;90%           7.56-7.65(m, 4H), 7.33-7.47(m,   phenylsulfanyl)-5-nitro-2-(4-           6H), 7.28(dd, J=7.5Hz,   toluenesulfonylamino)-           J′=2Hz, 1H), 7.13(m, 2H),   phenyl]-4-           6.97(s, 1H), 3.92(s, 3H),   toluenesulfonamide           2.42(s, 6H)        4d   (300MHz, acetone-d6):   N-[4-(4-hydroxy-   M−1=584(ESI−)   &lt;70%           7.57-7.68(m, 3H), 7.34-7.46(m,   phenylsulfanyl)-5-nitro-2-(4-           8H), 7.12(d, J=9Hz,   toluenesulfonylamino)-           2H), 6.92(s, 1H), 2.41(m,   phenyl]-4-           6H)   toluenesulfonamide        4e   (300MHz, acetone-d6):   N-[4-(4-chloro-   M−1=602(ESI−)   &gt;97%           7.67-7.73(m, 3H), 7.64(d, J=9Hz,   phenylsulfanyl)-5-nitro-2-(4-           2H), 7.56(d, J=9Hz,   toluenesulfonylamino)-           2H), 7.36-7.43(m, 6H),   phenyl]-4-           6.84(s, 1H), 2.41(m, 6H)   toluenesulfonamide        4f   (300MHz, acetone-d6):   N-[4-(2-chloro-   M−1=602(ESI−)   &gt;96%           7.72-7.82(m, 4H), 7.60-7.68(m,   phenylsulfanyl)-5-nitro-2-(4-           3H), 7.31-7.42(m, 6H),   toluenesulfonylamino)-           6.78(s, 1H), 2.38-2.44(m,   phenyl]-4-           6H)   toluenesulfonamide        4g   (300MHz, acetone-d6): 7.88(d,   N-[4-(3-chloro-   M−1=602(ESI−)   &gt;90%           J=9Hz, 1H), 7.53-7.78(m,   phenylsulfanyl)-5-nitro-2-(4-           6H), 7.35-7.47(m, 6H),   toluenesulfonylamino)-           6.90(s, 1H), 2.40(m, 6H)   phenyl]-4-               toluenesulfonamide        4h   (300MHz, acetone-d6): 7.67(s,   N-[4-(4-fluoro-   M−1=586(ESI−)   &gt;98%           1H), 7.59-7.66(m, 4H),   phenylsulfanyl)-5-nitro-2-(4-           7.36-7.50(m, 8H), 6.84(s,   toluenesulfonylamino)-           1H), 2.42(m, 6H)   phenyl]-4-               toluenesulfonamide        4i   (300MHz, acetone-d6):   N-[5-nitro-2-(4-   M−1=582(ESI−)   &gt;89%           7.59-7.67(m, 3H), 7.52(d, J=9Hz,   toluenesulfonylamino)-4-(p-           2H), 7.34-7.48(m, 8H),   tolylsulfanyl)-phenyl]-4-           6.89(s, 1H), 2.53(s, 3H),   toluenesulfonamide           2.41(m, 6H)        4j   (300MHz, acetone-d6): 7.71(s,   N-[5-nitro-2-(4-   M−1=582(ESI−)   &gt;97%           1H), 7.47-7.67(m, 6H),   toluenesulfonylamino)-4-(o-           7.34-7.43(m, 4H), 7.30(d, J=9Hz,   tolylsulfanyl)-phenyl]-4-           2H), 6.74(s, 1H)   toluenesulfonamide        4k   (300MHz, acetone-d6):   N-[5-nitro-2-(4-   M−1=582(ESI−)   &gt;89%           7.51-7.64(m, 4H), 7.32-7.49(m,   toluenesulfonylamino)-4-(m-           9H), 7.00(s, 1H), 2.48(s,   tolylsulfanyl)-phenyl]-4-           3H), 2.41(s, 6H)   toluenesulfonamide        4l   (300MHz, acetone-d6): 7.69(s,   N-[4-(2,4-dimethyl-   M−1=596(ESI−)   &gt;97%           1H), 7.62(d, J=7.5Hz,   phenylsulfanyl)-5-nitro-2-(4-           2H), 7.28-7.43(m, 9H), 6.74(s,   toluenesulfonylamino)-           1H), 2.50(s, 1H), 2.43(m,   phenyl]-4-           6H), 2.20(s, 3H)   toluenesulfonamide        4m   (300MHz, acetone-d6): 7.74(s,   N-[4-(2,6-dimethyl-   M−1=596(ESI−)   &gt;97%           1H), 7.63(d, J=7.5Hz,   phenylsulfanyl)-5-nitro-2-(4-           2H), 7.27-7.53(m, 8H), 6.67(s,   toluenesulfonylamino)-           1H), 2.43(m, 6H), 2.27(s,   phenyl]-4-           6H)   toluenesulfonamide        4n   (300MHz, acetone-d6):   N-[4-(2-isopropyl-   M−1=610(ESI−)   &gt;90%           7.26-7.76(m, 13H), 6.83(s,   phenylsulfanyl)-5-nitro-2-(4-           1H), 3.35(septet, J=6Hz,   toluenesulfonylamino)-           1H), 2.44(s, 6H), 1.16(d, J=6Hz,   phenyl]-4-           6H)   toluenesulfonamide        4o   (300MHz, acetone-d6):   N-[5-nitro-4-phenylsulfanyl-   M−1=568(ESI−)   &gt;97%           7.54-7.63(m, 8H), 7.31-7.44(m,   2-(4-toluenesulfonylamino)-           6H), 6.91(s, 1H), 2.44(m,   phenyl]-4-           6H)   toluenesulfonamide        4p   (300MHz, acetone-d6): 7.82(d,   N-[4-(furan-2-   M−1=572(ESI−)   &gt;81%           J=9Hz, 2H), 7.66(d, J=7.5Hz,   ylmethylsulfanyl)-5-nitro-2-           2H), 7.62(s, 1H),   (4-toluenesulfonylamino)-           7.54-7.58(m, 2H), 7.37-7.47(m,   phenyl]-4-           4H), 6.40-6.45(m, 2H),   toluenesulfonamide           4.15(s, 2H), 2.42(s, 6H)        4q   (300MHz, acetone-d6): 7.78(d,   N-[4-(4-chloro-   M−1=616(ESI−)   &gt;97%           J=9Hz, 2H), 7.66(s,   benzylsulfanyl)-5-nitro-2-(4-           1H), 7.62(d, J=9Hz, 2H),   toluenesulfonylamino)-           7.38-7.53(m, 9H), 4.12(s,   phenyl]-4-           2H), 2.41(s, 6H)   toluenesulfonamide        4r   (300MHz, acetone-d6): 7.84(d,   N-[4-(2-chloro-   M−1=616(ESI−)   &gt;86%           J=7.5Hz, 2H), 7.70(s,   benzylsulfanyl)-5-nitro-2-(4-           1H), 7.51-7.60(m, 2H), 7.36-7.48(m,   toluenesulfonylamino)-           7H), 4.21(s, 2H),   phenyl]-4-           2.42(s, 6H)   toluenesulfonamide        4s   (300MHz, acetone-d6): 7.82(d,   N-[4-(4-methoxy-   M−1=612(ESI−)   &gt;95%           J=7.5Hz, 2H), 7.60-7.66(m,   benzylsulfanyl)-5-nitro-2-(4-           3H), 7.53(s, 1H), 7.34-7.47(m,   toluenesulfonylamino)-           6H), 6.95(d, J=7.5Hz,   phenyl]-4-           2H), 4.08(s, 2H), 3.81(s,   toluenesulfonamide           3H), 2.42(s, 6H)        4t   (300MHz, acetone-d6): 7.81(d,   N-[4-benzylsulfanyl-5-nitro-   M+1=584   &gt;94%           J=9Hz, 2H), 7.66(s,   2-(4-toluenesulfonylamino)-   (ESI+)           1H), 7.64(d, J=9Hz, 2H),   phenyl]-4-           7.55(s, 1H), 7.34-7.49(m,   toluenesulfonamide           9H), 4.11(s, 1H), 2.45(s, 6H)        4u   (300MHz, acetone-d6): 8.45(s,   N-[5-(4-chloro-   M−1=450(ESI−)   &gt;81%           1H), 7.71(d, J=9Hz,   phenylsulfanyl)-2-           2H), 7.63(d, J=9Hz, 2H),   methanesulfonylamino-4-           7.22(s, 1H), 3.20(s, 3H),   nitro-phenyl]-           3.01(s, 3H)   methanesulfonamide        6   (300MHz, acetone-d6): 7.82(d,   N-[4-chloro-5-nitro-2-(4-   M−1=494(ESI−)   &gt;99%           J=9Hz, 2H), 7.64(d, J=9Hz,   toluenesulfonylamino)-           2H), 7.57(s, 1H), 7.53(s,   phenyl]-4-           1H), 7.45(d, J=9Hz,   toluenesulfonamide           2H), 7.42(d, J=9Hz, 2H),           2.41(s, 6H)        8   (300MHz, acetone-d6): 7.73(m,   N-[5-nitro-4-phenyl-2-(4-   M−1=536(ESI−)   &gt;91%           4H), 7.63(s, 1H), 7.37-7.47(m,   toluenesulfonylamino)-           7H), 7.17(s, 1H),   phenyl]-4-           7.08-7.14(m, 2H), 2.43(s,   toluenesulfonamide           6H)        9a   RR   N-[4-(morpholin-4-yl)-5-nitro-   RR   RR               2-(4-toluenesulfonylamino)-               phenyl]-4-               toluenesulfonamide        9b   RR   N-[4-(4-methyl-piperazin-1-   RR   RR               yl)-5-nitro-2-(4-               toluenesulfonylamino)-               phenyl]-4-               toluenesulfonamide        9c   RR   N-[5-nitro-4-(thiomorpholin-   RR   RR               4-yl)-2-(4-               toluenesulfonylamino)-               phenyl]-4-               toluenesulfonamide        9d   RR   N-[5-nitro-4-[(pyridin-3-   RR   RR               ylmethyl)-amino]-2-(4-               toluenesulfonylamino)-               phenyl]-4-               toluenesulfonamide        9e   RR   N-[5-nitro-4-[(pyridin-2-   RR   RR               ylmethyl)-amino]-2-(4-               toluenesulfonylamino)-               phenyl]-4-               toluenesulfonamide        9f   RR   N-[4-(4-methoxy-   RR   RR               benzylamino)-5-nitro-2-(4-               toluenesulfonylamino)-               phenyl]-4-               toluenesulfonamide        9g   RR   N-[4-(2-chloro-benzylamino)-   RR   RR               5-nitro-2-(4-               toluenesulfonylamino)-               phenyl]-4-               toluenesulfonamide        9h   RR   N-[4-(cyclohexylmethyl-   RR   RR               amino)-5-nitro-2-(4-               toluenesulfonylamino)-               phenyl]-4-               toluenesulfonamide        9i   RR   N-[4-(1-hydroxy-   RR   RR               cyclohexylmethyl-amino)-5-               nitro-2-(4-               toluenesulfonylamino)-               phenyl]-4-               toluenesulfonamide        9j   RR   N-[4-cyclohexylamino-5-   RR   RR               nitro-2-(4-               toluenesulfonylamino)-               phenyl]-4-               toluenesulfonamide        9k   RR   N-[4-[3-(5-methyl-1H-   RR   RR               pyrazol-4-yl)-propylamino]-5-               nitro-2-(4-               toluenesulfonylamino)-               phenyl]-4-               toluenesulfonamide        2   (300MHz, acetone-d6): 7.73(d,   N-[4-fluoro-2-(4-   ND   &gt;86%           J=8Hz, 2H), 7.55(d, J=8Hz,   toluenesulfonylamino)-           2H), 7.33-7.41(m, 4H),   phenyl]-4-           7.05(dd, J=9.9Hz, J′=2.7Hz,   toluenesulfonamide           1H), 6.73-6.86(m, 2H),           2.41(m, 6H)        6   (300MHz, acetone-d6): 8.55(br s,   N-[4-chloro-2-(4-   ND   &gt;95%           2H), 7.67(d, J=8Hz,   toluenesulfonylamino)-           2H), 7.60(d, J=8Hz, 2H),   phenyl]-4-           7.32-7.44(m, 4H), 7.17(d, J=2.5Hz,   toluenesulfonamide           1H), 7.07(dd, J=7Hz,           J′=2.5Hz, 1H), 6.97(d,           J=7Hz, 1H), 2.41(s, 6H)       12a   (300MHz, acetone-d6): 8.40(br s,   4-ethyl-N-[2-(4-ethyl-   M−1=565(ESI−)   &lt;70%           2H), 7.58-7.66(m, 4H),   benzenesulfonylamino)-4-(4-           7.34-7.41(m, 4H), 6.95(d, J=7.5Hz,   methoxy-phenoxy)-phenyl]-           2H), 6.79-6.88(m,   benzenesulfonamide           3H), 6.68(d, J=4Hz, 1H),           6.56(dd, J=9Hz, J′=4Hz,           1H), 3.80(s, 3H), 2.63-2.80(m,           4H), 1.20-1.35(m, 6H)       12b   (300MHz, acetone-d6): 8.46(br s,   4-isopropyl-N-[2-(4-   ND   &gt;75%           2H), 7.57-7.68(m, 4H),   isopropyl-           7.38-7.46(m, 4H), 6.98(d, J=7.5Hz,   benzenesulfonylamino)-4-(4-           2H), 6.88(d, J=7.5Hz,   methoxy-phenoxy)-phenyl]-           2H), 6.83(s, 1H), 6.73(d,   benzenesulfonamide           J=4Hz, 1H), 6.55(dd, J=7.5Hz,           J′=4Hz, 1H), 3.84(s,           3H), 3.01(septet, J=6Hz,           2H), 1.24-1.33(m, 12H)       12c   (300MHz, acetone-d6): 8.63(br s,   4-chloro-N-[2-(4-chloro-   M−1=577(ESI−)   &gt;74%           2H), 7.71(d, J=7.5Hz,   benzenesulfonylamino)-4-(4-           4H), 7.56-7.63(m, 4H), 6.94-6.99(m,   methoxy-phenoxy)-phenyl]-           3H), 6.87(d, J=7.5Hz,   benzenesulfonamide           2H), 6.71(dd, J=7.5Hz,           J′=3Hz, 1H), 6.57(d, J=3Hz,           1H), 3.83(s, 3H)       12d   (300MHz, acetone-d6): 8.47(br s,   4-fluoro-N-[2-(4-fluoro-   M−1=545(ESI−)   &lt;70%           2H), 8.69-8.80(m, 4H),   benzenesulfonylamino)-4-(4-           7.26-7.37(m, 4H), 6.85-6.99(m,   methoxy-phenoxy)-phenyl]-           5H), 6.70(dd, J=6Hz, J′=2Hz,   benzenesulfonamide           1H), 6.62(d, J=2Hz,           1H), 3.81(s, 3H)       12e   (300MHz, acetone-d6): 8.46(br s,   N-[4-(4-methoxy-phenoxy)-   M−1=693(ESI−)   &lt;70%           2H), 7.66-7.74(m, 4H),   2-(4-phenoxy-           7.46-7.53(m, 4H), 7.22-7.32(m,   benzenesulfonylamino)-           2H), 7.02-7.17(m, 8H),   phenyl]-4-phenoxy           6.88-6.98(m, 5H), 6.74-6.72(m,   benzenesulfonamide           2H), 3.81(s, 3H)       12f   (300MHz, acetone-d6):   N-[4-(4-methoxy-phenoxy)-   M−1=599(ESI−)   &gt;93%           8.39-8.56(m, 4H), 8.10(d, J=6Hz,   2-(3-nitro-           2H), 7.39(t, J=6Hz,   benzenesulfonylamino)-           2H), 6.99(d, J=7.5Hz, 1H),   phenyl]-3-nitro-           6.94(d, J=7.5Hz, 2H), 6.84(d,   benzenesulfonamide           J=7.5Hz, 2H), 6.71(dd,           J=7.5Hz, J′=3Hz, 1H),           6.58(d, J=3Hz, 1H), 3.83(s,           3H)       12g   (300MHz, acetone-d6): 8.30(br s,   N-[4-(4-methoxy-phenoxy)-   M−1=537(ESI−)   &gt;77%           2H), 7.30-7.47(br m,   2-           10H), 6.98-7.15(br m, 6H),   phenylmethanesulfonylamino-           6.72(br m, 1H), 4.51(s, 4H),   phenyl]-C-phenyl-           3.83(s, 3H)   methanesulfonamide       12h   (300MHz, acetone-d6):   naphthalene-1-sulfonic acid   M+1=611   &gt;87%           8.59-8.79(m, 4H), 8.19-8.28(m,   [4-(4-methoxy-phenoxy)-2-   (ESI+)           2H), 7.97-8.12(m, 4H),   (naphthalen-1-yl-           7.64-7.74(m, 4H), 7.49-7.56(m,   sulfonylamino)-phenyl]-           2H), 6.87(d, J=8Hz,   amide           2H),(6.61(d, J=8Hz, 2H),           6.55(d, J=7.5Hz, 1H), 6.31-6.38(m,           2H), 3.80(s, 3H),       12i   (300MHz, acetone-d6):   naphthalene-2-sulfonic acid   M−1=609(ESI−)   &gt;89%           8.51-8.62(m, 2H), 8.28(d, J=9Hz,   [4-(4-methoxy-phenoxy)-2-           2H), 7.94-8.12(m,   (naphthalen-2-yl-           6H), 7.62-7.82(m, 6H), 6.95(d,   sulfonylamino)-phenyl]-           J=6Hz, 1H), 6.49-6.77(m,   amide           6H)       12j   (300MHz, acetone-d6): 9.62(s,   N-[2-(4-acetamido-   M−1=623(ESI−)   &gt;97%           1H), 9.57.(s, 1H), 8.37(s,   benzenesulfonylamino)-4-(4-           1H), 8.34(s, 1H), 7.74-7.81(m,   methoxy-phenoxy)-phenyl]-           4H), 7.59(d, J=9Hz,   4-acetamido-           4H), 6.92-6.97(m, 3H), 6.83(d,   benzenesulfonamide           J=9Hz, 2H), 6.60-6.66(m,           2H), 3.81(s, 3H), 2.17(s,           3H), 2.12(s, 3H)       12k   (300MHz, acetone-d6): 8.32(s,   N-[2-(4-methoxy-   M−1=569(ESI−)   &gt;82%           2H), 7.59-7.66(m, 4H),   benzenesulfonylamino)-4-(4-           7.02-7.08(m, 4H), 6.95(d, J=9Hz,   methoxy-phenoxy)-phenyl]-           2H), 6.82-6.92(m,   4-methoxy-           3H), 6.58-6.64(m, 2H), 3.91(s,   benzenesulfonamide           3H), 3.88(s, 3H), 3.82(s,           3H)       12l   (300MHz, acetone-d6): 8.28(s,   butane-1-sulfonic acid [2-   M−1=469(ESI−)   ND           2H), 7.44(d, J=8Hz,   (butane-1-sulfonylamino)-4-           1H), 7.16(d, J=2.8Hz, 1H),   (4-methoxy-phenoxy)-           7.07(d, J=9Hz, 2H), 7.00(d,   phenyl]-amide           J=9Hz, 2H), 6.79(dd, J=7.5Hz,           J′=2.8Hz, 1H),           3.83(s, 3H), 3.10-3.20(m,           4H), 1/73-1.90(m, 4H), 1.40-1.54(m,           4H), 0.87-1.02(m,           6H)       12m   (300MHz, aceteone-d6):   N-[2-(3,4-dimethoxy-   M−1=629(ESI−)   &gt;95%           8.32(br s, 2H), 7.18-7.28(m,   benzenesulfonylamino)-4-(4-           3H), 7.14(d, J=1.9Hz, 1H),   methoxy-phenoxy)-phenyl]-           6.90-7.05(m, 5H), 6.79(d, J=8Hz,   3,4-dimethoxy-           2H), 6.66(dd, J=8Hz,   benzenesulfonamide           J′=2.5Hz, 1H), 6.53(d,           J=2.5Hz, 1H), 3.90(s, 3H),           3.82(s, 3H), 3.78(s, 3H),           3.73(s, 6H)       12n   (300MHz, acetone-d6): 8.46(br s,   N-[2-benzenesulfonylamino-   M−1=509(ESI−)   &gt;96%           2H), 7.62-7.75(m, 6H),   4-(4-methoxy-phenoxy)-           7.51-7.61(m, 4H), 6.96(d, J=8Hz,   phenyl]-benzenesulfonamide           2H), 6.80-6.88(m,           3H), 6.65(d, J=3.1Hz, 1H),           6.60(dd, J=8Hz, J′=3.1Hz,           1H),       12o   (300MHz, acetone-d6): 8.45(br s,   N-[2-(4-t-butyl-   M−1=621(ESI−)   &lt;70%           2H), 7.54-7.69(m, 8H),   benzenesulfonylamino)-4-(4-           6.97(d, J=8Hz, 2H), 6.80-6.89(m,   methoxy-phenoxy)-phenyl]-           3H), 6.76(d, J=3Hz,   4-t-butyl-           1H), 6.53(dd, J=7.5Hz,   benzenesulfonamide           J′=3Hz, 1H), 3.83(s, 3H),           1.35(s, 3H), 1.32(s, 3H)       12p   (300MHz, acetone-d6): 8.36(br s,   N-[4-(4-methoxy-phenoxy)-   M+1=539   &gt;76%           2H), 7.52-7.62(m, 4H),   2-(4-toluenesulfonylamino)-   (ESI+)           7.31-7.40(m, 4H), 6.96(d, J=8.5Hz,   phenyl]-4-           2H), 6.80-6.89(m,   toluenesulfonamide           3H), 6.66(d, J=2.5Hz, 1H),           6.58(dd, J=8Hz, J′=2.5Hz,           1H), 3.82(s, 3H), 2.41(s,           3H), 2.38(s, 3H)       12q   (300MHz, acetone-d6): 8.44(br s,   N-[4-(4-methoxy-phenoxy)-   M+1=595   &gt;90%           2H), 7.03(s, 2H), 6.99(s,   2-(2,4,6-   (ESI+)           2H), 6.93(d, J=7.5Hz,   trimethylbenzenesulfonylamino)-           2H), 6.74-6.82(m, 3H), 6.58(dd,   phenyl]-2,4,6-           J=7.5Hz, J′=2.8Hz,   trimethylbenzenesulfonamide           1H), 6.48(d, J=2.8Hz, 1H),           3.85(s, 3H), 2.48(m, 12H),           2.32(s, 3H), 2.28(s, 3H)       12r   (300MHz, acetone-d6):   N-[4-(4-methoxy-phenoxy)-   M+1=599 ESI+   &lt;70%           8.32-8.43(m, 4H), 7.91-8.01(m,   2-(4-           4H), 6.83-7.14(m, 8H),   nitrobenzenesulfonylamino)-           6.68(dd, J=8Hz, J′=2.8Hz,   phenyl]-4-           1H), 6.58(d, J=2.8Hz,   nitrobenzenesulfonamide           1H), 3.82(s, 3H),       12s   (300MHz, acetone-d6): 8.36(s,   N-[4-(5-hydroxy-pentyloxy)-   M+1=519   ND           1H), 8.22(s, 1H), 8.66(d,   2-(4-toluenesulfonylamino)-   (ESI+)           J=7.5Hz, 2H), 7.50(d, J=7.5Hz,   phenyl]-4-           2H), 7.24-7.37(m,   toluenesulfonamide           4H), 7.79(d, J=2Hz, 1H),           6.63(d, J=6Hz, 1H), 6.50(dd,           J=6Hz, J′=2Hz, 1H),           3.83(t, J=6Hz, 2H), 3.60(m,           2H), 2.40(s, 6H), 1.65-1.77(m,           2H), 1.42-1.62(m,           4H)       12t   (300MHz, acetone-d6): 8.48(br s,   N-[4-(4-fluoro-phenoxy)-2-   M−1=525(ESI−)   &lt;70%           2H), 7.56-7.64(m, 4H),   (4-toluenesulfonylamino)-           7.33-7.40(m, 4H), 7.15-7.22(m,   phenyl]-4-           2H), 6.88-6.95(m, 3H),   toluenesulfonamide           6.64-6.71(m, 2H), 2.41(m,           6H)       12u   (300MHz, acetone-d6): 8.57(br s,   N-[4-(naphthalene-2-yloxy)-   M−1=557(ESI−)   &lt;70%           2H), 7.74-8.02(m, 5H),   2-(4-toluenesulfonylamino)-           7.20-7.65(m, 10H), 7.12(dd,   phenyl]-4-           J=8Hz, J′=2Hz, 1H), 6.96(d,   toluenesulfonamide           J=8Hz, 1H), 6.63-6.70(m,           1H), 2.43(s, 3H), 2.37(s,           3H)       12v   (300MHz, acetone-d6): 8.43(br s,   N-[4-methoxy-2-(4-   M+1=447   &lt;70%           1H), 8.30(br s, 1H),   toluenesulfonylamino)-   (ESI+)           7.73(d, J=9Hz, 2H), 7.55(d,   phenyl]-4-           J=9Hz, 2H), 7.32-7.40(m,   toluenesulfonamide           4H), 6.84(d, J=3Hz,           1H), 6.71(d, J=7.5Hz, 1H),           6.53(dd, J=7.5Hz, J′=3Hz,           1H), 3.67(s, 3H), 2.41(s,           6H)       12w   (300MHz, acetone-d6): 8.47(br s,   N-[4-(4-chloro-phenoxy)-2-   M+1=543   &lt;70%           2H), 7.55-7.64(m, 4H),   (4-toluenesulfonylamino)-   (ESI+)           7.32-7.44(m, 6H), 6.96(d, J=7.5Hz,   phenyl]-4-           1H), 6.88(d, J=8Hz,   toluenesulfonamide           2H), 6.66-6.73(m, 2H),           2.39(m, 6H)       12x   (300MHz, acetone-d6): 8.50(br s,   N-[4-(3-carboxy-phenoxy)-2-   M−1=551(ESI−)   &lt;70%           2H), 7.85(d, J=7.5Hz,   (4-toluenesulfonylamino)-           1H), 7.51-7.65(m, 5H), 7.46(m,   phenyl]-4-           1H), 7.30-7.40(m, 4H),   toluenesulfonamide           7.27(dd, J=7.5Hz, J′=2.5Hz,           1H), 6.93(d, J=8Hz,           1H), 6.81(d, J=2.8Hz, 1H),           6.73(dd, J=8Hz, J′=2.8Hz,           1H), 2.40(s, 3H), 2.38(s,           3H)       12y   (300MHz, acetone-d6):   {3-[3,4-bis(4-   M−1=565(ESI−)   &lt;70%           7.55-7.65(m, 4H), 7.29-7.38(m,   toluenesulfonylamino)-           5H), 7.13(d, J=7Hz,   phenoxy]-phenyl}-acetic acid           1H), 6.92(m, 2H), 6.80(d, J=2.5Hz,           1H), 6.71(m, 1H),           6.62(dd, J=8Hz, J′=2.5Hz,           1H), 3.61(s, 2H), 2.41(s,           6H)       12z   (300MHz, acetone-d6): 8.03(d,   N-[4-(3-carboxy-phenoxy)-2-   M−1=551(ESI−)   &lt;70%           J=7.8Hz, 2H), 7.56-7.66(m,   (4-toluenesulfonylamino)-           4H), 7.32-7.40(m, 4H),   phenyl]-4-           7.06(d, J=7.5Hz, 1H), 6.87(d,   toluenesulfonamide           J=7.8Hz, 2H), 6.74-6.83(m,           2H), 2.40(s, 6H)       12aa   (300MHz, acetone-d6): 7.58(d,   {4-[3,4-bis(4-   M−1=565(ESI−)   &gt;75%           J=8Hz, 4H), 7.28-7.40(m,   toluenesulfonylamino)-           6H), 6.94(d, J=7.5Hz,   phenoxy]-phenyl}-acetic acid           1H), 6.81(d, J=8Hz, 2H),           6.62-6.71(m, 2H), 3.66(s,           2H), 2.43(s, 3H), 2.40(s, 3H)       12bb   (300MHz, acetone-d6): 8.39(s,   N-[4-(3-hydroxy-propoxy)-2-   M+1=491   ND           1H), 8.27(s, 1H), 7.71(d,   (4-toluenesulfonylamino)-   (ESI+)           J=8Hz, 2H), 7.55(d, J=8Hz,   phenyl]-4-           2H), 7.30-7.40(m, 4H),   toluenesulfonamide           6.84(d, J=3Hz, 1H), 6.70(d,           J=7Hz, 1H), 6.53(dd, J=7Hz,           J′=2.7Hz, 1H), 3.94(t,           J=6Hz, 2H), 3.66(t, J=5.7Hz,           2H), 2.41(s, 6H),           1.89(quintet, J=6Hz, 2H)       12cc   (300MHz, acetone-d6):8.32(br s,   N-[4-allyloxy-2-(4-   M+1=473(ESI+   ND           2H), 7.71(d, J=8Hz,   toluenesulfonylamino)-           2H), 7.54(d, J=8Hz, 2H),   phenyl]-4-           7.29-7.40(m, 4H), 6.84(d, J=3Hz,   toluenesulfonamide           1H), 6.68(d, J=7.5Hz,           1H) 6.54(dd, J=7.5Hz,           J′=3Hz, 1H), 5.89-6.05(m,           1H), 5.33(dd, J=16.5Hz, J′           2Hz, 1H), 5.20(dd, J=12Hz,           J′=2Hz, 1H), 4.44(m,           2H), 2.40(s, 6H)       12dd   (300MHz, acetone-d6): 8.40(s,   N-[4-(8-hydroxy-octyloxy)-2-   M+1=561   ND           1H), 8.28(s, 1H), 7.72(d,   (4-toluenesulfonylamino)-   (ESI+)           J=8Hz, 2H), 7.55(d, J=8Hz,   phenyl]-4-           2H), 8.30-8.40(m, 4H),   toluenesulfonamide           6.83(d, J=3Hz, 1H), 6.68(d,           J=8Hz, 1H), 6.52(dd, J=8Hz,           J′=3Hz, 1H), 3.84(t,           J=6Hz, 2H), 3.48-3.61(m,           3H), 2.41(s, 6H), 1.10-1.75(m,           12H)       12ee   (300MHz, acetone-d6): 8.41(s,   5-[3,4-bis-(4-   M+1=561   ND           1H), 8.30(s, 1H), 7.70(d,   toluenesulfonylamino)-   (ESI+)           J=8.5Hz, 2H), 7.55(d, J=8.5Hz,   phenoxy]-pentyl acetate           2H), 7.29-7.40(m,           4H), 6.83(d, J=2.8Hz, 1H),           6.69(d, J=8Hz, 1H), 6.53(dd,           J=8Hz, J′=2.8Hz,           1H), 4.04(t, J=6Hz, 2H),           3.85(t, J=6Hz, 2H), 2.38(s,           6H), 2.00(s, 3H), 1.59-1.81(m,           4H), 1.41-1.55(m,           2H)       12ff   (300MHz, acetone-d6): 8.55(br s,   N-[4-(4-chloro-   M−1=557(ESI−)   &gt;83%           1H), 8.48(br s, 1H),   phenylsulfanyl)-2-(4-           7.65(d, J=8Hz, 2H), 7.54(d,   toluenesulfonylamino)-           J=8Hz, 2H), 7.30-7.44(m,   phenyl]-4-           6H), 7.05-7.21(m, 4H),   toluenesulfonamide           6.88(d, J=2Hz, 1H), 2.42(s,           6H)       12gg   (300MHz, acetone-d6): 8.43(br s,   N-[4-(4-methoxy-   M+1=555   &gt;70%           2H), 7.60(d, J=8.5Hz,   phenylsulfanyl)-2-(4-   (ESI+)           2H), 7.53(d, J=8.5Hz, 2H),   toluenesulfonylamino)-           7.24-7.38(m, 6H), 7.03(d, J=8.5Hz,   phenyl]-4-           2H), 6.93(d, J=8Hz,   toluenesulfonamide           1H), 6.83(dd, J=8Hz; J′=2.5Hz,           1H), 6.74(d, J=2.5Hz,           1H), 3.86(s, 3H), 2.41(s,           3H), 2.37(s, 3H)       12hh   (300MHz, acetone-d6):   N-[4-butylsulfanyl-2-(4-   M−1=503(ESI−)   &gt;87%           7.56-7.68(m, 4H), 7.30-7.42(m,   toluenesulfonylamino)-           4H), 6.90-7.02(m, 3H),   phenyl]-4-           2.75(m, 4H), 2.37(m, 6H),   toluenesulfonamide           1.27-1.54(m, 8H), 0.91(t, J=6Hz,           6H)       15a   (300MHz, acetone-d6): 8.07(s,   N-[3-allyl-4-(4-methoxy-   ND   ND           2H), 7.43-7.53(m, 4H),   benzyloxy)-2-(4-           7.30-7.37(m, 4H), 7.26(d, J=7.5Hz,   toluenesulfonylamino)-           2H), 7.10(d, J=7.5Hz,   phenyl]-4-           1H), 6.99(d, J=7.5Hz,   toluenesulfonamide           1H), 6.94(d, J=7.5Hz, 2H),           5.53-5.68(m, 1H), 5.01(s,           2H), 4.78(dd, J=12Hz, J′=2Hz,           1H), 4.05(dd, J=15Hz,           J′=2Hz, 1H), 3.80(s,           3H), 2.95-3.02(m, 2H), 2.40(s,           3H), 2.36(s, 3H)       15b   (300MHz, acetone-d6): 8.41(s,   N-[4-(4-chloro-benzyloxy)-2-   M−1=555(ESI−)   ND           1H), 8.29(s, 1H), 7.66(d,   (4-toluenesulfonylamino)-           J=7.5Hz, 2H), 7.54(d, J=7.5Hz,   phenyl]-4-           2H), 7.43(m, 4H),   toluenesulfonamide           7.28-7.37(m, 4H), 6.95(d, J=3Hz,           1H), 6.68(d, J=7.5Hz,           1H), 6.60(dd, J=7.5Hz,           J′=3Hz, 1H), 5.01(s, 2H),           2.42(m, 6H)       15c   (300MHz, acetone-d6): 8.42(s,   N-[4-(3-chloro-benzyloxy)-2-   M−1=555(ESI−)   ND           1H), 8.30(s, 1H), 7.67(d,   (4-toluenesulfonylamino)-           J=7.8Hz, 2H), 7.53(d, J=7.5Hz,   phenyl]-4-           2H), 7.30-7.48(m,   toluenesulfonamide           8H), 6.96(d, J=2.6Hz, 1H),           6.68(d, J=7.5Hz, 1H), 6.61(dd,           J=7.5Hz, J′=2.6Hz,           1H), 5.02(s, 2H), 2.39(m,           6H)       15d   (300MHz, acetone-d6): 8.43(s,   N-[4-(2-chloro-benzyloxy)-2-   M−1=555(ESI−)   &lt;70%           1H), 8.32(s, 1H), 7.69(d,   (4-toluenesulfonylamino)-           J=8Hz, 2H), 7.27-7.59(m,   phenyl]-4-           9H), 6.91(d, J=3Hz, 1H),   toluenesulfonamide           6.76(d, J=8Hz, 1H), 6.65(dd,           J=8Hz, J′=3Hz, 1H),           5.05(s, 2H), 2.39(m, 6H)       15e   (300MHz, acetone-d6): 8.38(s,   N-[4-(4-methoxy-benzyloxy)-   M−1=551(ESI−)   &gt;73%           1H), 8.27(s, 1H), 7.67(d,   2-(4-toluenesulfonylamino)-           J=8Hz, 2H), 7.53(d, J=8Hz,   phenyl]-4-           2H), 7.28-7.38(m, 6H),   toluenesulfonamide           7.39-7.49(m, 3H), 6.67(d, J=7.5Hz,           1H), 6.58(dd, J=7.5Hz,           J′=2.5Hz, 1H), 4.90(s,           2H), 3.82(s, 3H), 2.39(m,           6H)       15f   (300MHz, acetone-d6): 8.42(s,   N-[4-cyclohexylmethoxy-2-   M+1=529   ND           1H), 8.30(s, 1H), 7.70(d,   (4-toluenesulfonylamino)-   (ESI+)           J=8Hz, 2H), 7.30-7.58(m,   phenyl]-4-           6H), 6.81(d, J=2.9Hz, 1H),   toluenesulfonamide           6.69(d, J=8Hz, 1H), 6.52(dd,           J=8Hz, J′=2.9Hz,           1H), 3.64(d, J=6.5Hz, 2H),           2.39(s, 6H), 1.60-1.90(m),           0.98-1.38(m)       15g   (300MHz, acetone-d6): 8.54(br s,   N-[4-(2-chloro-   M−1=571(ESI−)   &gt;87%           2H), 7.59-7.66(m, 4H),   benzylsulfanyl)-2-(4-           7.14-7.45(m, 8H), 7.08(s,   toluenesulfonylamino)-           1H), 6.95-6.99(m, 2H), 4.08(s,   phenyl]-4-           2H), 2.42(s, 3H), 2.37(s,   toluenesulfonamide           3H)       17a   (300MHz, acetone-d6): 8.61(s,   N-[4-(pyrazol-1-yl)-2-(4-   M−1=481(ESI−)   &gt;98%           1H), 8.53(s, 1H), 8.14(d,   toluenesulfonylamino)-           J=2Hz, 1H), 7.65-7.80(m,   phenyl]-4-           4H), 7.60(d, J=7.5Hz, 2H),   toluenesulfonamide           7.30-7.53(m, 6H), 7.01(d, J=7.5Hz,           1H), 6.51(m, 1H),           2.40(m, 6H)       17b   (300MHz, acetone-d6): 8.16(s,   N-[4-(benzimidazol-1-yl)-2-   M−1=531(ESI−)   &gt;98%           1H), 7.60-7.70(m, 5H),   (4-toluenesulfonyamino)-           7.21-7.48(m, 9H), 2.42(m,   phenyl]-4-           6H)   toluenesulfonamide       17c   (300MHz, acetone-d6): 8.24(s,   N-[4-dimethylamino-2-(4-   M+1=460   &gt;85%           1H), 8.10(s, 1H), 7.72(d,   toluenesulfonylamino)-   (ESI+)           J=7.5Hz, 2H), 7.54(d, J=7.5Hz,   phenyl]-4-           2H), 7.29-7.37(m,   toluenesulfonamide           4H), 6.57(d, J=3Hz, 1H),           6.54(d, J=9Hz, 1H), 6.27(dd,           J=9Hz, J′=3Hz, 1H),           2.38(m, 6H)       17d   (300MHz, acetone-d6): 8.06(br s,   N-[4-(imidazol-1-yl)-2-(4-   M+1=483   &gt;99%           1H), 7.72(d, J=9Hz,   toluenesulfonylamino)-   (ESI+)           2H), 7.66(d, J=9Hz, 2H),   phenyl]-4-           7.28-7.42(m, 8H), 7.13(d, J=7.5Hz,   toluenesulfonamide           1H), 2.39(s, 6H)       17e   (300MHz, acetone-d6):   N-{2-(4-   M−1=653(ESI−)   &gt;71%           7.62-7.74(m, 4H), 7.44-7.56(m,   toluenesulfonylamino)-4-[4-           4H), 7.27-7.37(m, 4H),   (toluene-4-sulfonyl)-           6.74(d, J=3Hz, 1H), 6.64(d,   piperazin-1-yl]-phenyl}-4-           J=7.8Hz, 1H), 6.51(dd,   toluenesulfonamide           J=7.8Hz, J′=3Hz, 1H),           3.02-3.18(m, 8H), 2.44(s,           3H), 2.37(s, 6H)       17f   (300MHz, acetone-d6): 8.33(br s,   N-[4-(morpholin-4-yl)-2-(4-   M−1=500(ESI−)   &gt;77%           1H), 8.22(br s, 1H),   toluenesulfonylamino)-           7.68(d, J=9Hz, 2H), 7.55(d,   phenyl]-4-           J=9Hz, 2H), 7.28-7.39(m,   toluenesulfonamide           4H), 6.74(d, J=2.5Hz,           1H), 6.67(d, J=7.5Hz, 1H),           6.54(dd, J=7.5Hz, J′=2.5Hz,           1H), 3.67-3.75(m, 4H),           2.93-3.02(m, 4H), 2.41(s,           6H)       21   (300MHz, acetone-d6): 8.64(br s,   N-[4-(4-chloro-phenyl)-2-(4-   M−1=525(ESI−)   &gt;70%           2H), 7.63-7.72(m, 4H),   toluenesulfonylamino)-           7.44(d, J=8Hz, 2H), 7.33-7.40(m,   phenyl]-4-           7H), 7.17-7.24(m,   toluenesulfonamide           2H), 2.40(s, 3H), 2.38(s, 3H)       22a   (300MHz, acetone-d6): 8.57(s,   N-[3-methoxy-2-(4-   M+1=447   ND           1H), 7.92(s, 1H), 7.79(d,   toluenesulfonylamino)-   (ESI+)           J=9Hz, 2H), 7.44(d, J=9Hz,   phenyl]-4-           2H), 7.34(d, J=9Hz,   toluenesulfonamide           2H), 7.28(d, J=9Hz, 2H),           7.11-7.22(m, 2H), 6.53(dd, J=7Hz,           J′=2.5Hz, 1H), 3.18(s,           3H), 2.44-2.51(m, 6H)       22b   RR   N-[2-(4-methoxy-phenyl)-   RR   RR               ethyl]-3,4-bis-(4-               toluenesulfonylamino)-               benzamide       22c   RR   N-t-butyl-3,4-bis-(4-   RR   RR               toluenesulfonylamino)-               benzamide       22d   RR   N-pyridin-3-yl-3,4-bis-(4-   RR   RR               toluenesulfonylamino)-               benzamide       22e   RR   N-phenyl-3,4-bis-(4-   RR   RR               toluenesulfonylamino)-               benzamide       22f   RR   N-(3-hydroxy-2,2-dimethyl-   RR   RR               propyl)-3,4-bis-(4-               toluenesulfonylamino)-               benzamide       22g   RR   N-naphthalen-1-ylmethyl-   RR   RR               3,4-bis-(4-               toluenesulfonylamino)-               benzamide       22h   RR   2-phenyl-N-[3,4-bis-(4-   RR   RR               toluenesulfonylamino)-               phenyl]-acetamide       22i   RR   N-[3,4-bis-(4-   RR   RR               toluenesulfonylamino)-               phenyl]-thiophene-2-               sulfonamide       22j   RR   3,5-dimethyl-N-[3,4-bis-(4-   RR   RR               toluenesulfonylamino)-               phenyl]-isoxazole-4-               sulfonamide       22k   RR   3,4-bis-(4-   RR   RR               toluenesulfonylamino)-               benzoic acid       22l   RR   N-[4-hydroxymethyl-2-(4-   RR   RR               toluenesulfonylamino-               phenyl]-4-               toluenesulfonamide       22m   RR   N-[2-methanesulfonylamino-   RR   RR               4-(4-methoxy-phenoxy)-               phenyl]-4-               toluenesulfonamide       22n   RR   3,5-dimethyl-N-[5-(4-   RR   RR               methoxy-phenoxy)-2-(4-               toluenesulfonylamino)-               phenyl]-isoxazole-4-               sulfonamide       22o   RR   N-[5-(4-methoxy-phenoxy)-   RR   RR               2-(4-toluenesulfonylamino)-               phenyl]-1-methyl-1H-               imidazole-4-sulfonamide       22p   RR   N-[2-methanesulfonylamino-   RR   RR               5-(4-methoxy-phenoxy)-               phenyl]-4-               toluenesulfonamide       22q   RR   N-{5-[4-(4-methoxy-   RR   RR               phenoxy)-2-(4-               toluenesulfonylamino)-               phenylsulfamoyl]-4-methyl-               thiazol-2-yl}-acetamide       22r   RR   3,5-dimethyl-N-[4-(4-   RR   RR               methoxy-phenoxy)-2-(4-               toluenesulfonylamino)-               phenyl]-isoxazole-4-               sulfonamide       22s   RR   N-[4-(4-methoxy-phenoxy)-   RR   RR               2-(4-toluenesulfonylamino)-               phenyl]-1-methyl-1H-               imidazole-4-sulfonamide       22t   RR   5-bromo-6-chloro-N-[4-(4-   RR   RR               methoxy-phenoxy)-2-(4-               toluenesulfonylamino)-               phenyl]-pyridine-3-               sulfonamide       22u   RR   7-chloro-N-[4-(4-methoxy-   RR   RR               phenoxy)-2-(4-               toluenesulfonylamino)-               phenyl]-               benzo[1,2,5]oxadiazole-4-               sulfonamide       22v   RR   5-isoxazol-3-yl-N-[4-(4-   RR   RR               methoxy-phenoxy)-2-(4-               toluenesulfonylamino)-               phenyl]-thiophene-2-               sulfonamide       22w   RR   methyl 4-[4-(4-methoxy-   RR   RR               phenoxy)-2-(4-               toluenesulfonylamino)-               phenylsulfamoyl]-1,2,5-               trimethyl-1H-pyrrole-3-               carboxylate       22x   RR   4-butyl-N-[4-(4-methoxy-   RR   RR               phenoxy)-2-(4-               toluenesulfonylamino)-               phenyl]-benzenesulfonamide       22y   RR   N-[5-(4-methoxy-phenoxy)-   RR   RR               2-(2-naphthalen-1-yl-               ethanesulfonylamino)-               phenyl]-4-               toluenesulfonamide       22z   RR   4-methanesulfonyl-N-[4-(4-   RR   RR               methoxy-phenoxy)-2-(4-               toluenesulfonylamino)-               phenyl]-benzenesulfonamide       22aa   RR   3-methoxy-N-[4-(4-methoxy-   RR   RR               phenoxy)-2-(4-               toluenesulfonylamino)-               phenyl]-benzenesulfonamide       22bb   RR   N-[4-(4-methoxy-phenoxy)-   RR   RR               2-(4-toluenesulfonylamino)-               phenyl]-5-bromo-thiophene-               2-sulfonamide       22cc   RR   N-[4-(4-methoxy-phenoxy)-   RR   RR               2-(4-toluenesulfonylamino)-               phenyl]-isoquinoline-5-               sulfonamide       22dd   RR   methyl 4-[5-(4-methoxy-   RR   RR               phenoxy)-2-(4-               toluenesulfonylamino)-               phenylsulfamoyl]-1,2,5-               trimethyl-1H-pyrrole-3-               carboxylate       22ee   RR   N-[4-(4-methoxy-phenoxy)-   RR   RR               2-(2-naphthalen-1-yl-               ethanesulfonylamino)-               phenyl]-4-               toluenesulfonamide       22ff   RR   4-methanesulfonyl-N-[5-(4-   RR   RR               methoxy-phenoxy)-2-(4-               toluenesulfonylamino)-               phenyl]-benzenesulfonamide       22gg   RR   5-bromo-N-[5-(4-methoxy-   RR   RR               phenoxy)-2-(4-               toluenesulfonylamino)-               phenyl]-thiophene-2-               sulfonamide       22hh   RR   2-methoxy-N-[5-(4-methoxy-   RR   RR               phenoxy)-2-(4-               toluenesulfonylamino)-               phenyl]-4-methyl-               benzenesulfonamide       22ii   RR   N-[4-(benzyloxyimino-   RR   RR               phenyl-methyl)-2-(4-               toluenesulfonylamino)-               phenyl]-4-               toluenesulfonamide       22jj   RR   N-[4-(hydroxyimino-phenyl-   RR   RR               methyl)-2-(4-               toluenesulfonylamino)-               phenyl]-4-               toluenesulfonamide       22kk   RR   N-[4-(methoxyimino-phenyl-   RR   RR               methyl)-2-(4-               toluenesulfonylamino)-               phenyl]-4-               toluenesulfonamide       22ll   RR   N-[5-(2-chloro-   RR   RR               benzylsulfanyl)-2-               methanesulfonylamino-               phenyl]-4-               toluenesulfonamide       22mm   RR   N-[4-(2-chloro-   RR   RR               benzylsulfanyl)-2-(4-               toluenesulfonylamino)-               phenyl]-4-               toluenesulfonamide       22nn   RR   N-[4-(2-chloro-   RR   RR               benzylsulfanyl)-2-               methanesulfonylamino-               phenyl]-4-               toluenesulfonamide       23   (300MHz, acetone-d6): 7.80(d,   N-[5-amino-4-(4-chloro-   M−1=572(ESI−)   &gt;86%           J=8.3Hz, 2H), 7.51(d, J=8.3Hz,   phenylsulfanyl)-2-(4-           2H), 7.38(d, J=8.3Hz,   toluenesulfonylamino)-           2H0, 7.24-7.32(m, 4H),   phenyl]-4-           7.03(s, 1H), 6.81(d, J=8Hz,   toluenesulfonamide           2H), 6.46(s, 1H), 2.40(s,           3H), 2.25(s, 3H)       24   (300MHz, acetone-d6): 7.96(d,   N-[2-(4-chloro-   ND   &lt;70%           J=8.5Hz, 2H), 7.86(d, J=8.5Hz,   phenylsulfanyl)-4,5-bis-(4-           2H), 7.53(s, 1H),   toluenesulfonylamino)-           7.30-7.45(m, 8H), 7.14(s,   phenyl]-acetamide           1H), 2.48(s, 3H), 2.45(s,           3H), 1.97(s, 3H)       33   (300MHz, acetone-d6): 8.64(s,   methyl 2-(4-methoxy-   ND   ND           1H), 8.47(s, 1H), 7.50-7.43(m,   phenoxy)-4,5-bis-(4-           4H), 7.29-7.40(m,   toluenesulfonylamino)-           4H), 7.25(s, 1H), 7.04(d, J=8Hz,   benzoate           2H), 6.83(d, J=8Hz,           2H), 6.72(s, 1H), 3.83(s,           3H), 6.71(s, 3H), 2.42(s, 6H)       34   (300MHz, acetone-d6): 7.60(d,   2-(4-methoxy-phenoxy)-4,5-   M−1=581(ESI−)   ND           J=7.8Hz, 2H), 7.53(d, J=7.8Hz,   bis-(4-           2H), 7.30-7.42(m,   toluenesulfonylamino)-           4H), 7.04(d, J=8Hz, 2H),   benzoic acid           6.87(d, J=8Hz, 2H), 6.73(s,           1H), 3.89(s, 3H), 2.40(m,           6H)       37   (300MHz, acetone-d6): 8.28(s,   N-[4-(4-methoxy-phenoxy)-   M+1=553   ND           1H), 8.18(s, 1H), 7.58(d,   5-methyl-2-(4-   (ESI+)           J=8.5Hz, 2H), 7.48(d, J=8.5Hz,   toluenesulfonylamino)-           2H), 7.27-7.38(m,   phenyl]-4-           4H), 6.87-6.96(m, 3H), 6.71(d,   toluenesulfonamide           J=9Hz, 2H), 6.32(s,           1H), 3.81(s, 3H), 2.43(s,           3H), 2.40(s, 3H)       38a   Sigma-Aldrich Rare   N-[4,5-dibromo-2-(4-   Aldrich   Aldrich           Chemicals Library   toluenesulfonylamino)-               phenyl]-4-               toluenesulfonamide       38b   RR   N-[4-(4-methoxy-phenoxy)-   RR   RR               2-(4-toluenesulfonylamino)-               5-trifluoromethyl-phenyl]-4-               toluenesulfonamide       38c   RR   N-[4-(2-chloro-   RR   RR               benzylsulfanyl)-5-fluoro-2-(4-               toluenesulfonylamino)-               phenyl]-4-               toluenesulfonamide       38d   RR   N-(4-(2-chloro-   RR   RR               phenylmethanesulfonyl)-5-               fluoro-2-(4-               toluenesulfonylamino)-               phenyl]-4-               toluenesulfonamide       42   (300MHz, acetone-d6): 7.61(d,   diethyl-5-(4-methoxy-   ND   &gt;86%           J=8Hz, 2H), 7.44(d, J=7.8Hz,   phenoxy)-2-(4-           1H), 7.36(d, J=8Hz,   toluenesulfonylamino)-           2H), 7.01(m, 4H), 6.74-6.83(m,   phenyl phosphate           2H), 3.96-4.11(m,           4H), 3.80(s, 3H), 2.40(s,           3H), 1.21(t, J=6Hz, 6H)       43   (300MHz, acetone-d6): 7.66(d,   [5-(4-methoxy-phenoxy)-2-   M−1=464   ND           J=8.5Hz, 2H), 7.44(d, J=8Hz,   (4-toluenesulfonylamino)-   (ESI−)           1H), 7.29(d, J=8.5Hz,   phenyl]-monophosphate           2H), 6.96(m, 4H), 6.68(m,           2H), 3.79(s, 3H), 2.36(s,           3H)       48   (300MHz, acetone-d6):   4-(4-methoxy-   M+1=555   ND           7.60-7.70(m, 4H), 7.38-7.49(m,   phenoxymethyl)-2-(4-   (ESI+)           5H), 7.25-7.36(m, 2H),   toluenesulfonyloxy)-phenyl           6.95(d, J=8Hz, 2H), 6.88(d,   4-toluenesulfonate           J=8Hz, 2H), 5.10(s,           2H), 3.77(s, 3H), 2.47(m,           6H)       51   (300MHz, acetone-d6): 9.90(br m,   N-[4-(4-chloro-   M−1=530(ESI−)   &gt;92%           2H), 8.72(s, 1H), 7.96(d,   phenylsulfanyl)-5-nitro-2-(4-           J=7.8Hz, 2H), 7.78(d, J=7.8Hz,   toluamido)-phenyl]-4-           2H), 7.64-7.73(m,   toluamide           3H), 7.60(d, J=7.8Hz, 2H),           7.28-7.38(m, 4H), 2.40(s,           3H), 2.35(s, 3H)       52   (300MHz, acetone-d6): 9.85(br s,   N-[4-(4-chloro-   M+1=487   ND           1H), 7.91-7.97(m, 6H),   phenylsulfanyl)-2-(4-   (ESI+)           7.30-7.44(m, 9H), 2.42(m,   toluoylamino)-phenyl]-4-           6H)   toluamide       53   (300MHz, acetone-d6):   N-[4-(4-chloro-   M+1=632   &gt;81%           7.66-7.74(m, 3H), 7.45-7.56(m,   phenylsulfanyl)-5-nitro-2-(4-   (ESI+)           10H), 6.75(s, 1H), 3.22(s,   toluenesulfonyl-methyl-           3H), 2.94(s, 3H), 2.61(s,   amino)-phenyl]-N-methyl-4-           3H), 2.50(s. 3H)   toluenesulfonamide       55   (300MHz, acetone-d6): 8.34(br s,   N-[2-amino-4-(4-chloro-   M+1=450   &gt;85%           1H), 7.70(d, J=7.5Hz,   phenylsulfanyl)-5-nitro-           2H), 7.61(m, 4H), 7.41(d, J=7.5Hz,   phenyl]-4-           2H), 6.15(s, 1H),   toluenesulfonamide           6.08(br s, 2H), 2.44(s, 3H)       56   (300MHz, acetone-d6): 9.11(s,   N-[2-amino-4-(4-chloro-   M−1=412(ESI−)   &gt;93%           1H), 8.38(s, 1H), 7.93(d,   phenylsulfanyl)-5-nitro-           J=7Hz, 2H), 7.68(d, J=7.8Hz,   phenyl]-4-toluamide           2H), 7.59(d, J=7.8Hz,           2H), 7.33(d, J=7.5Hz, 2H),           6.73(s, 1H), 2.42(s, 3H)       59   (300MHz, acetone-d6): 7.66(d,   N-[2-hydroxy-4-(4-methoxy-   M+1=386   ND           J=8Hz, 2H), 7.32(d, J=8Hz,   phenoxy)-phenyl]-4-   (ESI+)           2H), 7.14(d, J=8.2Hz,   toluenesulfonamide           1H), 6.95(m, 4H), 6.30-6.39(m,           2H), 3.79(s, 3H),           2.39(s, 3H)       60   (300MHz, acetone-d6): 7.95(s,   N-[2-methoxy-4-(4-methoxy-   ND   ND           1H), 7.62(d, J=8Hz,   phenoxy)-phenyl]-4-           2H), 7.25-7.38 m, 4H), 6.95(m,   toluenesulfonamide           4H), 6.50(d, J=2.8Hz,           1H), 6.40(dd, J=7.5Hz, J′=2.8Hz,           1H), 3.80(s, 3H),           3.50(s, 3H), 2.40(s, 3H)       61   (300MHz, acetone-d6): 7.57(d,   N-[2-methoxy-4-(4-methoxy-   M+1=414   ND           J=8Hz, 2H), 7.38(d, J=8Hz,   phenoxy)-phenyl]-N-methyl-   (ESI+)           2H), 7.15(d, J=7.8Hz,   4-toluenesulfonamide           2H), 7.04(d, J=7.5Hz,           2H), 6.98(d, J=7.5Hz, 2H),           6.55(d, J=3Hz, 1H), 6.37(dd,           J=7.8Hz, J′=3Hz,           1H), 3.82(s, 3H), 3.37(s,           3H), 3.16(s, 3H), 2.45(s, 3H)       62   (300MHz, acetone-d6): 8.16(s,   N-[2-(2-hydroxy-ethoxy)-4-   M−1=428(ESI−)   ND           1H), 7.62(d, J=7.5Hz,   (4-methoxy-phenoxy)-           2H), 7.42(d, J=8Hz, 1H),   phenyl]-4-           7.32(d, J=7.5Hz, 2H), 6.97(m,   toluenesulfonamide           4H), 6.53(d, J=2.5Hz,           1H), 6.46(dd, J=8Hz, J′=2.5Hz,           1H), 4.17(t, J=6.2Hz,           1H), 3.81(s, 3H), 3.74(t,           J=6Hz, 2H), 3.68(m, 2H),           2.38(s, 3H)       63   (300MHz, acetone-d6): 8.05(s,   N-[2-(3-hydroxy-propoxy)-4-   M+1=444   ND           1H), 7.61(d, J=7.8Hz,   (4-methoxy-phenoxy)-   (ESI+)           2H), 7.41(d, J=8.5Hz, 1H),   phenyl]-4-           7.32(d, J=7.8Hz, 2H), 6.96(m,   toluenesulfonamide           4H), 6.53(d, J=2.3Hz,           1H), 6.43(dd, J=8.5Hz, J′=2.3Hz,           1H), 3.72-3.85(m,           5H), 3.55-3.69(m, 3H), 2.39(s,           3H), 1.79(quintet, J=5.8Hz,           2H)       64   (300MHz, acetone-d6): 8.20(br s,   N-[2-(2,3-dihydroxy-   M−1=458(ESI−)   ND           1H), 7.60(d, J=7.5Hz,   propoxy)-4-(4-methoxy-           2H), 7.42(d, J=8Hz, 1H),   phenoxy)-phenyl]-4-           7.32(d, J=7.5Hz, 2H), 6.96(m,   toluenesulfonamide           4H), 6.54(d, J=2.8Hz,           1H), 6.47(dd, J=8Hz, J′=2.8Hz,           1H), 4.36(br s, 1H),           3.65-3.85(m, 7H), 3.54(m,           2H), 2.40(s, 3H)       65   (300MHz, acetone-d6): 8.28(br s,   [5-(4-methoxy-phenoxy)-2-   M+1=444   ND           1H), 7.66(d, J=7.8Hz,   (4-toluenesulfonylamino)-   (ESI+)           2H), 7.43(d, J=8Hz; 1H),   phenoxy]-acetic acid           7.30(d, J=7.8Hz, 2H), 6.96(m,           4H), 6.59(d, J=2.5Hz,           1H), 6.51(dd, J=8Hz, J′=2.5Hz,           1H), 4.53(s, 3H),           3.80(s, 3H), 2.39(s, 3H)       66   (300MHz, acetone-d6): 8.09(s,   N-[2-methoxy-5-(4-methoxy-   M+1=414   ND           1H), 7.60-7.68(m, 3H),   phenoxymethyl)-phenyl]-4-   (ESI+)           7.28(d, J=8Hz, 2H), 7.15(d,   toluenesulfonamide           J=8.2Hz, 1H), 6.83-6.96(m,           5H), 4.99(s, 2H), 3.76(s,           3H), 3.65(s, 3H), 2.37(s, 3H)       67   (300MHz, acetone-d6):   methyl 5-(4-methoxy-   M+1=427   ND           7.65-7.73(m, 3H), 7.33-7.42(m,   phenoxy)-2-(4-   (ESI+)           3H), 7.29-7.37(m, 1H),   toluenesulfonylamino)-           6.97(m, 4H), 3.78-3.84(m,   benzoate           6H), 2.38(s, 3H)       68   (300MHz, acetone-d6):   5-(4-methoxy-phenoxy)-2-(4-   M+1=414   ND           7.68-7.76(m, 3H), 7.49(d, J=2.8Hz,   toluenesulfonylamino)-   (ESI+)           1H), 7.35(d, J=8Hz,   benzoic acid           2H), 7.22(dd, J=8Hz, J′=2.8Hz,           1H), 6.97(m, 4H),           6.76(s, 1H), 3.81(s, 3H),           2.39(s, 3H)       69   (300MHz, acetone-d6): 9.50(s,   N-[4-(4-chloro-   ND   &gt;98%           1H), 8.12(d, J=3Hz,   phenylsulfanyl)-3-nitro-           1H), 7.75(d, J=7.8Hz, 2H),   phenyl]-4-           7.54-7.63(m, 4H), 7.34-7.44(m,   toluenesulfonamide           3H), 6.93(d, J=7.8Hz,           1H), 2.39(s, 3H)       70   (300MHz, acetone-d6): 8.12(d,   N-[3-(4-chloro-   M−1=433(ESI−)   &gt;86%           J=7.8Hz, 1H), 7.51-7.72(m,   phenylsulfanyl)-4-nitro-           6H), 7.40(d, J=7.5Hz,   phenyl]-4-           2H), 7.17(dd, J=7.8Hz, J′=2.8Hz,   toluenesulfonamide           1H), 6.79(d, J=2.8Hz,           1H), 2.44(s, 3H)       71a   RR   N-[2-amino-5-(4-methoxy-   RR   RR               phenoxy)-phenyl]-4-               toluenesulfonamide       71b   RR   6-cyano-N-[4-(4-methoxy-   RR   RR               phenoxy)-2-(4-               toluenesulfonylamino)-               phenyl]-nicotinamide       71c   RR   N-[4-(4-methoxy-phenoxy)-   RR   RR               2-(4-toluenesulfonylamino)-               phenyl]-6-trifluoromethyl-               nicotinamide       71d   RR   N-[2-(4-cyano-benzylamino)-   RR   RR               5-(4-methoxy-phenoxy)-               phenyl]-4-               toluenesulfonamide       71e   RR   N-(4-{[4-(4-methoxy-   RR   RR               phenoxy)-2-(4-               toluenesulfonylamino)-               phenylamino]-methyl}-               phenyl)-acetamide       71f   RR   N-[2-[(benzofuran-2-   RR   RR               ylmethyl)-amino]-5-(4-               methoxy-phenoxy)-phenyl]-               4-toluenesulfonamide       71g   RR   N-{5-(4-methoxy-phenoxy)-   RR   RR               2-[(quinolin-2-ylmethyl)-               amino]-phenyl}-4-               toluenesulfonamide       71h   RR   N-[5-(4-methoxy-phenoxy)-   RR   RR               2-(4-toluenesulfonylamino)-               phenyl]-5-methyl-pyrazine-2-               carboxamide       71i   RR   N-[2-amino-5-(4-methoxy-   RR   RR               phenoxy)-benzyl]-4-               toluenesulfonamide       71j   RR   N-[2-cyano-4-(4-methoxy-   RR   RR               phenoxy)-phenyl]-4-               toluenesulfonamide       71k   RR   5-(4-methoxy-phenoxy)-2-(4-   RR   RR               toluenesulfonylamino)-               benzamide       71l   RR   N-[2-amino-4-(4-methoxy-   RR   RR               phenoxy)-phenyl]-4-               toluenesulfonamide       71m   RR   N-[4-(4-methoxy-phenoxy)-   RR   RR               2-(4-toluenesulfonylamino-               methyl)-phenyl]-4-               toluenesulfonamide       71n   RR   N-[2-aminomethyl-4-(4-   RR   RR               methoxy-phenoxy)-phenyl]-               4-toluenesulfonamide       71o   RR   N-[3-[benzoyl-(4-   RR   RR               toluenesulfonyl)-amino]-4-(4-               toluenesulfonylamino)-               phenyl]-benzamide       71p   RR   N-[5-(4-methoxy-phenoxy)-   RR   RR               2-(4-toluenesulfonylamino)-               benzyl]-4-toluamide       71q   RR   N-[5-(4-methoxy-phenoxy)-   RR   RR               2-(4-toluenesulfonylamino)-               phenyl]-4-toluamide       71r   RR   N-[4-(4-methoxy-phenoxy)-   RR   RR               2-(4-toluenesulfonylamino)-               phenyl]-4-toluamide       71s   RR   N-[4-(4-methoxy-phenoxy)-   RR   RR               2-(4-toluenesulfonylamino)-               phenyl]-2-phenyl-acetamide       71t   RR   N-[2-amino-5-(4-methoxy-   RR   RR               phenoxy)-phenyl]-N-methyl-               4-toluenesulfonamide       71u   RR   N-{4-(4-methoxy-phenoxy)-   RR   RR               2-[(quinolin-2-ylmethylene)-               amino]-phenyl}-4-               toluenesulfonamide       71v   RR   4-(4-methoxy-   RR   RR               phenoxymethyl)-2-(4-               toluenesulfonylamino)-               benzamide       71w   RR   N-[2-aminomethyl-5-(4-   RR   RR               methoxy-phenoxymethyl)-               phenyl]-4-               toluenesulfonamide       71x   RR   N-[2-   RR   RR               (methanesulfonylamino-               methyl)-5-(4-methoxy-               phenoxymethyl)-phenyl]-6-               methyl-naphthalene-2-               sulfonamide       71y   RR   N-(4-morpholin-4-yl-5-nitro-   RR   RR               2-(4-toluoylamino)-phenyl)-               4-toluamide       71z   RR   N-[5-(4-methoxy-phenoxy)-   RR   RR               2-(4-toluenesulfonylamino)-               phenyl]-butyramide       71aa   RR   N-[4-(cyclohexylmethyl-   RR   RR               amino)-5-nitro-2-(4-               toluoylamino)-phenyl]-4-               toluamide       71bb   RR   N-{4-[(naphthalen-1-   RR   RR               ylmethyl)-amino]-5-nitro-2-               (4-toluoylamino)-phenyl}-4-               toluamide       71cc   RR   N-[2-amino-4-(4-methoxy-   RR   RR               phenoxy)-5-nitro-phenyl]-4-               toluenesulfonamide       71dd   RR   N-[4-(4-methoxy-phenoxy)-   RR   RR               2-(4-toluenesulfonyl-methyl-               amino)-phenyl]-4-               toluenesulfonamide       71ee   RR   N-[2-amino-4-(4-methoxy-   RR   RR               phenoxy)-5-trifluoromethyl-               phenyl]-4-               toluenesulfonamide       71ff   RR   N-[4-(4-methoxy-   RR   RR               phenoxymethyl)-2-(4-               toluenesulfonylamino)-               benzyl]-4-toluamide       71gg   RR   N-[2-amino-5-(4-methoxy-   RR   RR               phenoxy)-4-trifluoromethyl-               phenyl]-4-               toluenesulfonamide       71hh   RR   N-[4-(4-methoxy-phenoxy)-   RR   RR               2-(4-methyl-benzylamino)-               phenyl]-4-               toluenesulfonamide       71ii   RR   N-{4-(4-methoxy-phenoxy)-   RR   RR               2-[3-(4-toluenesulfonyl)-               ureido]-phenyl}-4-               toluenesulfonamide       71jj   RR   N-[5-(4-methoxy-phenoxy)-   RR   RR               2-(4-methyl-benzylamino)-               phenyl]-4-               toluenesulfonamide       71kk   RR   N-[2-amino-5-(2-chloro-   RR   RR               benzylsulfanyl)-phenyl]-4-               toluenesulfonamide       71ll   RR   N-[2-amino-4-(2-chloro-   RR   RR               benzylsulfanyl)-5-nitro-               phenyl]-7-chloro-               benzo[1,2,5]oxadiazole-4-               sulfonamide       71mm   RR   N-(4-ethyl-phenyl)-4-   RR   RR               methoxy-2-(4-               toluenesulfonylamino)-               benzenesulfonamide       71nn   RR   N-[4-(2-chloro-   RR   RR               phenylmethanesulfonyl)-2-               (4-toluenesulfonylamino)-               phenyl]-4-               toluenesulfonamide       72a   RR   6-(4-methoxy-phenoxy)-1-(4-   RR   RR               toluenesulfonyl)-1,3-dihydro-               benzoimidazol-2-one       72b   RR   5-(4-methoxy-phenoxy)-1-(4-   RR   RR               toluenesulfonyl)-1,3-dihydro-               benzoimidazol-2-one       72c   RR   5-(4-methoxy-phenoxy)-1,3-   RR   RR               bis-(4-toluenesulfonyl)-1,3-               dihydro-benzoimidazol-2-               one       72d   RR   5-(4-methoxy-phenoxy)-1,3-   RR   RR               dihydro-               benzo[1,2,5]thiadiazole 2,2-               dioxide       72e   RR   5-(4-methoxy-phenoxy)-1,3-   RR   RR               dihydro-benzoimidazol-2-               one       72f   RR   5-(4-methoxy-phenoxy)-1-(4-   RR   RR               toluenesulfonyl)-1,3-dihydro-               benzo[1,2,5]thiadiazole 2,2-               dioxide                  
 
     Example 16  
      Specificity of Sulfonamide-Based Inhibitors for Src  
      Recombinant human Src was expressed using the baculovirus-insect cell system and purified as published (Budde et al., 1993 and 2000). Recombinant Csk and the FGF receptor (FGFr) were expressed as glutathione-5-transferase fusion proteins using the pGEX expression vector and  E. coli , and purified as described (Sun &amp; Budde, 1995).  
      The tyrosine kinase activity of Src, Csk and FGFr was determined using poly E 4 Y and  32 P-ATP. Briefly, enzymes were assayed in a reaction mixture consisting of 0.15 M EPPS-NaOH (pH 8.0) with 6 mM MgCl 2 , 0.2 mM γ 32 P-ATP (0.2-0.4 mCi/μmol), 10% glycerol, 0.1% Triton X-100, and poly E 4 Y. Poly E 4 Y is a synthetic peptide whose phosphorylation is measured in this assay by the addition of the radioactively labeled phosphate from the ATP (Budde et al., 1995). For screening assays, 50 μg/ml poly E 4 Y was used, and for K i  determinations variable concentrations (0, 20, 30, 75, and 150 μg/ml) of poly E 4 Y were used. When ATP was varied (0, 50, 100 and 250 μM), poly E 4 Y was kept constant at 150 μg/ml.  
      Compounds were identified as especially good inhibitors of Src if they possessed an IC 50  of 10 μM or less. However, all of the disclosed compounds have excellent potential, and numerous other commercial candidates will emerge after further experimentation.  
               TABLE 2                          Formula I Compounds                                 % Inhibition           IC50 (μM)   at 15 ug/mL                                                     Compound #   R1   R2   R3   X1   Y1   Src   Csk   FGFr   Src (%)               2   p-(C6H4)CH3   p-(C6H4)CH3   F   —   —   NI   NI   NI   ND       4a   p-(C6H4)CH3   p-(C6H4)CH3   p-(C6H4)OCH3   S   —   3.4   10.8   5.8   ND       4b   p-(C6H4)CH3   p-(C6H4)CH3   o-(C6H4)OCH3   S   —   7   15   20   ND       4c   p-(C6H4)CH3   p-(C6H4)CH3   m-(C6H4)OCH3   S   —   3.5   8.3   7.5   ND       4d   p-(C6H4)CH3   p-(C6H4)CH3   p-(C6H4)OH   S   —   5.5   23.9   23.9   ND       4e   p-(C6H4)CH3   p-(C6H4)CH3   p-(C6H4)Cl   S   —   8   23   1.7   ND       4f   p-(C6H4)CH3   p-(C6H4)CH3   o-(C6H4)Cl   S   —   2.5   10.8   10.8   ND       4g   p-(C6H4)CH3   p-(C6H4)CH3   m-(C6H4)Cl   S   —   1.6   9.1   5.8   ND       4h   p-(C6H4)CH3   p-(C6H4)CH3   p-(C6H4)F   S   —   1.8   8.6   7.8   ND       4i   p-(C6H4)CH3   p-(C6H4)CH3   p-(C6H4)CH3   S   —   1.7   10.3   5.1   ND       4j   p-(C6H4)CH3   p-(C6H4)CH3   o-(C6H4)CH3   S   —   1.7   12   8.6   ND       4k   p-(C6H4)CH3   p-(C6H4)CH3   m-(C6H4)CH3   S   —   1.9   9.4   3.1   ND       4l   p-(C6H4)CH3   p-(C6H4)CH3   3,5-(C6H3)(CH3)2   S   —   1.5   6.4   3.7   ND       4m   p-(C6H4)CH3   p-(C6H4)CH3   2,6-(C6H3)(CH3)2   S   —   1   5.4   4.7   ND       4n   p-(C6H4)CH3   p-(C6H4)CH3   o-(C6H4)[CH(CH3)2]   S   —   1.3   5.7   4.3   ND       4o   p-(C6H4)CH3   p-(C6H4)CH3   C6H5   S   —   1.3   5.7   1.8   ND       4p   p-(C6H4)CH3   p-(C6H4)CH3   2-furyl   S   CH2   1.6   11.3   7.3   ND       4q   p-(C6H4)CH3   p-(C6H4)CH3   p-(C6H4)Cl   S   CH2   1   4.1   2.7   ND       4r   p-(C6H4)CH3   p-(C6H4)CH3   o-(C6H4)Cl   S   CH2   0.65   4.2   1.9   ND       4s   p-(C6H4)CH3   p-(C6H4)CH3   p-(C6H4)OCH3   S   CH2   1.3   5.7   4.3   ND       4t   p-(C6H4)CH3   p-(C6H4)CH3   C6H5   S   CH2   1.2   5.5   ND   ND       4u   CH3   CH3   p-(C6H4)Cl   S   —   590   333   188   ND       6   p-(C6H4)CH3   p-(C6H4)CH3   Cl   —   —   1060   172   20.2   ND       8   p-(C6H4)CH3   p-(C6H4)CH3   C6H5   —   —   1.7   10.4   4.9   ND       9a   p-(C6H4)CH3   p-(C6H4)CH3   morpholin-4-yl   —   —   ND   ND   ND    13*       9b   p-(C6H4)CH3   p-(C6H4)CH3   N-Me-piperazin-1-yl   —   —   ND   ND   ND    2       9c   p-(C6H4)CH3   p-(C6H4)CH3   thiomorpholin-4-yl   —   —   ND   ND   ND   15       9d   p-(C6H4)CH3   p-(C6H4)CH3   3-pyridyl   NH   CH2   NI   ND   ND    19*       9e   p-(C6H4)CH3   p-(C6H4)CH3   2-pyridyl   NH   CH2   ND   ND   ND   15       9f   p-(C6H4)CH3   p-(C6H4)CH3   p-(C6H4)OCH3   NH   CH2   ND   ND   ND   17       9g   p-(C6H4)CH3   p-(C6H4)CH3   o-(C6H4)Cl   NH   CH2   54   ND   ND   65       9h   p-(C6H4)CH3   p-(C6H4)CH3   cyclohexyl   NH   CH2   ND   ND   ND   22       9i   p-(C6H4)CH3   p-(C6H4)CH3   cyclohexyl-1-ol   NH   CH2   ND   ND   ND   18       9j   p-(C6H4)CH3   p-(C6H4)CH3   cyclohexyl   O   —   ND   ND   ND    4       9k   p-(C6H4)CH3   p-(C6H4)CH3   5-Me-pyrazol-4-yl   O   (CH2)3   ND   ND   ND   13                 *= assayed at 50 μg/mL            NI = not determined            NI = no inhibition at 100 μg/mL             
 
     
       
         
           
               
             
               
                 TABLE 3 
               
               
                   
               
               
                   
               
               
                 Formula II Compounds 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
            
               
                 Compound # 
                 R4 
                 R5 
                 R6 
               
               
                   
               
               
                  2 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 F 
               
               
                  6 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 Cl 
               
               
                 12a 
                 p-(C6H4)(CH2CH3) 
                 p-(C6H4)(CH2CH3) 
                 p-(C6H4)OCH3 
               
               
                 12b 
                 p-(C6H4)[CH(CH3)2] 
                 p-(C6H4)[CH(CH3)2] 
                 p-(C6H4)OCH3 
               
               
                 12c 
                 p-(C6H4)Cl 
                 p-(C6H4)Cl 
                 p-(C6H4)OCH3 
               
               
                 12d 
                 p-(C6H4)F 
                 p-(C6H4)F 
                 p-(C6H4)OCH3 
               
               
                 12e 
                 p-(C6H4)OC6H5 
                 p-(C6H4)OC6H5 
                 p-(C6H4)OCH3 
               
               
                 12f 
                 m-(C6H4)NO2 
                 m-(C6H4)NO2 
                 p-(C6H4)OCH3 
               
               
                 12g 
                 CH2(C6H5) 
                 CH2(C6H5) 
                 p-(C6H4)OCH3 
               
               
                 12h 
                 1-naphthyl 
                 1-naphthyl 
                 p-(C6H4)OCH3 
               
               
                 12i 
                 2-naphthyl 
                 2-naphthyl 
                 p-(C6H4)OCH3 
               
               
                 12j 
                 p-(C6H4)NH(C═O)CH3 
                 p- 
                 p-(C6H4)OCH3 
               
               
                   
                   
                 (C6H4)NH(C═O)CH3 
               
               
                 12k 
                 p-(C6H4)OCH3 
                 p-(C6H4)OCH3 
                 p-(C6H4)OCH3 
               
               
                 12l 
                 (CH2)3CH3 
                 (CH2)3CH3 
                 p-(C6H4)OCH3 
               
               
                 12m 
                 3,4-(C6H3)(OCH3)2 
                 3,4-(C6H3)(OCH3)2 
                 p-(C6H4)OCH3 
               
               
                 12n 
                 C6H5 
                 C6H5 
                 p-(C6H4)OCH3 
               
               
                 12o 
                 p-(C6H4)[C(CH3)]3 
                 p-(C6H4)[C(CH3)]3 
                 p-(C6H4)OCH3 
               
               
                 12p 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
               
               
                 12q 
                 2,4,6-(C6H2)(CH3)3 
                 2,4,6-(C6H2)(CH3)3 
                 p-(C6H4)OCH3 
               
               
                 12r 
                 p-(C6H4)NO2 
                 p-(C6H4)NO2 
                 p-(C6H4)OCH3 
               
               
                 12s 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 (CH2)4CH2OH 
               
               
                 12t 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 p-(C6H4)F 
               
               
                 12u 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 2-naphthyl 
               
               
                 12v 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 CH3 
               
               
                 12w 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 p-(C6H4)Cl 
               
               
                 12x 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 m-(C6H4)CO2H 
               
               
                 12y 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 m-(C6H4)CH2CO2H 
               
               
                 12z 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 p-(C6H4)CO2H 
               
               
                 12aa 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 p-(C6H4)CH2CO2H 
               
               
                 12bb 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 CH2CH2CH2OH 
               
               
                 12cc 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 allyl 
               
               
                 12dd 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 (CH2)7CH2OH 
               
               
                 12ee 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 (CH2)7CH2OC(═0)CH3 
               
               
                 12ff 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 p-(C6H4)Cl 
               
               
                 12gg 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
               
               
                 12hh 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 (CH2)3CH3 
               
               
                 15a 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
               
               
                 15b 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 p-(C6H4)Cl 
               
               
                 15c 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 m-(C6H4)Cl 
               
               
                 15d 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 o-(C6H4)Cl 
               
               
                 15e 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
               
               
                 15f 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 cyclohexyl 
               
               
                 15g 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 o-(C6H4)Cl 
               
               
                 17a 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 pyrazol-1-yl 
               
               
                 17b 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 benzimidazol-1-yl 
               
               
                 17c 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 N(CH3)2 
               
               
                 17d 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 imidazol-1-yl 
               
               
                 17e 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 N-(4- 
               
               
                   
                   
                   
                 toluenesulfonyl)piperazin- 
               
               
                   
                   
                   
                 1-yl 
               
               
                 17f 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 morpholin-4-yl 
               
               
                 21 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 p-(C6H4)Cl 
               
               
                 22a 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 — 
               
               
                 22b 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 p-CH2CH2(C6H4)OCH3 
               
               
                 22c 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 C(CH3)3 
               
               
                 22d 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 3-pyridyl 
               
               
                 22e 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 C6H5 
               
               
                 22f 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 CH2C(CH3)2CH2OH 
               
               
                 22g 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 CH2(naphth-1-yl) 
               
               
                 22h 
                 p-(C64H)CH3 
                 p-(C6H4)CH3 
                 CH2C6H5 
               
               
                 22i 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 2-thienyl 
               
               
                 22j 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 3,5-dimethylisoxazol-4-yl 
               
               
                 22k 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 OH 
               
               
                 22l 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 OH 
               
               
                 22m 
                 p-(C6H4)CH3 
                 CH3 
                 p-(C6H4)OCH3 
               
               
                 22n 
                 p-(C6H4)CH3 
                 3.5-dimethylisoxazol- 
                 p-(C6H4)OCH3 
               
               
                   
                   
                 4-yl 
               
               
                 22o 
                 p-(C6H4)CH3 
                 1-methylimidazol-4- 
                 p-(C6H4)OCH3 
               
               
                   
                   
                 yl 
               
               
                 22p 
                 CH3 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
               
               
                 22q 
                 4-methyl-2- 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
               
               
                   
                 acetamidothiazol-5-yl 
               
               
                 22r 
                 3,5-dimethylisoxazol-4-yl 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
               
               
                 22s 
                 1-methylimidazol-4-yl 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
               
               
                 22t 
                 5-Br-6-Cl-pyrid-3-yl 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
               
               
                 22u 
                 7-Cl- 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
               
               
                   
                 benzo[1,2,5]oxadiazol-4- 
               
               
                   
                 yl 
               
               
                 22v 
                 5-[3-(isoxazolyl)]thien-2- 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
               
               
                   
                 yl 
               
               
                 22w 
                 1,2,5-trimethyl-3- 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
               
               
                   
                 carbomethoxypyrrol-4-yl 
               
               
                 22x 
                 p- 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
               
               
                   
                 (C6H4)CH2CH2CH2CH3 
               
               
                 22y 
                 2-(1-naphthyl)ethyl 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
               
               
                 22z 
                 p-(C6H4)SO2CH3 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
               
               
                 22aa 
                 m-(C6H4)OCH3 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
               
               
                 22bb 
                 5-bromothien-2-yl 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
               
               
                 22cc 
                 isoquinolin-5-yl 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
               
               
                 22dd 
                 p-(C6H4)CH3 
                 1,2,5-trimethyl-3- 
                 p-(C6H4)OCH3 
               
               
                   
                   
                 carbomethoxypyrrol- 
               
               
                   
                   
                 4-yl 
               
               
                 22ee 
                 p-(C6H4)CH3 
                 2-(1-naphthyl)ethyl 
                 p-(C6H4)OCH3 
               
               
                 22ff 
                 p-(C6H4)CH3 
                 p-(C6H4)SO2CH3 
                 p-(C6H4)OCH3 
               
               
                 22gg 
                 p-(C6H4)CH3 
                 5-bromothien-2-yl 
                 p-(C6H4)OCH3 
               
               
                 22hh 
                 p-(C6H4)CH3 
                 2-methoxy-4- 
                 p-(C6H4)OCH3 
               
               
                   
                   
                 methylphenyl 
               
               
                 22ii 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 C6H5 
               
               
                 22jj 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 C6H5 
               
               
                 22kk 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 C6H5 
               
               
                 22ll 
                 CH3 
                 p-(C6H4)CH3 
                 o-(C6H4)Cl 
               
               
                 22mm 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 o-(C6H4)Cl 
               
               
                 22nn 
                 p-(C6H4)CH3 
                 Me 
                 o-(C6H4)Cl 
               
               
                   
               
            
           
           
               
               
               
            
               
                   
                   
                 % Inhibition 
               
               
                   
                 IC50 (μM) 
                 at 15 μg/mL 
               
            
           
           
               
               
               
               
               
               
               
               
            
               
                 Compound # 
                 R7 
                 X2 
                 Y2 
                 Src 
                 Csk 
                 FGFr 
                 Src (%) 
               
               
                   
               
               
                  2 
                 H 
                 — 
                 — 
                 NI 
                 NI 
                 NI 
                 ND 
               
               
                  6 
                 H 
                 — 
                 — 
                 NI 
                 NI 
                 736 
                 ND 
               
               
                 12a 
                 H 
                 O 
                 — 
                 23 
                 NI 
                 44 
                 ND 
               
               
                 12b 
                 H 
                 O 
                 — 
                 18.5 
                 NI 
                 45 
                 ND 
               
               
                 12c 
                 H 
                 O 
                 — 
                 8.6 
                 95 
                 19 
                 ND 
               
               
                 12d 
                 H 
                 O 
                 — 
                 24 
                 73 
                 35 
                 ND 
               
               
                 12e 
                 H 
                 O 
                 — 
                 19 
                 NI 
                 46 
                 ND 
               
               
                 12f 
                 H 
                 O 
                 — 
                 20 
                 NI 
                 35 
                 ND 
               
               
                 12g 
                 H 
                 O 
                 — 
                 35 
                 102 
                 70 
                 ND 
               
               
                 12h 
                 H 
                 O 
                 — 
                 9 
                 98 
                 36 
                 ND 
               
               
                 12i 
                 H 
                 O 
                 — 
                 8 
                 NI 
                 48 
                 ND 
               
               
                 12j 
                 H 
                 O 
                 — 
                 50 
                 NI 
                 192 
                 ND 
               
               
                 12k 
                 H 
                 O 
                 — 
                 21 
                 88 
                 44 
                 ND 
               
               
                 12l 
                 H 
                 O 
                 — 
                 40 
                 NI 
                 81 
                 ND 
               
               
                 12m 
                 H 
                 O 
                 — 
                 54 
                 NI 
                 NI 
                 ND 
               
               
                 12n 
                 H 
                 O 
                 — 
                 29 
                 NI 
                 24 
                 ND 
               
               
                 12o 
                 H 
                 O 
                 — 
                 7.2 
                 NI 
                 22 
                 ND 
               
               
                 12p 
                 H 
                 O 
                 — 
                 28 
                 NI 
                 26 
                 ND 
               
               
                 12q 
                 H 
                 O 
                 — 
                 39 
                 NI 
                 42 
                 ND 
               
               
                 12r 
                 H 
                 O 
                 — 
                 6.6 
                 NI 
                 15 
                 ND 
               
               
                 12s 
                 H 
                 O 
                 — 
                 ND 
                 ND 
                 ND 
                  9* 
               
               
                 12t 
                 H 
                 O 
                 — 
                 19 
                 105 
                 40 
                 ND 
               
               
                 12u 
                 H 
                 O 
                 — 
                 12 
                 104 
                 38 
                 ND 
               
               
                 12v 
                 H 
                 O 
                 — 
                 69 
                 NI 
                 145 
                 ND 
               
               
                 12w 
                 H 
                 O 
                 — 
                 5.5 
                 185 
                 15.3 
                 ND 
               
               
                 12x 
                 H 
                 O 
                 — 
                 9.5 
                 72 
                 31 
                 ND 
               
               
                 12y 
                 H 
                 O 
                 — 
                 11 
                 104 
                 26 
                 ND 
               
               
                 12z 
                 H 
                 O 
                 — 
                 9 
                 118 
                 24 
                 ND 
               
               
                 12aa 
                 H 
                 O 
                 — 
                 6.7 
                 77 
                 10.6 
                 ND 
               
               
                 12bb 
                 H 
                 O 
                 — 
                 NI 
                 NI 
                 NI 
                 ND 
               
               
                 12cc 
                 H 
                 O 
                 — 
                 ND 
                 ND 
                 ND 
                 19 
               
               
                 12dd 
                 H 
                 O 
                 — 
                 ND 
                 ND 
                 ND 
                 36 
               
               
                 12ee 
                 H 
                 O 
                 — 
                 131 
                 ND 
                 ND 
                 ND 
               
               
                 12ff 
                 H 
                 S 
                 — 
                 4 
                 8.6 
                 3.6 
                 ND 
               
               
                 12gg 
                 H 
                 S 
                 — 
                 16 
                 NI 
                 17 
                 ND 
               
               
                 12hh 
                 H 
                 S 
                 — 
                 18 
                 NI 
                 30 
                 ND 
               
               
                 15a 
                 CH2CHCH2 
                 O 
                 CH2 
                 212 
                 ND 
                 ND 
                 ND 
               
               
                 15b 
                 H 
                 O 
                 CH2 
                 14 
                 NI 
                 88 
                 ND 
               
               
                 15c 
                 H 
                 O 
                 CH2 
                 27 
                 NI 
                 54 
                 ND 
               
               
                 15d 
                 H 
                 O 
                 CH2 
                 14 
                 59 
                 66 
                 ND 
               
               
                 15e 
                 H 
                 O 
                 CH2 
                 15 
                 NI 
                 132 
                 ND 
               
               
                 15f 
                 H 
                 O 
                 CH2 
                 42 
                 NI 
                 91 
                 ND 
               
               
                 15g 
                 H 
                 S 
                 CH2 
                 11 
                 NI 
                 NI 
                 ND 
               
               
                 17a 
                 H 
                 — 
                 — 
                 46 
                 214 
                 64 
                 ND 
               
               
                 17b 
                 H 
                 — 
                 — 
                 21 
                 83 
                 ND 
                 ND 
               
               
                 17c 
                 H 
                 — 
                 — 
                 39 
                 NI 
                 98 
                 ND 
               
               
                 17d 
                 H 
                 — 
                 — 
                 51 
                 NI 
                 3.1 
                 ND 
               
               
                 17e 
                 H 
                 — 
                 — 
                 19 
                 NI 
                 21 
                 ND 
               
               
                 17f 
                 H 
                 — 
                 — 
                 38 
                 NI 
                 50 
                 ND 
               
               
                 21 
                 H 
                 — 
                 — 
                 8.6 
                 NI 
                 23 
                 ND 
               
               
                 22a 
                 OCH3 
                 H 
                 — 
                 NI 
                 NI 
                 NI 
                 ND 
               
               
                 22b 
                 H 
                 C(═0) 
                 NH 
                 ND 
                 ND 
                 ND 
                 25 
               
               
                 22c 
                 H 
                 C(═O) 
                 NH 
                 300 
                 ND 
                 ND 
                 ND 
               
               
                 22d 
                 H 
                 C(═O) 
                 NH 
                 ND 
                 ND 
                 ND 
                  0 
               
               
                 22e 
                 H 
                 C(═O) 
                 NH 
                 149 
                 ND 
                 ND 
                 ND 
               
               
                 22f 
                 H 
                 C(═O) 
                 NH 
                 ND 
                 ND 
                 ND 
                  3 
               
               
                 22g 
                 H 
                 C(═O) 
                 NH 
                 18 
                 ND 
                 ND 
                 ND 
               
               
                 22h 
                 H 
                 NH 
                 C(═O) 
                 47 
                 ND 
                 ND 
                 ND 
               
               
                 22i 
                 H 
                 NH 
                 SO2 
                 ND 
                 ND 
                 ND 
                 26 
               
               
                 22j 
                 H 
                 NH 
                 SO2 
                 25 
                 ND 
                 ND 
                 ND 
               
               
                 22k 
                 H 
                 C(═O) 
                 — 
                 ND 
                 NI 
                 ND 
                 ND 
               
               
                 22l 
                 H 
                 CH2 
                 — 
                 ND 
                 ND 
                 ND 
                  5 
               
               
                 22m 
                 H 
                 O 
                 — 
                 ND 
                 ND 
                 ND 
                 22 
               
               
                 22n 
                 H 
                 O 
                 — 
                 ND 
                 ND 
                 ND 
                  5 
               
               
                 22o 
                 H 
                 O 
                 — 
                 ND 
                 ND 
                 ND 
                  0 
               
               
                 22p 
                 H 
                 O 
                 — 
                 ND 
                 ND 
                 ND 
                 17 
               
               
                 22q 
                 H 
                 O 
                 — 
                 154 
                 ND 
                 ND 
                 ND 
               
               
                 22r 
                 H 
                 O 
                 — 
                 335 
                 ND 
                 ND 
                 ND 
               
               
                 22s 
                 H 
                 O 
                 — 
                 ND 
                 ND 
                 ND 
                  3 
               
               
                 22t 
                 H 
                 O 
                 — 
                 44 
                 ND 
                 ND 
                 ND 
               
               
                 22u 
                 H 
                 O 
                 — 
                 20 
                 ND 
                 ND 
                 ND 
               
               
                 22v 
                 H 
                 O 
                 — 
                 ND 
                 ND 
                 ND 
                 22 
               
               
                 22w 
                 H 
                 O 
                 — 
                 ND 
                 ND 
                 ND 
                  6 
               
               
                 22x 
                 H 
                 O 
                 — 
                 36 
                 ND 
                 ND 
                 ND 
               
               
                 22y 
                 H 
                 O 
                 — 
                 20 
                 ND 
                 ND 
                 ND 
               
               
                 22z 
                 H 
                 O 
                 — 
                 174 
                 ND 
                 ND 
                 ND 
               
               
                 22aa 
                 H 
                 O 
                 — 
                 133 
                 ND 
                 ND 
                 ND 
               
               
                 22bb 
                 H 
                 O 
                 — 
                 19.5 
                 ND 
                 ND 
                 ND 
               
               
                 22cc 
                 H 
                 O 
                 — 
                 45 
                 ND 
                 ND 
                 ND 
               
               
                 22dd 
                 H 
                 O 
                 — 
                 ND 
                 ND 
                 ND 
                  5 
               
               
                 22ee 
                 H 
                 O 
                 — 
                 50 
                 ND 
                 ND 
                 ND 
               
               
                 22ff 
                 H 
                 O 
                 — 
                 ND 
                 ND 
                 ND 
                  2 
               
               
                 22gg 
                 H 
                 O 
                 — 
                 24 
                 ND 
                 ND 
                 ND 
               
               
                 22hh 
                 H 
                 O 
                 — 
                 ND 
                 ND 
                 ND 
                 17 
               
               
                 22ii 
                 H 
                 C(═NOCH2C6H5) 
                 — 
                 64 
                 ND 
                 ND 
                 ND 
               
               
                 22jj 
                 H 
                 C(═NOH) 
                 — 
                 ND 
                 ND 
                 ND 
                 16 
               
               
                 22kk 
                 H 
                 C(═NOCH3) 
                 — 
                 ND 
                 ND 
                 ND 
                 23 
               
               
                 22ll 
                 H 
                 S 
                 CH2 
                 ND 
                 ND 
                 ND 
                 17 
               
               
                 22mm 
                 H 
                 S 
                 CH2 
                 11 
                 ND 
                 ND 
                 ND 
               
               
                 22nn 
                 H 
                 S 
                 CH2 
                 ND 
                 ND 
                 ND 
                 21 
               
               
                   
               
               
                   *= assayed at 50 μg/mL    
               
               
                   ND = not determined    
               
               
                   NI = no inhibition at 100 μg/mL    
               
            
           
         
       
     
     
       
         
           
               
             
               
                 TABLE 4 
               
             
            
               
                   
               
               
                   
               
               
                 Formula III Compounds 
               
            
           
           
               
               
               
            
               
                   
                   
                 % Inhibition 
               
               
                   
                 IC50 (μM) 
                 at 15 μg/mL 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
               
            
               
                 Compound # 
                 R8 
                 R9 
                 R10 
                 R11 
                 X3 
                 Y3 
                 Src 
                 Csk 
                 FGFr 
                 Src (%) 
               
               
                   
               
            
           
           
               
               
               
               
               
               
               
               
               
               
               
            
               
                 23 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 p-(C6H4)Cl 
                 NH2 
                 S 
                 — 
                 58 
                 280 
                  56 
                 ND 
               
               
                 24 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 p-(C6H4)Cl 
                 NHC(═O)CH3 
                 S 
                 — 
                 NI 
                 NI 
                 515 
                 ND 
               
               
                 33 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
                 CO2CH3 
                 O 
                 — 
                 67 
                 NI 
                 NI 
                 ND 
               
               
                 34 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
                 CO2H 
                 O 
                 — 
                 77 
                 ND 
                 ND 
                 ND 
               
               
                 37 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
                 CH3 
                 O 
                 — 
                 118 
                 ND 
                 ND 
                 ND 
               
               
                 38a 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 Br 
                 Br 
                 — 
                 — 
                 31 
                 NI 
                 110 
                 ND 
               
               
                 38b 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
                 CF3 
                 O 
                 — 
                 ND 
                 ND 
                 ND 
                 50 
               
               
                 38c 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 o-(C6H4)Cl 
                 F 
                 S 
                 CH2 
                 2.2 
                 ND 
                 ND 
                 ND 
               
               
                 38d 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 o-(C6H4)Cl 
                 F 
                 SO2 
                 CH2 
                 13 
                 ND 
                 ND 
                 ND 
               
               
                   
               
               
                   ND = not determined    
               
               
                   NI = no inhibition at 100 μg/mL    
               
            
           
         
       
     
     
       
         
           
               
             
               
                 TABLE 5 
               
               
                   
               
               
                   
               
               
                 Formula IV Compounds 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
               
               
            
               
                 Compound 
                 R12 
                 R13 
                 R14 
                 R15 
                 A 
               
               
                   
               
               
                 42 
                 p-(C6H4)CH3 
                 OP(═O)(OCH2CH3)2 
                 p-(C6H4)OCH3 
                 H 
                 NHSO2 
               
               
                 43 
                 p-(C6H4)CH3 
                 OP(═O)(OH)2 
                 p-(C6H4)OCH3 
                 H 
                 NHSO2 
               
               
                 48 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
                 H 
                 O-SO2 
               
               
                 51 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 p-(C6H4)Cl 
                 NO2 
                 NHC(═O) 
               
               
                 52 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 p-(C6H4)Cl 
                 H 
                 NHC(═O) 
               
               
                 53 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 p-(C6H4)Cl 
                 NO2 
                 N(CH3)SO2 
               
               
                 55 
                 p-(C6H4)CH3 
                 NH2 
                 p-(C6H4)Cl 
                 NO2 
                 NHSO2 
               
               
                 56 
                 p-(C6H4)CH3 
                 NH2 
                 p-(C6H4)Cl 
                 NO2 
                 NHC(═O) 
               
               
                 59 
                 p-(C6H4)CH3 
                 OH 
                 p-(C6H4)OCH3 
                 H 
                 NHSO2 
               
               
                 60 
                 p-(C6H4)CH3 
                 OCH3 
                 p-(C6H4)OCH3 
                 H 
                 NHSO2 
               
               
                 61 
                 p-(C6H4)CH3 
                 OCH3 
                 p-(C6H4)OCH3 
                 H 
                 N(CH3)SO2 
               
               
                 62 
                 p-(C6H4)CH3 
                 CH2CH2OH 
                 p-(C6H4)OCH3 
                 H 
                 NHSO2 
               
               
                 63 
                 p-(C6H4)CH3 
                 CH2CH2CH2OH 
                 p-(C6H4)OCH3 
                 H 
                 NHSO2 
               
               
                 64 
                 p-(C6H4)CH3 
                 rac-CH2CH(OH)CH2OH 
                 p-(C6H4)OCH3 
                 H 
                 NHSO2 
               
               
                 65 
                 p-(C6H4)CH3 
                 CH2CO2H 
                 p-(C6H4)OCH3 
                 H 
                 NHSO2 
               
               
                 66 
                 OCH3 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
                 H 
                 — 
               
               
                 67 
                 p-(C6H4)CH3 
                 CO2CH3 
                 p-(C6H4)OCH3 
                 H 
                 NHSO2 
               
               
                 68 
                 p-(C6H4)CH3 
                 CO2H 
                 p-(C6H4)OCH3 
                 H 
                 NHSO2 
               
               
                 69 
                 p-(C6H4)CH3 
                 H 
                 p-(C6H4)Cl 
                 NO2 
                 NHSO2 
               
               
                 70 
                 H 
                 p-(C6H4)CH3 
                 p-(C6H4)Cl 
                 NO2 
                 — 
               
               
                 71a 
                 NH2 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
                 H 
                 — 
               
               
                 71b 
                 2-cyanopyrid-5-yl 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
                 H 
                 NHC(═O) 
               
               
                 71c 
                 2-trifluoromethylpyrid-5-yl 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
                 H 
                 NHC(═O) 
               
               
                 71d 
                 p-(C6H4)CN 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
                 H 
                 NHCH2 
               
               
                 71e 
                 p-(C6H4)NHC(═O)CH3 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
                 H 
                 NHCH2 
               
               
                 71f 
                 benzofuran-2-yl 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
                 H 
                 NHCH2 
               
               
                 71g 
                 quinolin-2-yl 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
                 H 
                 NHCH2 
               
               
                 71h 
                 5-methyl-pyrazin-2-yl 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
                 H 
                 NHC(═O) 
               
               
                 71i 
                 p-(C6H4)CH3 
                 NH2 
                 p-(C6H4)OCH3 
                 H 
                 CH2NHSO2 
               
               
                 71j 
                 CN 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
                 H 
                 — 
               
               
                 71k 
                 CO2H 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
                 H 
                 — 
               
               
                 71l 
                 p-(C6H4)CH3 
                 NH2 
                 p-(C6H4)OCH3 
                 H 
                 NHSO2 
               
               
                 71m 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
                 H 
                 NHSO2 
               
               
                 71n 
                 p-(C6H4)CH3 
                 CH2NH2 
                 p-(C6H4)OCH3 
                 H 
                 NHSO2 
               
               
                 71o 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 C6H5 
                 H 
                 NHSO2 
               
               
                 71p 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
                 H 
                 NHSO2 
               
               
                 71q 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
                 H 
                 NHSO2 
               
               
                 71r 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
                 H 
                 NHC(═O) 
               
               
                 71s 
                 C6H5 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
                 H 
                 NHC(═O)CH2 
               
               
                 71t 
                 NH2 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
                 H 
                 — 
               
               
                 71u 
                 p-(C6H4)CH3 
                 quinolin-2-yl 
                 p-(C6H4)OCH3 
                 H 
                 NHSO2 
               
               
                 71v 
                 C(═O)NH2 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
                 H 
                 — 
               
               
                 71w 
                 CH2NH2 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
                 H 
                 — 
               
               
                 71x 
                 CH3 
                 6-methylnaphth-2-yl 
                 p-(C6H4)OCH3 
                 H 
                 CH2NHSO2 
               
               
                 71y 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 morpholin-4-yl 
                 NO2 
                 NHC(═O) 
               
               
                 71z 
                 p-(C6H4)CH3 
                 CH2CH2CH3 
                 p-(C6H4)OCH3 
                 H 
                 NHSO2 
               
               
                 71aa 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 cyclohexyl 
                 NO2 
                 NHC(═O) 
               
               
                 71bb 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 naphth-1-yl 
                 NO2 
                 NHC(═O) 
               
               
                 71cc 
                 p-(C6H4)CH3 
                 NH2 
                 p-(C6H4)OCH3 
                 NO2 
                 NHSO2 
               
               
                 71dd 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
                 H 
                 NHSO2 
               
               
                 71ee 
                 p-(C6H4)CH3 
                 NH2 
                 p-(C6H4)OCH3 
                 CF3 
                 NHSO2 
               
               
                 71ff 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
                 H 
                 CH2NHC(═O) 
               
               
                 71gg 
                 NH2 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
                 CF3 
                 — 
               
               
                 71hh 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
                 H 
                 NHSO2 
               
               
                 71ii 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
                 H 
                 NHSO2 
               
               
                 71jj 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
                 H 
                 NHCH2 
               
               
                 71kk 
                 NH2 
                 p-(C6H4)CH3 
                 o-(C6H4)Cl 
                 H 
                 — 
               
               
                 71ll 
                 7-chloro- 
                 NH2 
                 o-(C6H4)Cl 
                 NO2 
                 NHSO2 
               
               
                   
                 benzo[1,2,5]oxadiazol-4-yl 
               
               
                 71mm 
                 p-(C6H4)CH2CH3 
                 p-(C6H4)CH3 
                 CH3 
                 H 
                 SO2NH 
               
               
                 71nn 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 o-(C6H4)Cl 
                 H 
                 NHSO2 
               
               
                   
               
            
           
           
               
               
               
            
               
                   
                   
                 % Inhibition 
               
               
                   
                 IC50 (μM) 
                 at 15 μg/mL 
               
            
           
           
               
               
               
               
               
               
               
               
               
            
               
                   
                 Compound 
                 B 
                 X4 
                 Y4 
                 Src 
                 Csk 
                 FGFr 
                 Src % 
               
               
                   
                   
               
               
                   
                 42 
                 — 
                 O 
                 — 
                  65 
                 NI 
                 109 
                 ND 
               
               
                   
                 43 
                 — 
                 O 
                 — 
                  13 
                 NI 
                 29 
                 ND 
               
               
                   
                 48 
                 O-SO2 
                 CH2 
                 O 
                 102 
                 NI 
                 NI 
                 ND 
               
               
                   
                 51 
                 NHC(═O) 
                 S 
                 — 
                 153 
                  51 
                 40 
                 ND 
               
               
                   
                 52 
                 NHC(═O) 
                 S 
                 — 
                  51 
                 NI 
                 NI 
                 ND 
               
               
                   
                 53 
                 N(CH3)SO2 
                 S 
                 — 
                 388 
                 261 
                 254 
                 ND 
               
               
                   
                 55 
                 — 
                 S 
                 — 
                  33 
                 NI 
                 2.2 
                 ND 
               
               
                   
                 56 
                 — 
                 S 
                 — 
                 NI 
                 NI 
                 410 
                 ND 
               
               
                   
                 59 
                 — 
                 O 
                 — 
                  65 
                 NI 
                 65 
                 ND 
               
               
                   
                 60 
                 — 
                 O 
                 — 
                 129 
                 NI 
                 NI 
                 ND 
               
               
                   
                 61 
                 — 
                 O 
                 — 
                 177 
                 NI 
                 NI 
                 ND 
               
               
                   
                 62 
                 O 
                 O 
                 — 
                 126 
                  15 
                 NI 
                 ND 
               
               
                   
                 63 
                 O 
                 O 
                 — 
                 212 
                 NI 
                 NI 
                 ND 
               
               
                   
                 64 
                 O 
                 O 
                 — 
                 189 
                 NI 
                 NI 
                 ND 
               
               
                   
                 65 
                 O 
                 O 
                 — 
                 169 
                 NI 
                 NI 
                 ND 
               
               
                   
                 66 
                 NHSO2 
                 CH2 
                 O 
                 119 
                 NI 
                 162 
                 ND 
               
               
                   
                 67 
                 — 
                 O 
                 — 
                 NI 
                 NI 
                 246 
                 ND 
               
               
                   
                 68 
                 — 
                 O 
                 — 
                 133 
                 303 
                 NI 
                 ND 
               
               
                   
                 69 
                 — 
                 S 
                 — 
                 1970  
                 986 
                 NI 
                 ND 
               
               
                   
                 70 
                 NHSO2 
                 S 
                 — 
                 599 
                 369 
                 251 
                 ND 
               
               
                   
                 71a 
                 NHSO2 
                 O 
                 — 
                 ND 
                 ND 
                  ND 
                 13 
               
               
                   
                 71b 
                 NHSO2 
                 O 
                 — 
                 ND 
                 ND 
                 ND 
                  0 
               
               
                   
                 71c 
                 NHSO2 
                 O 
                 — 
                 ND 
                 ND 
                 ND 
                  5 
               
               
                   
                 71d 
                 NHSO2 
                 O 
                 — 
                 557 
                 ND 
                 ND 
                 ND 
               
               
                   
                 71e 
                 NHSO2 
                 O 
                 — 
                 203 
                 ND 
                 ND 
                 ND 
               
               
                   
                 71f 
                 NHSO2 
                 O 
                 — 
                 627 
                 ND 
                 ND 
                 ND 
               
               
                   
                 71g 
                 NHSO2 
                 O 
                 — 
                 ND 
                 ND 
                 ND 
                 10 
               
               
                   
                 71h 
                 NHSO2 
                 O 
                 — 
                 ND 
                 ND 
                 ND 
                  0 
               
               
                   
                 71i 
                 — 
                 O 
                 — 
                 ND 
                 ND 
                 ND 
                 13 
               
               
                   
                 71j 
                 NHSO2 
                 O 
                 — 
                 254 
                 ND 
                 ND 
                 ND 
               
               
                   
                 71k 
                 NHSO2 
                 O 
                 — 
                 262 
                 ND 
                 ND 
                 ND 
               
               
                   
                 71l 
                 — 
                 O 
                 — 
                  62 
                 ND 
                 ND 
                 ND 
               
               
                   
                 71m 
                 CH2NHSO2 
                 O 
                 — 
                 136 
                 ND 
                 ND 
                 ND 
               
               
                   
                 71n 
                 — 
                 O 
                 — 
                 1300  
                 ND 
                 ND 
                 ND 
               
               
                   
                 71o 
                 N[C(═O)C6H5)] 
                 O 
                 C(═O) 
                  39 
                 ND 
                 ND 
                 ND 
               
               
                   
                   
                 SO2 
               
               
                   
                 71p 
                 CH2NHC(═O) 
                 O 
                 — 
                 108 
                 ND 
                 ND 
                 ND 
               
               
                   
                 71q 
                 NHC(═O) 
                 O 
                 — 
                  99 
                 ND 
                 ND 
                 ND 
               
               
                   
                 71r 
                 NHSO2 
                 O 
                 — 
                 159 
                 ND 
                 ND 
                 ND 
               
               
                   
                 71s 
                 NHSO2 
                 O 
                 — 
                 ND 
                 ND 
                 ND 
                 10 
               
               
                   
                 71t 
                 N(CH3)SO2 
                 O 
                 — 
                 ND 
                 ND 
                 ND 
                  0 
               
               
                   
                 71u 
                 E/Z N═C 
                 O 
                 — 
                 ND 
                 ND 
                 ND 
                  6 
               
               
                   
                 71v 
                 NHSO2 
                 CH2 
                 O 
                 ND 
                 ND 
                 ND 
                 10 
               
               
                   
                 71w 
                 NHSO2 
                 CH2 
                 O 
                 ND 
                 ND 
                 ND 
                  9 
               
               
                   
                 71x 
                 NHSO2 
                 CH2 
                 O 
                 ND 
                 ND 
                 ND 
                 20 
               
               
                   
                 71y 
                 NHC(═O) 
                 — 
                 — 
                 ND 
                 ND 
                 ND 
                 14 
               
               
                   
                 71z 
                 NHC(═O) 
                 O 
                 — 
                 ND 
                 ND 
                 ND 
                  5 
               
               
                   
                 71aa 
                 NHC(═O) 
                 NH 
                 CH2 
                 ND 
                 ND 
                 ND 
                  0 
               
               
                   
                 71bb 
                 NHC(═O) 
                 NH 
                 CH2 
                 ND 
                 ND 
                 ND 
                 22 
               
               
                   
                 71cc 
                 — 
                 O 
                 — 
                 ND 
                 ND 
                 ND 
                 15 
               
               
                   
                 71dd 
                 N(CH3)SO2 
                 O 
                 — 
                 172 
                 ND 
                 ND 
                 ND 
               
               
                   
                 71ee 
                 — 
                 O 
                 — 
                 ND 
                 ND 
                 ND 
                 21 
               
               
                   
                 71ff 
                 NHSO2 
                 CH2 
                 O 
                 ND 
                 ND 
                 ND 
                  4 
               
               
                   
                 71gg 
                 NHSO2 
                 O 
                 — 
                 ND 
                 ND 
                 ND 
                 19 
               
               
                   
                 71hh 
                 NH2CH2 
                 O 
                 — 
                 ND 
                 ND 
                 ND 
                 23 
               
               
                   
                 71ii 
                 NHC(═O) 
                 O 
                 — 
                 ND 
                 ND 
                 ND 
                 21 
               
               
                   
                   
                 NHSO2 
               
               
                   
                 71jj 
                 NHSO2 
                 O 
                 — 
                 ND 
                 ND 
                 ND 
                 19 
               
               
                   
                 71kk 
                 NHSO2 
                 S 
                 CH2 
                 ND 
                 ND 
                 ND 
                 29 
               
               
                   
                 71ll 
                 — 
                 S 
                 CH2 
                 ND 
                 ND 
                 ND 
                 26 
               
               
                   
                 71mm 
                 NHSO2 
                 O 
                 — 
                 ND 
                 ND 
                 ND 
                 19 
               
               
                   
                 71nn 
                 NHSO2 
                 SO2 
                 CH2 
                 ND 
                 ND 
                 ND 
                 46 
               
               
                   
                   
               
               
                   
                   ND = not determined    
               
               
                   
                   NI = no inhibition at 100 μg/mL    
               
            
           
         
       
     
     
       
         
           
               
             
               
                 TABLE 6 
               
             
            
               
                   
               
               
                   
               
               
                 Formula V Compounds 
               
            
           
           
               
               
               
            
               
                   
                   
                 % Inhibition 
               
               
                   
                 IC50 (μM) 
                 at 15 μg/mL 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
            
               
                 Compound# 
                 R16 
                 R17 
                 R18 
                 X5 
                 Y5 
                 Src 
                 Csk 
                 FGFr 
                 Src (%) 
               
               
                   
               
            
           
           
               
               
               
               
               
               
               
               
               
               
            
               
                 72a 
                 H 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
                 O 
                 C(═O) 
                 ND 
                 ND 
                 ND 
                 21 
               
               
                 72b 
                 p-(C6H4)CH3 
                 H 
                 p-(C6H4)OCH3 
                 O 
                 C(═O) 
                 ND 
                 ND 
                 ND 
                 19 
               
               
                 72c 
                 p-(C6H4)CH3 
                 p-(C6H4)CH3 
                 p-(C6H4)OCH3 
                 O 
                 C(═O) 
                 ND 
                 ND 
                 ND 
                 22 
               
               
                 72d 
                 H 
                 H 
                 p-(C6H4)OCH3 
                 O 
                 SO2 
                 ND 
                 ND 
                 ND 
                 12 
               
               
                 72e 
                 H 
                 H 
                 p-(C6H4)OCH3 
                 O 
                 C(═O) 
                 ND 
                 ND 
                 ND 
                 4 
               
               
                 72f 
                 p-(C6H4)CH3 
                 H 
                 p-(C6H4)OCH3 
                 O 
                 SO2 
                 ND 
                 ND 
                 ND 
                 14 
               
               
                   
               
               
                   ND = not determined    
               
            
           
         
       
     
     REFERENCES  
     
         
          Atwell, et al, J. Med. Chem. 1972, 15 (611-615).  
          Audeenko, S A. Russian J. Org. Chem. 1998, 34 (515-524).  
          Barnekow A: Functional Aspects of the c-src Gene:  Crit. Rev. Oncogenesis  1:277-292, 1989.  
          Bezverkhii, N P, Zinukov, V D, Kremlev, M M. J. Org. Chem USSR (Eng. Trans), 1982, 18 (1959-1960).  
          Bezverkhii, N P, Zinukov, V D, Kremlev, M M. J. Org. Chem USSR (Eng. Trans), 1984, 20 (303-06, 339-43 and 947-50)  
          Bjelfman C, Hedborg R, Johansson I, Nordenskjold M, Pahlman S: Expression of the Neuronal form of pp60c-src in Neuroblastoma in Relation to Clinical Stage and Prognosis.  Cancer Res  50:6908-6914, 1990.  
          Budde R J A, Ke S, and Levin V A: Activity of pp60c-src in 60 Different Cell Lines Derived from Human Tumors.  Cancer Biochem. Biophys.  14:171-175, 1994.  
          Budde R J A, Ramdas L, and Ke S: Recombinant Src from Baculovirus-infected Insect Cells: Purification and Characterization.  Preparative Biochemistry  23:493-515, 1993.  
          Cambridge Dictionary of Biology, New York, 1990.  
          Cartwright C A, Meisler A I, Eckhart W: Activation of the pp60c-src Protein Kinase is an Early Event in Colonic Carcinogenesis.  Proc Natl Acad Sci USA.  87:558-562, 1990.  
          Fanning P, Bulovas K, Saini K S, Libertino J A, Joyce A D, Summerhayes I C: Elevated Expression of pp60c-src in Low Grade Human Bladder Carcinoma.  Cancer Res  52:1457-1462, 1992.  
          Heterocycles, 1987, 26 (2433)  
          Jessup J M, Gallick G E: The Biology of Colorectal Carcinoma.  Curr Problems in Cancer  16:263-328, 1993.  
          J. Med. Chem. 1963, 6, (599-601).  
          J. Med. Chem. 1992, 35 (4455).  
          Kitanaka A, Waki M, Kamono H, Tanaka T: Antisense Src Expression Inhibits Proliferation and Erythropoietin-induced Erythroid Differentiation of K562 Human Leukemia Cells.  Biochem Biophysic Res Commun  201:1534-1540, 1994.  
          Kostic, S., Soskic, V., Joksimovic, J. Arzneim. Forsch. 1994, 44 (697-702).  
          Lynch S A, Brugge J S, Fromowitz F, Glantz L, Wang P, Caruso R, Viola M V: Increased Expression of the Src Proto-oncogene in the Leukemia and a Subgroup of B-cell Lymphomas.  Leukemia  7:1416-1422, 1993.  
          Merck Manual, The Seventeenth Edition, West Point, Pa., 1999.  
          Park S H, Kang S H, Lim S H, Oh H S, Lee K H: Design and Synthesis of Small Chemical Inhibitors Containing Different Scaffolds for Lck SH2 Domain.  Bioorg  &amp;  Med Chem Lett  13:3455-3459, 2003.  
          Partanen S: Immunohistochemically Demonstrated pp60c-src in Human Breast Carcinoma.  Oncology Reports  1:603-606, 1994.  
          Sinha S and Corey S J: Implications for Src Kinases in Hematopoiesis: Signal Transduction Therapeutics.  Journal of Hematotherapy  &amp;  Stem Cell Research  8:465-480, 1999.  
          Soriano P, Montogomery C, Geske R, Bradley A: Targeted Disruption of the c-src Proto-oncogene Leads to oOteopetrosis in Mice.  Cell  64:693-702, 1991.  
          Sridhar R, Hanson-Painton O, Cooper D R: Protein Kinases as Therapeutic Targets.  Pharm Res  17:1345-1353, 2000.  
          Staley C, Parikh N, and Gallick G: Decreased Tumorigenicity of a Human Colon Adenocarcinoma Cell Line by an Antisense Expression Vector Specific for Src.  Cell Growth  &amp;  Differentiation  8:269-274, 1997.  
          Takeshima E, Hamaguchi M, Watanabe T, Akiyama S, Kataoka M, Ohnishi Y, Xiao H, Nagai Y, Takaagi H: Aberrant Elevation of Tyrosine-specific Phosphorylation in Human Gastric Cancer Cells.  Japan J Cancer Res  82:1428-1435, 1991.  
          Termuhlen P M, Curley S A, Talamonti M S, Saboorian M H, Gallick G E: Site-specific Differences in pp60c-src Activity in Human Colorectal Metastases.  J Surg Res  54:293-298, 1993.  
          U.S. Pat. No. 2,258,162 (1938).  
          U.S. Pat. No. 6,503,914 (2003).  
          Waki M, Kitanaka A, Kamano H, Tanaka T, Kubota Y, Ohnishi H, Takahara J, Irino S: Antisense SRC Expression Inhibits U937 Human Leukemia Cell Proliferation in Conjunction with Reduction of c-MYB Expression.  Biochem Biophys Res Commun  201:1001-1007, 1994.  
          Wiener J R, Nakano K, Kruzelock R P, Bucana C D, Bast R C, Gallick, G E: Decreased Src Tyrosine Kinase Activity Inhibits Malignant Human Ovarian Cancer Tumor Growth in a Nude Mouse Model.  Clinical Cancer Research  5: 2164-2170, 1999.